var title_f28_16_28928="Drugs Crohns children";
var content_f28_16_28928=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F65046&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F65046&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Induction and maintenance therapies commonly used in the treatment of Crohn's disease in children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"7\" width=\"14%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        US trade name(s)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose in children",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose in adults",
"       </td>",
"       <td class=\"subtitle1\">",
"        Indication",
"       </td>",
"       <td class=\"subtitle1\">",
"        Important side effects",
"       </td>",
"       <td class=\"subtitle1\">",
"        Comments",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"7\">",
"        Glucocorticoids",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Prednisone or Prednisolone",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        1 to 2 mg/kg/day PO (maximum, 60 mg/dose), then taper after two weeks if patient is in remission",
"       </td>",
"       <td>",
"        40 to 60 mg/day PO, then taper after two weeks if patient is in remission",
"       </td>",
"       <td>",
"        Short-term induction therapy for moderate Crohn's disease.",
"       </td>",
"       <td>",
"        Facial swelling, moodiness, sleep disturbance, hirsutism, adrenal suppression (with physiologic doses for more than two to three weeks); hyperglycemia, osteoporosis, increased risk of varicella infection; cataracts, aseptic necrosis of bone.",
"       </td>",
"       <td>",
"        Onset of action rapid (3 to 14 days). Long-term use causes growth failure; not appropriate for long-term use.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Budesonide (enteric coated)",
"       </td>",
"       <td rowspan=\"2\">",
"        Entocort",
"       </td>",
"       <td colspan=\"2\">",
"        <em>",
"         Age &ge;6 years:",
"        </em>",
"       </td>",
"       <td rowspan=\"2\">",
"        Short-term induction therapy for mild to moderate Crohn's disease affecting the",
"        <em>",
"         ileum and right colon",
"        </em>",
"        .",
"       </td>",
"       <td rowspan=\"2\">",
"        Similar to prednisone, but fewer systemic effects including adrenal suppression.",
"       </td>",
"       <td rowspan=\"2\">",
"        May be less effective than prednisone. Pediatric dosing is based on limited data from clinical trials in children six years and older. Taper by 3 mg increments as tolerated, for a total course of up to three months.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         9 mg/day PO, then taper",
"         <sup>",
"          [1]",
"         </sup>",
"        </p>",
"        <p>",
"         <em>",
"          Or:",
"         </em>",
"        </p>",
"        0.45 mg/kg/day PO (maximum dose 9 mg/day), then taper",
"        <sup>",
"         [2]",
"        </sup>",
"       </td>",
"       <td class=\"indent1\">",
"        9 mg/day PO, then taper",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Methylprednisolone",
"       </td>",
"       <td>",
"        Solu-Medrol",
"       </td>",
"       <td>",
"        1 mg/kg q 12 hours IV (maximum 30 mg per dose)",
"       </td>",
"       <td>",
"        25 to 35 mg q 12 hours IV",
"       </td>",
"       <td>",
"        Induction of remission in severe Crohn's disease of the small bowel and colon.",
"       </td>",
"       <td>",
"        As described above for other systemic corticosteroids.",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"7\">",
"        Aminosalicylates (derivatives of 5-aminosalicylate, 5-ASA)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\" colspan=\"7\">",
"        Mesalamine*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Time-released",
"       </td>",
"       <td class=\"sublist_other\">",
"        Pentasa",
"       </td>",
"       <td class=\"sublist_other\">",
"        50 to 75 mg/kg/day PO in three to four divided doses (maximum 1 gram/dose)",
"        <sup>",
"         [3]",
"        </sup>",
"       </td>",
"       <td class=\"sublist_other\">",
"        <p>",
"         <em>",
"          Induction:",
"         </em>",
"        </p>",
"        <p>",
"         4 to 6 g/day PO in three to four divided doses",
"        </p>",
"        <p>",
"         <em>",
"          Maintenance:",
"         </em>",
"        </p>",
"        2 to 4 g/day PO in three to four divided doses",
"       </td>",
"       <td class=\"sublist_other\">",
"        <p>",
"         Maintenance of remission in mild mucosal Crohn's disease in",
"         <em>",
"          small bowel or colon",
"         </em>",
"         .",
"        </p>",
"        May also be useful for initial therapy in patients with mild disease.",
"       </td>",
"       <td class=\"sublist_other\">",
"        Generally well-tolerated. Rare reactions include rashes, pancreatitis, and interstitial nephritis (rare but serious).",
"       </td>",
"       <td class=\"sublist_other\">",
"        <p>",
"         Low efficacy (35 to 40 percent, versus 30 percent for placebo in randomized studies).",
"        </p>",
"        <p>",
"         Capsules may be opened and sprinkled on soft food.",
"        </p>",
"        <p>",
"         Patient adherence can be a problem because of requirement for frequent dosing.",
"        </p>",
"        Suggest monitoring BUN/creatinine, urine analysis, CBC and LFTs (eg, twice yearly).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        pH-released",
"       </td>",
"       <td class=\"sublist_other\">",
"        Asacol",
"       </td>",
"       <td class=\"sublist_other\">",
"        50 to 80 mg/kg/day PO divided in three or four doses (maximum 1 gram/dose)",
"       </td>",
"       <td class=\"sublist_other\">",
"        3.6 to 4.8 g/day PO, in three to four divided doses",
"       </td>",
"       <td class=\"sublist_other\">",
"        <p>",
"         Maintenance of remission in mild mucosal Crohn's disease",
"         <em>",
"          (ileum or colon)",
"         </em>",
"         .",
"        </p>",
"        May also be useful for initial therapy in patients with mild disease.",
"       </td>",
"       <td class=\"sublist_other\">",
"        As above.",
"       </td>",
"       <td class=\"sublist_other\">",
"        <p>",
"         Low efficacy (35 to 40 percent, versus 30 percent for placebo in randomized studies).",
"        </p>",
"        <p>",
"         Patient adherence can be a problem because of requirement for frequent dosing.",
"        </p>",
"        Suggest monitoring BUN/creatinine, urine analysis, CBC and LFTs (eg, twice yearly).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sulfasalazine",
"       </td>",
"       <td>",
"        <p>",
"         Azulfidine",
"        </p>",
"        Sulfazine",
"       </td>",
"       <td>",
"        50 to 75 mg/kg/day PO, divided in three or four doses (maximum 1 g/dose)",
"       </td>",
"       <td>",
"        <p>",
"         <em>",
"          Induction:",
"         </em>",
"        </p>",
"        <p>",
"         1 g PO, three to four times daily",
"        </p>",
"        <p>",
"         <em>",
"          Maintenance:",
"         </em>",
"        </p>",
"        1 g PO, two to three times daily",
"       </td>",
"       <td>",
"        <p>",
"         Maintenance of remission in mild mucosal",
"         <em>",
"          colonic",
"         </em>",
"         Crohn's disease.",
"        </p>",
"        May also be useful for initial therapy in patients with mild disease.",
"       </td>",
"       <td>",
"        <p>",
"         Sulfasalazine consists of a 5-ASA component linked to sulfapyridine; hypersensitivity to the sulfonamide component is common (drug fever, arthritis, or rash).",
"        </p>",
"        <p>",
"         Headache, photosensitivity, leukopenia, hepatitis.",
"        </p>",
"        Rare but serious reactions include pancreatitis, pericarditis, myocarditis, and pneumonitis.",
"       </td>",
"       <td>",
"        <p>",
"         To minimize side effects, start treatment at a low dose and increase to full dose as tolerated over one to two weeks.",
"        </p>",
"        <p>",
"         Low efficacy (35 to 40 percent, versus 30 percent for placebo in randomized studies).",
"        </p>",
"        <p>",
"         Also give folic acid, 1 mg daily.",
"        </p>",
"        Suggest monitoring BUN/creatinine, urine analysis, CBC and LFTs (eg, twice yearly).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"7\">",
"        Nutritional therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Elemental or polymeric formula - no other food by mouth",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Dose to meet nutritional needs for four to six weeks",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Mucosal Crohn's disease, growth failure.",
"       </td>",
"       <td>",
"        Formulas may be administered orally or by nasogastric tube.",
"       </td>",
"       <td>",
"        Efficacy 50 to 60 percent; children may refuse NG, NPO; may relapse rapidly once feeds discontinued.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"7\">",
"        Immunomodulators",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         Mercaptopurine",
"        </p>",
"        (also known as 6-mercaptopurine, 6MP)",
"       </td>",
"       <td>",
"        Purinethol",
"       </td>",
"       <td>",
"        <p>",
"         1 to 1.5 mg/kg/day PO",
"         <sup>",
"          &Delta;",
"         </sup>",
"         (maximum dose 150 mg/day)",
"         <sup>",
"          [3]",
"         </sup>",
"        </p>",
"        Much lower doses are used for patients with reduced TPMT activity (see \"comments\")",
"       </td>",
"       <td>",
"        <p>",
"         1 to 1.5 mg/kg/day PO (maximum dose 150 mg/day)",
"         <sup>",
"          [3]",
"         </sup>",
"        </p>",
"        Much lower doses are used for patients with reduced TPMT activity (see \"comments\")",
"       </td>",
"       <td>",
"        Maintenance of remission in medically refractory Crohn's disease, especially for patients with growth failure or fistulizing disease.",
"       </td>",
"       <td>",
"        <p>",
"         Pancreatitis, myelosuppression, hepatitis, pneumonitis, opportunistic infections.",
"        </p>",
"        <p>",
"         Hypersensitivity (drug fever, arthritis or rash). Anorexia, nausea, vomiting.",
"        </p>",
"        Increased risk of lymphoma (usually related to concomitant Epstein-Barr virus [EBV] infection).",
"       </td>",
"       <td>",
"        <p>",
"         Assess thiopurine methyltransferase (TPMT) genotype or enzyme activity prior to starting therapy. Dosage should then be modified based on the TPMT genotype or activity.",
"        </p>",
"        Starting dosage of Mercaptopurine should be modified based on the TPMT genotype or activity:",
"        <sup>",
"         [4]",
"        </sup>",
"        <ul>",
"         <li>",
"          TPMT genotype 1/1 (normal or increased activity): 1 to 1.5 mg/kg/day",
"         </li>",
"         <li>",
"          TPMT genotype 1/3a (reduced activity): 0.5 mg/kg/day",
"         </li>",
"         <li>",
"          TPMT genotype 3a/3a (absent activity): Mercaptopurine or azathioprine should not be used",
"         </li>",
"        </ul>",
"        <br/>",
"        <p>",
"         Monitor CBC, LFTs and amylase/lipase during therapy.",
"        </p>",
"        Slow onset of therapeutic effects (three to four months). Therapeutic drug level monitoring available. Possible risks of birth defects. Increased risk of lymphoma.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Azathioprine",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        <p>",
"         1.5 to 2.5 mg/kg/day PO (maximum dose 200 mg/day)",
"         <sup>",
"          [3]",
"         </sup>",
"        </p>",
"        Much lower doses are used for patients with reduced TPMT activity (see \"comments\")",
"       </td>",
"       <td>",
"        <p>",
"         1.5 to 2.5 mg/kg/day PO (maximum dose 200 mg/day)",
"         <sup>",
"          [3]",
"         </sup>",
"        </p>",
"        Much lower doses are used for patients with reduced TPMT activity (see \"comments\")",
"       </td>",
"       <td>",
"        Same as Mercaptopurine; these are maintenance agents only.",
"       </td>",
"       <td>",
"        Same as Mercaptopurine.",
"       </td>",
"       <td>",
"        <p>",
"         Assess thiopurine methyltransferase (TPMT) genotype or enzyme activity prior to starting therapy.",
"        </p>",
"        <p>",
"         Starting dosage of Azathioprine should then be modified based on the TPMT genotype or activity:",
"         <sup>",
"          [4]",
"         </sup>",
"        </p>",
"        <ul>",
"         <li>",
"          TPMT genotype 1/1 (normal or increased activity): 2 to 2.5 mg/kg/day",
"         </li>",
"         <li>",
"          TPMT genotype 1/3a (reduced activity): 1 mg/kg/day",
"         </li>",
"         <li>",
"          TPMT genotype 3a/3a (absent activity): Mercaptopurine or azathioprine should not be used.",
"         </li>",
"        </ul>",
"        <p>",
"         Monitor CBC, LFTs and amylase/lipase during therapy.",
"        </p>",
"        Azathioprine is metabolized to 6-MP in the liver. Slow onset of therapeutic effects (three to four months). Adverse effects are the same as 6-MP.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Methotrexate",
"       </td>",
"       <td>",
"        <p>",
"         Reumatrex",
"        </p>",
"        Trexall",
"       </td>",
"       <td>",
"        15 to 25 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        /week SQ (maximum dose 25 mg once weekly for induction, 15 mg once weekly for maintenance)",
"       </td>",
"       <td>",
"        <p>",
"         <em>",
"          Induction:",
"         </em>",
"        </p>",
"        <p>",
"         15 to 25 mg SQ weekly",
"        </p>",
"        <p>",
"         <em>",
"          Maintenance:",
"         </em>",
"        </p>",
"        15 mg SQ weekly",
"       </td>",
"       <td>",
"        <p>",
"         Refractory Crohn's disease.",
"        </p>",
"        Primarily used as maintenance therapy.",
"       </td>",
"       <td>",
"        Bone marrow suppression, hepatotoxicity, oral ulcers, nausea, pneumonitis.",
"       </td>",
"       <td>",
"        <p>",
"         Contraindicated in pregnancy.",
"        </p>",
"        <p>",
"         Monitor CBC and LFTs during therapy.",
"        </p>",
"        <p>",
"         Folic acid 1 mg daily should be given to all patients.",
"        </p>",
"        The oral route of administration also has been used for maintenance of remission.",
"        <sup>",
"         [5]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"7\">",
"        Anti-tumor necrosis factor (TNF) inhibitors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         Infliximab",
"        </p>",
"        (chimeric monoclonal antibody, 75 percent humanized)",
"       </td>",
"       <td>",
"        Remicade",
"       </td>",
"       <td>",
"        <p>",
"         <em>",
"          Induction:",
"         </em>",
"        </p>",
"        <p>",
"         5 mg/kg per dose IV, at weeks zero, two, and six. (May increase to 10 mg/kg if response is incomplete).",
"        </p>",
"        <p>",
"         <em>",
"          Maintenance:",
"         </em>",
"        </p>",
"        5 mg/kg per dose IV, every eight weeks (may increase to 10 mg/kg if response is incomplete, and/or decrease the interval between infusions)",
"       </td>",
"       <td>",
"        <p>",
"         <em>",
"          Induction:",
"         </em>",
"        </p>",
"        <p>",
"         5 mg/kg per dose IV, at weeks zero, two, and six. (May increase to 10 mg/kg if response is incomplete).",
"        </p>",
"        <p>",
"         <em>",
"          Maintenance:",
"         </em>",
"        </p>",
"        5 mg/kg per dose IV, every eight weeks (may increase to 10 mg/kg if response is incomplete, and/or decrease the interval between infusions)",
"       </td>",
"       <td>",
"        Refractory Crohn's disease.",
"       </td>",
"       <td>",
"        <p>",
"         Infusion reactions, infections, psoriasis.",
"        </p>",
"        <p>",
"         Increased risk of tuberculosis.",
"        </p>",
"        Increased risk of lymphoma, including hepatosplenic T-cell lymphoma.",
"       </td>",
"       <td>",
"        <p>",
"         Evaluate with tuberculin skin test or chest x-ray prior to starting therapy.",
"        </p>",
"        Monitor CBC and LFTs during therapy.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         Adalimumab",
"        </p>",
"        (humanized monoclonal antibody)",
"       </td>",
"       <td>",
"        Humira",
"       </td>",
"       <td>",
"        <p>",
"         Dosing used in clinical trials in children:",
"         <sup>",
"          [6]",
"         </sup>",
"        </p>",
"        <p>",
"         <em>",
"          Induction:",
"         </em>",
"        </p>",
"        <p>",
"         &lt;40 kg: 80 mg/dose SQ on week zero, followed by 40 mg on week two",
"        </p>",
"        <p>",
"         &ge;40 kg: 160 mg/dose SQ on week zero, followed by 80 mg on week two",
"        </p>",
"        <p>",
"         <em>",
"          Maintenance:",
"         </em>",
"        </p>",
"        <p>",
"         (start on week four)",
"        </p>",
"        <p>",
"         &lt;40 kg: 20 mg/dose SQ every two weeks",
"        </p>",
"        &ge;40 kg: 40 mg SQ every two weeks",
"       </td>",
"       <td>",
"        <p>",
"         <em>",
"          Induction:",
"         </em>",
"        </p>",
"        <p>",
"         160 mg SQ first dose",
"        </p>",
"        <p>",
"         80 mg SQ two weeks later",
"        </p>",
"        <p>",
"         <em>",
"          Maintenance:",
"         </em>",
"        </p>",
"        40 mg SQ on alternate weeks thereafter. Some patients may require weekly maintenance therapy,",
"        <sup>",
"         [7]",
"        </sup>",
"        or a higher maintenance dose.",
"       </td>",
"       <td>",
"        Refractory Crohn's disease.",
"       </td>",
"       <td>",
"        Infections, increased risk of lymphoma and tuberculosis.",
"       </td>",
"       <td>",
"        <p>",
"         Little published data in children and adolescents.",
"        </p>",
"        <p>",
"         Sometimes used as rescue therapy for children failing to respond to Infliximab.",
"        </p>",
"        <p>",
"         Evaluate with tuberculosis skin test prior to starting therapy.",
"        </p>",
"        Monitor CBC and LFTs during therapy.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"7\">",
"        Antibiotics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ciprofloxacin",
"       </td>",
"       <td>",
"        Cipro",
"       </td>",
"       <td>",
"        <p>",
"         <em>",
"          Induction of remission:",
"         </em>",
"        </p>",
"        <p>",
"         Dose not established in children",
"         <sup>",
"          &loz;",
"         </sup>",
"        </p>",
"        <p>",
"         <em>",
"          Treatment of infectious complications:",
"         </em>",
"        </p>",
"        20 to 30 mg/kg/day PO, divided in three doses (up to 500 mg/dose)",
"        <sup>",
"         [3]",
"        </sup>",
"       </td>",
"       <td>",
"        <p>",
"         <em>",
"          Induction of remission:",
"         </em>",
"        </p>",
"        250 to 500 mg PO, twice or three times daily",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        <p>",
"         Induction of remission in perianal or mucosal disease.",
"        </p>",
"        Treatment of infectious complications (eg, abdominal or perianal abscess).",
"       </td>",
"       <td>",
"        <p>",
"         Hypersensitivity reactions.",
"        </p>",
"        <p>",
"         Risk of C. difficile colitis.",
"        </p>",
"        Tendon inflammation and rupture; arthropathy, photosensitivity.",
"       </td>",
"       <td>",
"        Moderate efficacy. Avoid in pregnancy.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Metronidazole",
"       </td>",
"       <td>",
"        Flagyl",
"       </td>",
"       <td>",
"        <p>",
"         <em>",
"          Induction of remission:",
"         </em>",
"        </p>",
"        <p>",
"         Dose not established in children",
"         <sup>",
"          &loz;",
"         </sup>",
"        </p>",
"        <p>",
"         <em>",
"          Treatment of infectious complications:",
"         </em>",
"        </p>",
"        20 to 30 mg/kg/day PO, divided in three doses (up to 500 mg/dose)",
"        <sup>",
"         [3,8]",
"        </sup>",
"       </td>",
"       <td>",
"        <p>",
"         <em>",
"          Induction of remission:",
"         </em>",
"        </p>",
"        250 to 500 mg PO, twice or three times daily",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        Same as ciprofloxacin, postoperative recurrence.",
"       </td>",
"       <td>",
"        Nausea, disulfiram reaction (occurs with ingestion of alcohol), alteration of taste. Peripheral neuropathy often develops with chronic use.",
"       </td>",
"       <td>",
"        <p>",
"         May delay recurrence of mucosal disease after surgical resection.",
"        </p>",
"        Avoid in pregnancy.",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     BUN: blood urea nitrogen; CBC: complete blood count; LFTs: liver function tests (ie, alanine aminotransferase, ALT, and aspartate aminotransferase, AST); NG: nasogastric; NPO: nil per os (nothing by mouth); 6-MP: 6-mercaptopurine; PO: per os (by mouth); IM: intramuscular; SQ: subcutaneous route of administration.",
"     <br/>",
"     * Outside of the United States, mesalamine is known as mesalazine.",
"     <br/>",
"     &Delta; Some patients (especially younger children) may benefit from 6-MP doses above this range (eg, up to 2 mg/kg/day), if appropriately monitored for toxicity.",
"     <br/>",
"     <span class=\"lozenge\">",
"      &loz;",
"     </span>",
"     There is some evidence in adults that ciprofloxacin and/or metronidazole have modest efficacy to induce remission in Crohn's disease; typical doses used for this purpose are 10 to 20 mg/kg/day, divided in two or three doses, with courses ranging from two to six months.",
"     <sup>",
"      [9]",
"     </sup>",
"     The efficacy and doses of these antibiotics for induction of remission in children with Crohn's disease have not been established. (Refer to topic review on antibiotics for treatment of inflammatory bowel disease).",
"     <br/>",
"     &sect; Although metronidazole is defined by the US Food and Drug Adminstration as a Pregnancy risk catogory B drug, we are reluctant to prescribe it during pregnancy because existing safety information is based on short duration of treatment.",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br/>",
"     <ol>",
"      <li>",
"       Escher JC, European Collaborative Research Group on Budesonide in Paediatric IBD. Budesonide versus prednisolone for the treatment of active Crohn's disease in children: a randomized, double-blind, controlled, multicentre trial. Eur J Gastroenterol Hepatol 2004; 16:47.",
"      </li>",
"      <li>",
"       Levine A, Broide E, Stein M, et al. Evaluation of oral budesonide for treatment of mild and moderate exacerbations of Crohn's disease in children. J Pediatr 2002; 140:75.",
"      </li>",
"      <li>",
"       Rufo PA, Denson LA, Sylvester FA, et al. Health supervision in the management of children and adolescents with IBD: NASPGHAN recommendations. J Pediatr Gastroenterol Nutr 2012; 55:93.",
"      </li>",
"      <li>",
"       Levesque BG, Loftus EV. Initiating azathioprine for Crohn's disease. Clin Gastroenterol Hepatol 2012; 10:460.",
"      </li>",
"      <li>",
"       Stevens MC, Baldassano RN, York A, et al. The bioavailability of oral methotrexate in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2005; 40:445.",
"      </li>",
"      <li>",
"       Hyams JS, Griffiths A, Markowitz J, et al. Safety and efficacy of adalimumab for moderate to severe Crohn's disease in children. Gastroenterology 2012; 143:365.",
"      </li>",
"      <li>",
"       Panaccione R, Colombel JF, Sandborn WJ, et al. Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn's disease. Aliment Pharmacol Ther 2010; 31:1296.",
"      </li>",
"      <li>",
"       Levine A, Turner D. Combined azithromycin and metronidazole therapy is effective in inducing remission in pediatric Crohn's disease. J Crohns Colitis 2011; 5:222.",
"      </li>",
"      <li>",
"       Lichtenstein GR, Hanauer SB, Sandborn WJ, Practice Parameters Committee of American College of Gastroenterology. Management of Crohn's disease in adults. Am J Gastroenterol 2009; 104:465.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_16_28928=[""].join("\n");
var outline_f28_16_28928=null;
var title_f28_16_28929="Postpneumonectomy empyema PA";
var content_f28_16_28929=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F80828&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F80828&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 624px\">",
"   <div class=\"ttl\">",
"    Late postpneumonectomy empyema and bronchopleural fistula",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 604px; height: 319px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chest radiograph of a patient three months (left) and 12 months (right) after surgery shows a new air-fluid level (arrow) consistent with an empyema and bronchopleural fistula.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Richard Irwin, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_16_28929=[""].join("\n");
var outline_f28_16_28929=null;
var title_f28_16_28930="Multiple solar purpura";
var content_f28_16_28930=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F70793&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F70793&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Solar purpura",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple purpuric patches are present on the arm.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_16_28930=[""].join("\n");
var outline_f28_16_28930=null;
var title_f28_16_28931="Phrenic nerve invasion";
var content_f28_16_28931=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F71610&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F71610&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Phrenic nerve invasion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 314px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Coronal multiplanar reformation of a CT of the thorax shows a left upper lobe tumor with extension to the hilum and mediastinum. There is involvement of the left phrenic nerve with elevation of the left hemidiaphragm.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_16_28931=[""].join("\n");
var outline_f28_16_28931=null;
var title_f28_16_28932="Goiter MRI";
var content_f28_16_28932=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F50840&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F50840&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Coronal (top) and axial (bottom) MRI scan of a giant intrathoracic goiter",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 402px; height: 537px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    There is marked tracheal narrowing; venous collaterals in the subcutaneous fat of the anterior chest wall suggest chronic superior vena cava (SVC) compression.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_16_28932=[""].join("\n");
var outline_f28_16_28932=null;
var title_f28_16_28933="Bullous impetigo pediatric";
var content_f28_16_28933=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F59762&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F59762&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Bullous impetigo",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 379px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_16_28933=[""].join("\n");
var outline_f28_16_28933=null;
var title_f28_16_28934="Olanzapine: Patient drug information";
var content_f28_16_28934=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Olanzapine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"     see \"Olanzapine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/24/34185?source=see_link\">",
"     see \"Olanzapine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F203156\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      ZyPREXA&reg;;",
"     </li>",
"     <li>",
"      ZyPREXA&reg; IntraMuscular;",
"     </li>",
"     <li>",
"      ZyPREXA&reg; Relprevv&trade;;",
"     </li>",
"     <li>",
"      ZyPREXA&reg; Zydis&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F203157\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Olanzapine ODT&reg;;",
"     </li>",
"     <li>",
"      Apo-Olanzapine&reg;;",
"     </li>",
"     <li>",
"      Ava-Olanzapine;",
"     </li>",
"     <li>",
"      CO Olanzapine;",
"     </li>",
"     <li>",
"      CO Olanzapine ODT;",
"     </li>",
"     <li>",
"      Mylan-Olanzapine;",
"     </li>",
"     <li>",
"      Olanzapine ODT;",
"     </li>",
"     <li>",
"      PHL-Olanzapine;",
"     </li>",
"     <li>",
"      PHL-Olanzapine ODT;",
"     </li>",
"     <li>",
"      PMS-Olanzapine;",
"     </li>",
"     <li>",
"      PMS-Olanzapine ODT;",
"     </li>",
"     <li>",
"      Riva-Olanzapine;",
"     </li>",
"     <li>",
"      Riva-Olanzapine ODT;",
"     </li>",
"     <li>",
"      Sandoz-Olanzapine;",
"     </li>",
"     <li>",
"      Sandoz-Olanzapine ODT;",
"     </li>",
"     <li>",
"      Teva-Olanzapine;",
"     </li>",
"     <li>",
"      Teva-Olanzapine OD;",
"     </li>",
"     <li>",
"      Zyprexa&reg;;",
"     </li>",
"     <li>",
"      Zyprexa&reg; Intramuscular;",
"     </li>",
"     <li>",
"      Zyprexa&reg; Zydis&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10028644\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700570",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a higher chance of death in older adults who take this drug for mental problems caused by dementia. Most of the deaths were linked to heart disease or infection. This drug is not approved to treat mental problems caused by dementia.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s3689022",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Zyprexa&reg; Relprevv&trade;:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3689042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause you to be very tired, agitated, and confused after you get it. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3689023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may only get this drug from the Zyprexa&reg; Relprevv&trade; Patient Care Program.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10028646\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691951",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat mania.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692035",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat psychosis. It may take 6 weeks to see the full effect.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691808",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat low mood (depression).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10028645\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702625",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to olanzapine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10028650\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697204",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor. This drug may raise blood sugar.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a family history of high blood sugar (diabetes), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697268",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high cholesterol or triglyceride levels, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are overweight, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697320",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have Parkinson's disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697329",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have PKU, talk with your doctor. Some products have phenylalanine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have seizures, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698422",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check your blood sugar as you have been told by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696701",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Be careful in hot weather. Drink lots of fluids to stop fluid loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10028651\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698279",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698143",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High cholesterol level.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698155",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hostility.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698392",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698139",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High blood sugar. This most often goes back to normal when drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698162",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to sleep.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10028653\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699075",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low mood (depression), thoughts of killing yourself, nervousness, emotional ups and downs, thinking that is not normal, anxiety, or lack of interest in life.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699057",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Big change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699055",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shakiness, trouble moving around, or stiffness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698985",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not sweating during activities or in warm temperatures.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699003",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Seizures.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698644",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble swallowing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699112",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698963",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       More trips to the bathroom, more thirst, or weight loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698670",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, if you get pregnant while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10028648\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705488",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral-disintegrating tablet:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694164",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not push the tablet out of the foil when opening. Use dry hands to take it from the foil. Place on your tongue and let it melt. Water is not needed. Do not swallow it whole. Do not chew, break, or crush it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695985",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a muscle.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10028649\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10028654\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use oral-disintegrating tablet right after opening. Throw away any part of opened pouch that is not used.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699585",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       The shot will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10028655\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10921 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-17F8E0A872-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_16_28934=[""].join("\n");
var outline_f28_16_28934=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203156\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203157\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028644\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028646\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028645\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028650\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028651\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028653\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028648\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028649\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028654\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028655\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=related_link\">",
"      Olanzapine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/24/34185?source=related_link\">",
"      Olanzapine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_16_28935="Epidemiology and pathogenesis of premenstrual syndrome and premenstrual dysphoric disorder";
var content_f28_16_28935=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology and pathogenesis of premenstrual syndrome and premenstrual dysphoric disorder",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/16/28935/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/16/28935/contributors\">",
"     Kimberly A Yonkers, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/16/28935/contributors\">",
"     Robert F Casper, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/16/28935/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/16/28935/contributors\">",
"     Robert L Barbieri, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/16/28935/contributors\">",
"     William F Crowley, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/16/28935/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/16/28935/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/16/28935/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 17, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The premenstrual syndrome (PMS) and the more severe variant of premenstrual dysphoric disorder (PMDD), also called late luteal phase dysphoric disorder in previous versions of the Diagnostic and Statistical Manual (DSM), are characterized by the presence of physical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    behavioral symptoms that occur repetitively in the second half of the menstrual cycle and often the first few days of menses. The symptoms of PMS or PMDD are severe enough that they interfere with some aspects of the woman's life (eg, family or other social relations, work in or outside the home, etc). The most common physical manifestation is abdominal bloating [",
"    <a class=\"abstract\" href=\"UTD.htm?28/16/28935/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Breast tenderness and headaches are also common (",
"    <a class=\"graphic graphic_table graphicRef86227 \" href=\"UTD.htm?19/49/20240\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/52/39751?source=see_link\">",
"     \"Clinical manifestations and diagnosis of premenstrual syndrome and premenstrual dysphoric disorder\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis of PMDD is discussed in greater detail elsewhere. The clinical manifestations, diagnosis, and treatment of",
"    <span class=\"nowrap\">",
"     PMS/PMDD",
"    </span>",
"    are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/52/39751?source=see_link\">",
"     \"Clinical manifestations and diagnosis of premenstrual syndrome and premenstrual dysphoric disorder\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/10/3241?source=see_link\">",
"     \"Treatment of premenstrual syndrome and premenstrual dysphoric disorder\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Premenstrual dysphoric disorder (PMDD), as defined by the American Psychiatric Association DSM-IV, can be differentiated from PMS by the presence of at least one affective symptom, such as mood swings, irritability,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    depression [",
"    <a class=\"abstract\" href=\"UTD.htm?28/16/28935/abstract/3\">",
"     3",
"    </a>",
"    ]. Premenstrual symptoms are common, affecting up to 75 percent of women with regular menstrual cycles. Clinically significant PMS occurs in 3 to 8 percent of women [",
"    <a class=\"abstract\" href=\"UTD.htm?28/16/28935/abstract/1,4\">",
"     1,4",
"    </a>",
"    ], while PMDD affects about 2 percent of women.",
"   </p>",
"   <p>",
"    The prevalence of PMS in the population has been overestimated because of the failure to apply strict inclusion criteria. Estimates as high as 80 percent have been reported, based upon the inclusion of women who have some form of premenstrual mood or physical symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?28/16/28935/abstract/5\">",
"     5",
"    </a>",
"    ]. The problem with these estimates is that they do not consider whether symptoms are moderate to severe or if they interfere with functioning. When one applies strict inclusion criteria for PMDD, estimates are around 2 percent, as illustrated by three community studies that used prospective ratings to determine the diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/16/28935/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/52/39751?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical manifestations and diagnosis of premenstrual syndrome and premenstrual dysphoric disorder\", section on 'Evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Premenstrual syndrome has been described in diverse cultural settings, even among women who are not generally aware of the disorder. As an example, similar rates of the disorder have been reported in Mediterranean countries, the Middle East, Iceland, Kenya, and New Zealand [",
"    <a class=\"abstract\" href=\"UTD.htm?28/16/28935/abstract/9-12\">",
"     9-12",
"    </a>",
"    ]. In an international survey of 7226 women in Europe, South America, and Asia, the frequency of PMS symptoms was similar across countries and regions, but women in some countries, such as Pakistan, were less familiar with the term PMS when compared with European women [",
"    <a class=\"abstract\" href=\"UTD.htm?28/16/28935/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In another study, black women were less likely to experience PMDD than white women. The prevalence of PMDD was 2.9 percent among black women versus 4.4 percent among white women [",
"    <a class=\"abstract\" href=\"UTD.htm?28/16/28935/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H255917\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of studies have explored the role of genetic factors in the predisposition to PMS and PMDD. The majority have found a strong genetic component [",
"    <a class=\"abstract\" href=\"UTD.htm?28/16/28935/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. In one of the largest twin studies, premenstrual symptoms were found to be highly heritable, although there was also contribution from environmental factors. Developmental factors and a predisposition toward the development of other mood disorders did not strongly influence the risk of having premenstrual symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?28/16/28935/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other possible risk factors for the development of PMDD include lower education and cigarette smoking [",
"    <a class=\"abstract\" href=\"UTD.htm?28/16/28935/abstract/17\">",
"     17",
"    </a>",
"    ], a history of traumatic events or anxiety disorder, and higher &ldquo;daily hassle scores&rdquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?28/16/28935/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Preliminary evidence suggests that risk for premenstrual dysphoric disorder is associated with genetic variation in ESR1, the estrogen receptor alpha gene [",
"    <a class=\"abstract\" href=\"UTD.htm?28/16/28935/abstract/19,20\">",
"     19,20",
"    </a>",
"    ].",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H255765\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The available evidence suggests that PMS is a disorder triggered by changes in gonadal steroids during the luteal phase in susceptible women. This is thought to result from the interaction of cyclic changes in ovarian steroids with central neurotransmitters. The neurotransmitter that is most implicated in the manifestations of PMS is serotonin, although there is evidence to implicate beta-endorphin, gamma-aminobutyric acid (GABA), and the autonomic nervous system.",
"   </p>",
"   <p>",
"    In addition, some of the systemic manifestations, such as the feeling of bloating, may be produced by peripheral mechanisms. There may also be a role for trace elements in the pathogenesis of PMS.",
"    <br/>",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Ovarian steroids",
"    </span>",
"    &nbsp;&mdash;&nbsp;A central role for ovarian steroids in the etiology of PMS is strongly supported by a series of experiments in which \"medical ovariectomy\" using a GnRH agonist led to dramatic resolution of PMS symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?28/16/28935/abstract/5,21\">",
"     5,21",
"    </a>",
"    ]. However, cyclic changes in ovarian steroids do",
"    <strong>",
"     not",
"    </strong>",
"    appear to be the sole cause of PMS symptoms, as daily serum estrogen and progesterone concentrations are similar in women with",
"    <span class=\"nowrap\">",
"     PMS/PMDD",
"    </span>",
"    and controls [",
"    <a class=\"abstract\" href=\"UTD.htm?28/16/28935/abstract/22,23\">",
"     22,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Deficiencies in progesterone, progesterone metabolites (some of which have anxiolytic properties), and the progesterone receptor have also been proposed as possible mediators of",
"    <span class=\"nowrap\">",
"     PMS/PMDD.",
"    </span>",
"    However, as noted, serum progesterone concentrations are normal in women with PMS. In addition, serum concentrations of the progesterone metabolites, allopregnanolone and pregnenolone, are similar in women with PMS compared with normal women [",
"    <a class=\"abstract\" href=\"UTD.htm?28/16/28935/abstract/24\">",
"     24",
"    </a>",
"    ]. Lastly, blocking the effect of progesterone in the luteal phase with a progesterone receptor antagonist (mifepristone) does not alleviate the symptoms of PMS [",
"    <a class=\"abstract\" href=\"UTD.htm?28/16/28935/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although women with PMS have normal concentrations of serum estrogen and progesterone, they may have an",
"    <strong>",
"     abnormal response",
"    </strong>",
"    to normal hormonal changes. In a double blind crossover trial of 20 patients with PMS, for example, the 10 women who received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/41/4760?source=see_link\">",
"     leuprolide",
"    </a>",
"    had a significant decrease in symptoms compared with women who received placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?28/16/28935/abstract/21\">",
"     21",
"    </a>",
"    ]. However, administration of either estrogen or progesterone in addition to leuprolide resulted in a significant recurrence of symptoms. In contrast, no changes in mood occurred in 15 normal women who received the same regimen, or in five women with PMS who were given leuprolide plus placebo postmenopausal hormone therapy. These findings suggest that gonadal steroids are necessary, but not sufficient, to cause symptoms of PMS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Neurotransmitters",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon in vitro data and animal studies, there is evidence that cyclic fluctuations in circulating estrogen and progesterone cause marked changes in the opioid [",
"    <a class=\"abstract\" href=\"UTD.htm?28/16/28935/abstract/26\">",
"     26",
"    </a>",
"    ], GABA [",
"    <a class=\"abstract\" href=\"UTD.htm?28/16/28935/abstract/27\">",
"     27",
"    </a>",
"    ], and serotonin [",
"    <a class=\"abstract\" href=\"UTD.htm?28/16/28935/abstract/28\">",
"     28",
"    </a>",
"    ] systems. At one time, the most attractive hypothesis for the pathogenesis of PMS was that the symptom constellation resulted from steroid-induced changes in the opioid system. Differences in peripheral beta-endorphin levels have been observed in women with PMS compared with controls in the periovulatory and premenstrual phases of the cycle [",
"    <a class=\"abstract\" href=\"UTD.htm?28/16/28935/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]. However, attempts to confirm these peripheral findings with provocative tests to probe central opiate activity have not been successful [",
"    <a class=\"abstract\" href=\"UTD.htm?28/16/28935/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The potential role of the GABAergic system in PMS has not been extensively investigated. However, in vitro data suggesting this system is modulated by progestin have been corroborated indirectly by the observation that the benzodiazepine",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/31/31224?source=see_link\">",
"     alprazolam",
"    </a>",
"    is effective in treating PMS symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?28/16/28935/abstract/33\">",
"     33",
"    </a>",
"    ]. In addition, low levels of the progesterone metabolite allopregnanolone, which enhances GABA-A receptor function and possesses anxiolytic effects, was thought to play an effect [",
"    <a class=\"abstract\" href=\"UTD.htm?28/16/28935/abstract/34\">",
"     34",
"    </a>",
"    ]. However, data on whether levels differ between symptomatic and asymptomatic women have been conflicting [",
"    <a class=\"abstract\" href=\"UTD.htm?28/16/28935/abstract/24,34\">",
"     24,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At the present time, the evidence is most supportive for a major role of serotonin in the etiology of PMS. This can be illustrated by the following findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with PMS, when compared to controls, have lower whole blood serotonin and platelet serotonin uptake and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/41/41624?source=see_link\">",
"       imipramine",
"      </a>",
"      binding during the luteal phase of the menstrual cycle [",
"      <a class=\"abstract\" href=\"UTD.htm?28/16/28935/abstract/35-39\">",
"       35-39",
"      </a>",
"      ], and higher cerebrospinal fluid levels of the serotonin metabolite 5-hydroxyindoleacetic acid as compared with the dopamine metabolite homovanillic acid [",
"      <a class=\"abstract\" href=\"UTD.htm?28/16/28935/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The symptoms of PMS are ameliorated by the serotonin agonist fenfluramine [",
"      <a class=\"abstract\" href=\"UTD.htm?28/16/28935/abstract/41\">",
"       41",
"      </a>",
"      ], and aggravated by acute depletion of the serotonin precursor tryptophan [",
"      <a class=\"abstract\" href=\"UTD.htm?28/16/28935/abstract/42\">",
"       42",
"      </a>",
"      ]. In addition, serotonin reuptake inhibitors, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"       fluoxetine",
"      </a>",
"      , are one of the most effective drugs for the treatment of PMS.",
"     </li>",
"     <li>",
"      Administration of metergoline, a serotonin antagonist, to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"       fluoxetine",
"      </a>",
"      -treated women with PMDD causes a return of mood symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?28/16/28935/abstract/43\">",
"       43",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/10/3241?source=see_link\">",
"       \"Treatment of premenstrual syndrome and premenstrual dysphoric disorder\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Vitamins and minerals",
"    </span>",
"    &nbsp;&mdash;&nbsp;Attempts to detect vitamin deficiency in women with PMS have been unsuccessful. No differences in vitamin E, vitamin A, or vitamin B6 levels have been found [",
"    <a class=\"abstract\" href=\"UTD.htm?28/16/28935/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. However, in one cohort study, women with high intakes of the B vitamins thiamine and riboflavin from food sources were less likely to develop PMS than those who had low intakes [",
"    <a class=\"abstract\" href=\"UTD.htm?28/16/28935/abstract/46\">",
"     46",
"    </a>",
"    ]. No significant associations were seen between PMS and dietary intake of other B vitamins. Intake of B vitamins from supplements was not associated with a lower risk of PMS. Treatment with vitamin B6 was reported to be more effective than placebo in two systematic reviews; their conclusions were limited by the low quality of most of the trials [",
"    <a class=\"abstract\" href=\"UTD.htm?28/16/28935/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/10/3241?source=see_link\">",
"     \"Treatment of premenstrual syndrome and premenstrual dysphoric disorder\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several reports have suggested that patients with PMS may have lower levels of intracellular magnesium over the course of the menstrual cycle [",
"    <a class=\"abstract\" href=\"UTD.htm?28/16/28935/abstract/49,50\">",
"     49,50",
"    </a>",
"    ], although studies of altered serum levels have produced inconsistent results [",
"    <a class=\"abstract\" href=\"UTD.htm?28/16/28935/abstract/51-53\">",
"     51-53",
"    </a>",
"    ]. One well-conducted study showed an improvement in total PMS symptom scores and affective symptoms with the administration of magnesium pyrrolidone carboxylic acid (360 mg three times daily in the second half of the menstrual cycle) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/16/28935/abstract/54\">",
"     54",
"    </a>",
"    ]. These findings must be confirmed before the use of magnesium can be advocated for the treatment of PMS. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/10/3241?source=see_link\">",
"     \"Treatment of premenstrual syndrome and premenstrual dysphoric disorder\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?41/10/42146?source=see_link\">",
"       \"Patient information: Premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?13/12/13510?source=see_link\">",
"       \"Patient information: Premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H151092800\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The premenstrual syndrome (PMS) is characterized by the presence of",
"      <strong>",
"       both",
"      </strong>",
"      &nbsp;physical and behavioral symptoms that occur repetitively in the second half of the menstrual cycle and interfere with some aspects of the woman's life. Premenstrual dysphoric disorder (PMDD) is a severe form of PMS in which symptoms of anger, irritability, and internal tension are prominent. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/52/39751?source=see_link\">",
"       \"Clinical manifestations and diagnosis of premenstrual syndrome and premenstrual dysphoric disorder\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Clinically significant PMS affects 3 to 8 percent of women with regular menstrual cycles, while true PMDD affects only about 2 percent of women in this group. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Both genetic and environmental factors play a role in the development of premenstrual symptoms. (See",
"      <a class=\"local\" href=\"#H255917\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Preliminary evidence suggests that risk for premenstrual dysphoric disorder is associated with genetic variation in ESR1, the estrogen receptor alpha gene. (See",
"      <a class=\"local\" href=\"#H255917\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other possible risk factors for the development of PMDD include lower education and cigarette smoking, and a history of traumatic events or anxiety disorder. (See",
"      <a class=\"local\" href=\"#H255917\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the normal menstrual cycle, cyclic fluctuations in luteal phase estrogen and progesterone concentrations cause marked changes in neurotransmitters, most notably, the serotonin system. (See",
"      <a class=\"local\" href=\"#H255765\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Women with",
"      <span class=\"nowrap\">",
"       PMS/PMDD",
"      </span>",
"      have normal concentrations of serum estrogen and progesterone, but they appear to have an",
"      <strong>",
"       abnormal neurotransmitter response",
"      </strong>",
"      (in particular, serotonin) to luteal phase hormonal changes. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Neurotransmitters'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among the neurotransmitters, serotonin appears to play the most important role in the etiology of",
"      <span class=\"nowrap\">",
"       PMS/PMDD,",
"      </span>",
"      as illustrated by the following observations:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Selective serotonin reuptake inhibitors are the most effective therapy for the disorder. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/10/3241?source=see_link\">",
"       \"Treatment of premenstrual syndrome and premenstrual dysphoric disorder\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      When women with PMDD who are symptom-free on SSRI therapy are subsequently treated with a serotonin antagonist, they experience a return in their mood symptoms. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Neurotransmitters'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Limited data suggest that high intake of vitamin B6 (from the diet, but not from supplements) is associated with a lower risk of",
"      <span class=\"nowrap\">",
"       PMS/PMDD.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Vitamins and minerals'",
"      </a>",
"      above.) The efficacy of B6 for the treatment of",
"      <span class=\"nowrap\">",
"       PMS/PMDD",
"      </span>",
"      is not well established. However, systematic reviews of low quality studies have reported that administration of B6 in doses up to 100",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      is more effective than placebo for the treatment of this disorder. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/10/3241?source=see_link\">",
"       \"Treatment of premenstrual syndrome and premenstrual dysphoric disorder\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/16/28935/abstract/1\">",
"      Deuster PA, Adera T, South-Paul J. Biological, social, and behavioral factors associated with premenstrual syndrome. Arch Fam Med 1999; 8:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/16/28935/abstract/2\">",
"      Hartlage SA, Freels S, Gotman N, Yonkers K. Criteria for premenstrual dysphoric disorder: secondary analyses of relevant data sets. Arch Gen Psychiatry 2012; 69:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/16/28935/abstract/3\">",
"      Epperson CN, Steiner M, Hartlage SA, et al. Premenstrual dysphoric disorder: evidence for a new category for DSM-5. Am J Psychiatry 2012; 169:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/16/28935/abstract/4\">",
"      Borenstein J, Chiou CF, Dean B, et al. Estimating direct and indirect costs of premenstrual syndrome. J Occup Environ Med 2005; 47:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/16/28935/abstract/5\">",
"      Budeiri DJ, Li Wan Po A, Dornan JC. Clinical trials of treatments of premenstrual syndrome: entry criteria and scales for measuring treatment outcomes. Br J Obstet Gynaecol 1994; 101:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/16/28935/abstract/6\">",
"      Rivera-Tovar AD, Frank E. Late luteal phase dysphoric disorder in young women. Am J Psychiatry 1990; 147:1634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/16/28935/abstract/7\">",
"      Soares CN, Cohen LS, Otto MW, Harlow BL. Characteristics of women with premenstrual dysphoric disorder (PMDD) who did or did not report history of depression: a preliminary report from the Harvard Study of Moods and Cycles. J Womens Health Gend Based Med 2001; 10:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/16/28935/abstract/8\">",
"      Gehlert S, Song IH, Chang CH, Hartlage SA. The prevalence of premenstrual dysphoric disorder in a randomly selected group of urban and rural women. Psychol Med 2009; 39:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/16/28935/abstract/9\">",
"      Raja SN, Feehan M, Stanton WR, McGee R. Prevalence and correlates of the premenstrual syndrome in adolescence. J Am Acad Child Adolesc Psychiatry 1992; 31:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/16/28935/abstract/10\">",
"      Monagle L, Dan A, Krogh V, et al. Perimenstrual symptom prevalence rates: an Italian-American comparison. Am J Epidemiol 1993; 138:1070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/16/28935/abstract/11\">",
"      Rupani NP, Lema VM. Premenstrual tension among nurses in Nairobi, Kenya. East Afr Med J 1993; 70:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/16/28935/abstract/12\">",
"      Sveinsd&oacute;ttir H, Marteinsd&oacute;ttir G. Retrospective assessment of premenstrual changes in Icelandic women. Health Care Women Int 1991; 12:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/16/28935/abstract/13\">",
"      Dennerstein L, Lehert P, Heinemann K. Global study of women's experiences of premenstrual symptoms and their effects on daily life. Menopause Int 2011; 17:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/16/28935/abstract/14\">",
"      Pilver CE, Kasl S, Desai R, Levy BR. Health advantage for black women: patterns in pre-menstrual dysphoric disorder. Psychol Med 2011; 41:1741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/16/28935/abstract/15\">",
"      Kendler KS, Karkowski LM, Corey LA, Neale MC. Longitudinal population-based twin study of retrospectively reported premenstrual symptoms and lifetime major depression. Am J Psychiatry 1998; 155:1234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/16/28935/abstract/16\">",
"      Treloar SA, Heath AC, Martin NG. Genetic and environmental influences on premenstrual symptoms in an Australian twin sample. Psychol Med 2002; 32:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/16/28935/abstract/17\">",
"      Cohen LS, Soares CN, Otto MW, et al. Prevalence and predictors of premenstrual dysphoric disorder (PMDD) in older premenopausal women. The Harvard Study of Moods and Cycles. J Affect Disord 2002; 70:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/16/28935/abstract/18\">",
"      Perkonigg A, Yonkers KA, Pfister H, et al. Risk factors for premenstrual dysphoric disorder in a community sample of young women: the role of traumatic events and posttraumatic stress disorder. J Clin Psychiatry 2004; 65:1314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/16/28935/abstract/19\">",
"      Miller A, Vo H, Huo L, et al. Estrogen receptor alpha (ESR-1) associations with psychological traits in women with PMDD and controls. J Psychiatr Res 2010; 44:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/16/28935/abstract/20\">",
"      Huo L, Straub RE, Roca C, et al. Risk for premenstrual dysphoric disorder is associated with genetic variation in ESR1, the estrogen receptor alpha gene. Biol Psychiatry 2007; 62:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/16/28935/abstract/21\">",
"      Schmidt PJ, Nieman LK, Danaceau MA, et al. Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome. N Engl J Med 1998; 338:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/16/28935/abstract/22\">",
"      Andersch B, Abrahamsson L, Wendestam C, et al. Hormone profile in premenstrual tension: effects of bromocriptine and diuretics. Clin Endocrinol (Oxf) 1979; 11:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/16/28935/abstract/23\">",
"      Taylor JW. Plasma progesterone, oestradiol 17 beta and premenstrual symptoms. Acta Psychiatr Scand 1979; 60:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/16/28935/abstract/24\">",
"      Schmidt PJ, Purdy RH, Moore PH Jr, et al. Circulating levels of anxiolytic steroids in the luteal phase in women with premenstrual syndrome and in control subjects. J Clin Endocrinol Metab 1994; 79:1256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/16/28935/abstract/25\">",
"      Chan AF, Mortola JF, Wood SH, Yen SS. Persistence of premenstrual syndrome during low-dose administration of the progesterone antagonist RU 486. Obstet Gynecol 1994; 84:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/16/28935/abstract/26\">",
"      Wardlaw SL, Thoron L, Frantz AG. Effects of sex steroids on brain beta-endorphin. Brain Res 1982; 245:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/16/28935/abstract/27\">",
"      Majewska MD, Harrison NL, Schwartz RD, et al. Steroid hormone metabolites are barbiturate-like modulators of the GABA receptor. Science 1986; 232:1004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/16/28935/abstract/28\">",
"      Bethea CL. Regulation of progestin receptors in raphe neurons of steroid-treated monkeys. Neuroendocrinology 1994; 60:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/16/28935/abstract/29\">",
"      Chuong CJ, Coulam CB, Kao PC, et al. Neuropeptide levels in premenstrual syndrome. Fertil Steril 1985; 44:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/16/28935/abstract/30\">",
"      Chuong CJ, Hsi BP, Gibbons WE. Periovulatory beta-endorphin levels in premenstrual syndrome. Obstet Gynecol 1994; 83:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/16/28935/abstract/31\">",
"      Giannini AJ, Martin DM, Turner CE. Beta-endorphin decline in late luteal phase dysphoric disorder. Int J Psychiatry Med 1990; 20:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/16/28935/abstract/32\">",
"      Chuong CJ, Hsi BP. Effect of naloxone on luteinizing hormone secretion in premenstrual syndrome. Fertil Steril 1994; 61:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/16/28935/abstract/33\">",
"      Smith S, Rinehart JS, Ruddock VE, Schiff I. Treatment of premenstrual syndrome with alprazolam: results of a double-blind, placebo-controlled, randomized crossover clinical trial. Obstet Gynecol 1987; 70:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/16/28935/abstract/34\">",
"      Rapkin AJ, Morgan M, Goldman L, et al. Progesterone metabolite allopregnanolone in women with premenstrual syndrome. Obstet Gynecol 1997; 90:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/16/28935/abstract/35\">",
"      Rapkin AJ, Edelmuth E, Chang LC, et al. Whole-blood serotonin in premenstrual syndrome. Obstet Gynecol 1987; 70:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/16/28935/abstract/36\">",
"      Taylor DL, Mathew RJ, Ho BT, Weinman ML. Serotonin levels and platelet uptake during premenstrual tension. Neuropsychobiology 1984; 12:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/16/28935/abstract/37\">",
"      Ashby CR Jr, Carr LA, Cook CL, et al. Alteration of platelet serotonergic mechanisms and monoamine oxidase activity in premenstrual syndrome. Biol Psychiatry 1988; 24:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/16/28935/abstract/38\">",
"      Steege JF, Stout AL, Knight DL, Nemeroff CB. Reduced platelet tritium-labeled imipramine binding sites in women with premenstrual syndrome. Am J Obstet Gynecol 1992; 167:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/16/28935/abstract/39\">",
"      Rojansky N, Halbreich U, Zander K, et al. Imipramine receptor binding and serotonin uptake in platelets of women with premenstrual changes. Gynecol Obstet Invest 1991; 31:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/16/28935/abstract/40\">",
"      Eriksson E, Alling C, Andersch B, et al. Cerebrospinal fluid levels of monoamine metabolites. A preliminary study of their relation to menstrual cycle phase, sex steroids, and pituitary hormones in healthy women and in women with premenstrual syndrome. Neuropsychopharmacology 1994; 11:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/16/28935/abstract/41\">",
"      Brzezinski AA, Wurtman JJ, Wurtman RJ, et al. d-Fenfluramine suppresses the increased calorie and carbohydrate intakes and improves the mood of women with premenstrual depression. Obstet Gynecol 1990; 76:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/16/28935/abstract/42\">",
"      Menkes DB, Coates DC, Fawcett JP. Acute tryptophan depletion aggravates premenstrual syndrome. J Affect Disord 1994; 32:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/16/28935/abstract/43\">",
"      Roca CA, Schmidt PJ, Smith MJ, et al. Effects of metergoline on symptoms in women with premenstrual dysphoric disorder. Am J Psychiatry 2002; 159:1876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/16/28935/abstract/44\">",
"      Chuong CJ, Dawson EB, Smith ER. Vitamin A levels in premenstrual syndrome. Fertil Steril 1990; 54:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/16/28935/abstract/45\">",
"      Chuong CJ, Dawson EB, Smith ER. Vitamin E levels in premenstrual syndrome. Am J Obstet Gynecol 1990; 163:1591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/16/28935/abstract/46\">",
"      Chocano-Bedoya PO, Manson JE, Hankinson SE, et al. Dietary B vitamin intake and incident premenstrual syndrome. Am J Clin Nutr 2011; 93:1080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/16/28935/abstract/47\">",
"      Wyatt KM, Dimmock PW, Jones PW, Shaughn O'Brien PM. Efficacy of vitamin B-6 in the treatment of premenstrual syndrome: systematic review. BMJ 1999; 318:1375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/16/28935/abstract/48\">",
"      Whelan AM, Jurgens TM, Naylor H. Herbs, vitamins and minerals in the treatment of premenstrual syndrome: a systematic review. Can J Clin Pharmacol 2009; 16:e407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/16/28935/abstract/49\">",
"      Sherwood RA, Rocks BF, Stewart A, Saxton RS. Magnesium and the premenstrual syndrome. Ann Clin Biochem 1986; 23 ( Pt 6):667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/16/28935/abstract/50\">",
"      Facchinetti, F, Borella, P, Fioroni, L, et al. Reduction of monocyte's magnesium in patients affected by premenstrual syndrome. J Psychosom Obstet Gynaecol 1990; 11:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/16/28935/abstract/51\">",
"      Rosenstein DL, Elin RJ, Hosseini JM, et al. Magnesium measures across the menstrual cycle in premenstrual syndrome. Biol Psychiatry 1994; 35:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/16/28935/abstract/52\">",
"      Cerin A, Collins A, Landgren BM, Eneroth P. Hormonal and biochemical profiles of premenstrual syndrome. Treatment with essential fatty acids. Acta Obstet Gynecol Scand 1993; 72:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/16/28935/abstract/53\">",
"      Posaci C, Erten O, Uren A, Acar B. Plasma copper, zinc and magnesium levels in patients with premenstrual tension syndrome. Acta Obstet Gynecol Scand 1994; 73:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/16/28935/abstract/54\">",
"      Facchinetti F, Borella P, Sances G, et al. Oral magnesium successfully relieves premenstrual mood changes. Obstet Gynecol 1991; 78:177.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7380 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-194.187.108.93-69C8FD1B77-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_16_28935=[""].join("\n");
var outline_f28_16_28935=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H151092800\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H255917\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H255765\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Ovarian steroids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Neurotransmitters",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Vitamins and minerals",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H151092800\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/7380\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7380|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/49/20240\" title=\"table 1\">",
"      Mean effect size symptom rating PMDD",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/52/39751?source=related_link\">",
"      Clinical manifestations and diagnosis of premenstrual syndrome and premenstrual dysphoric disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/12/13510?source=related_link\">",
"      Patient information: Premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?41/10/42146?source=related_link\">",
"      Patient information: Premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/10/3241?source=related_link\">",
"      Treatment of premenstrual syndrome and premenstrual dysphoric disorder",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_16_28936="High altitude pulmonary edema";
var content_f28_16_28936=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   High altitude pulmonary edema",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/16/28936/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/16/28936/contributors\">",
"     Scott A Gallagher, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/16/28936/contributors\">",
"     Peter Hackett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/16/28936/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/16/28936/contributors\">",
"     Daniel F Danzl, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/16/28936/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/16/28936/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/16/28936/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 14, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anyone who travels to high altitude, whether a recreational hiker, professional mountain climber, or rescue worker, is at risk of developing high altitude illness. High altitude pulmonary edema (HAPE) is a life-threatening form of such illness.",
"   </p>",
"   <p>",
"    The pathophysiology, clinical presentation, treatment, and prevention of HAPE are reviewed here. Other forms of high altitude illness are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/6/1130?source=see_link\">",
"     \"Acute mountain sickness and high altitude cerebral edema\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/18/297?source=see_link\">",
"     \"High altitude illness: Physiology, risk factors, and general prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;High altitude pulmonary edema (HAPE) is the abnormal accumulation of water in the lung due to a breakdown in the pulmonary blood-gas barrier, triggered by hypobaric hypoxia. This breakdown develops from a number of maladaptive responses to hypoxia, including poor ventilatory response, increased sympathetic tone, exaggerated and uneven pulmonary vasoconstriction (pulmonary hypertension), inadequate production of endothelial nitric oxide, and overproduction of endothelin [",
"    <a class=\"abstract\" href=\"UTD.htm?28/16/28936/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The end result is a patchy accumulation of extravascular fluid in the alveolar spaces that impairs respiration and can, in severe cases, prove fatal.",
"   </p>",
"   <p>",
"    Genetics likely play an important role in the risk of HAPE, as suggested by the marked variability in individual susceptibility and the higher rates of recurrence among some individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?28/16/28936/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    High mean pulmonary artery (PA) pressure, in excess of 35 to 40 mmHg, appears to be the initiating event. Specific segmental and subsegmental capillary beds with relatively less vasoconstriction are disproportionately exposed to elevated microvascular pressures (&gt;20 mmHg) that arise from the elevated mean PA pressure. This uneven vasoconstriction and regional overperfusion result in failure of the alveolar-capillary barrier and patchy pulmonary edema.",
"   </p>",
"   <p>",
"    As disruption of the alveolar-capillary barrier progresses, high molecular weight proteins, cells, and fluid leak into the alveolar space. Eventually, basement endothelial and epithelial cell membranes are disrupted, leading to alveolar hemorrhage.",
"   </p>",
"   <p>",
"    A striking feature of HAPE is the rapid reversibility of this process with descent or the administration of oxygen. Pulmonary vascular resistance returns to normal within days after descent to low altitude.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY AND RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;HAPE generally occurs above 2500 m (8000 ft) (",
"    <a class=\"graphic graphic_table graphicRef63999 \" href=\"UTD.htm?8/24/8588\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef50199 \" href=\"UTD.htm?0/4/71\">",
"     table 2",
"    </a>",
"    ). The risk depends upon individual susceptibility, altitude attained, rate of ascent, and time spent at altitude. At approximately 4500 m (14,800 ft) the incidence of HAPE ranges from 0.2 to 6 percent, depending upon the rate of ascent. At 5500 m the incidence ranges between 2 and 15 percent, again depending upon rate of ascent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/16/28936/abstract/2,4,5\">",
"     2,4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Symptoms of acute mountain sickness (AMS) develop in a high percentage of those with HAPE [",
"    <a class=\"abstract\" href=\"UTD.htm?28/16/28936/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. HAPE and high altitude cerebral edema (HACE) may also occur concomitantly. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/6/1130?source=see_link\">",
"     \"Acute mountain sickness and high altitude cerebral edema\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Factors associated with an increased incidence of HAPE include male gender, cold ambient temperatures, preexisting respiratory infection, and vigorous exertion [",
"    <a class=\"abstract\" href=\"UTD.htm?28/16/28936/abstract/6\">",
"     6",
"    </a>",
"    ]. Preexisting conditions or anatomic abnormalities that lead to increased pulmonary blood flow, pulmonary hypertension, or increased pulmonary vascular reactivity may predispose to HAPE, even at altitudes below 2500 m. These include primary pulmonary hypertension, congenital absence of one pulmonary artery, and left-to-right intracardiac shunts, such as atrial septal defects and ventricular septal defects.",
"   </p>",
"   <p>",
"    A patent foramen ovale (PFO), in the setting of rising pulmonary vascular resistance (PVR) during hypoxic pulmonary vasoconstriction (HPV), may reverse the direction of blood flow, shunting blood from right to left and further exacerbating hypoxemia. PFO is four times more common among HAPE-susceptible individuals. Larger PFOs correlate directly with increased arterial hypoxemia, and a trend toward an increased risk of developing HAPE [",
"    <a class=\"abstract\" href=\"UTD.htm?28/16/28936/abstract/1\">",
"     1",
"    </a>",
"    ]. Whether PFO contributes to HAPE or is merely a marker of increased vascular reactivity and susceptibility remains unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Clinical presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;HAPE generally begins with a subtle, nonproductive cough, mild shortness of breath, and difficulty walking uphill [",
"    <a class=\"abstract\" href=\"UTD.htm?28/16/28936/abstract/8\">",
"     8",
"    </a>",
"    ]. Such nonspecific symptoms are easily mistaken for a benign upper respiratory tract infection or attributed to normal breathlessness at altitude or exhaustion. Initial symptoms typically appear two to four days after arrival at a new altitude. Occasionally, HAPE develops precipitously. This occurs more often at night or after severe exertion. It almost never develops after a week at the same altitude.",
"   </p>",
"   <p>",
"    As HAPE progresses, dyspnea becomes noticeable at rest and severe with any attempt at exertion. Even walking on a level surface becomes an effort. A cardinal clinical feature of HAPE is the early progression from dyspnea with exertion to dyspnea at rest. In about 50 percent of cases, HAPE is accompanied by acute mountain sickness [",
"    <a class=\"abstract\" href=\"UTD.htm?28/16/28936/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/6/1130?source=see_link\">",
"     \"Acute mountain sickness and high altitude cerebral edema\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As symptoms progress, the cough can become productive of pink, frothy sputum and may produce frank blood [",
"    <a class=\"abstract\" href=\"UTD.htm?28/16/28936/abstract/9\">",
"     9",
"    </a>",
"    ]. Severely restricted exercise tolerance becomes debilitating and severe hypoxemia may become life-threatening without prompt descent or supplemental oxygen. Severe hypoxemia may cause drowsiness or concomitant high altitude cerebral edema [",
"    <a class=\"abstract\" href=\"UTD.htm?28/16/28936/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On physical examination, tachycardia, tachypnea, and low-grade fever (up to 38&ordm;C) are common. Inspiratory crackles may be more prominent in the right middle lobe initially, but become bilateral and diffuse as HAPE progresses. Auscultation of the right middle lobe is best performed at the mid-lateral chest wall. Pulse oximetry reveals saturation values at least 10 points lower than expected for the altitude, and may be as low as 40 to 50 percent. Typically, the patient appears better than expected for the severity of hypoxemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Presentation in children",
"    </span>",
"    &nbsp;&mdash;&nbsp;In children, HAPE presents as increasing respiratory distress over one to two days, but may develop more precipitously. Young children and infants may manifest only pallor and depressed consciousness or other nonspecific symptoms such as increased fussiness, crying, decreased appetite, decreased playfulness, disrupted sleep, and possibly vomiting [",
"    <a class=\"abstract\" href=\"UTD.htm?28/16/28936/abstract/10-13\">",
"     10-13",
"    </a>",
"    ]. In infants, increased pulmonary artery pressure and fetal shunting, with or without HAPE, can cause severe hypoxemia. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Pathophysiology'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Of note, HAPE alone does not cause an elevation in body temperature over 38&ordm;C, and young children with a higher fever should be assessed in standard fashion. However, respiratory infection and HAPE can coexist. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/14/22762?source=see_link\">",
"     \"Fever without a source in children 3 to 36 months of age\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The differential diagnosis in children includes pneumonia, undetected intracardiac shunts, and in infants opening of fetal shunts in response to high altitude pulmonary hypertension. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/15/4344?source=see_link\">",
"     \"Pathophysiology of left to right shunts\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/19/8506?source=see_link\">",
"     \"Pathophysiology and clinical features of isolated ventricular septal defects in infants and children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26201?source=see_link\">",
"     \"Classification and clinical features of isolated atrial septal defects in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/3/38970?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical features and diagnosis of community-acquired pneumonia in children\", section on 'Clinical presentation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Diagnostic studies and tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with AMS and HACE, the diagnosis of HAPE is based upon the history and physical examination. However, chest radiography is useful and reveals characteristic patchy alveolar infiltrates, predominantly in the right central hemithorax, which become more confluent and bilateral as the illness progresses (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef80267 \" href=\"UTD.htm?2/21/2384\">",
"     image 1",
"    </a>",
"    ). In a few cases, HAPE may not take this classic radiographic appearance [",
"    <a class=\"abstract\" href=\"UTD.htm?28/16/28936/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the radiographic appearance of HAPE may mimic that of infectious infiltrates, we often find a significant discrepancy between the extensive infiltrates on x-ray and the clinical status of the patient, who often does not appear severely ill and steadily improves with oxygen therapy. In contrast, a patient with a comparable chest x-ray due to pneumonia would appear critically ill and likely require intubation and mechanical ventilation.",
"   </p>",
"   <p>",
"    Computerized tomography (CT) of the chest reveals findings similar to those of plain x-ray (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef67452 \" href=\"UTD.htm?26/50/27428\">",
"     image 2",
"    </a>",
"    ). Echocardiography reveals increased pulmonary artery (PA) pressure and sometimes right heart dysfunction and paradoxical septal motion.",
"   </p>",
"   <p>",
"    In HAPE, the white blood cell count is typically elevated but brain natriuretic peptide (BNP) is typically not. An elevated BNP suggests a diagnosis other than isolated HAPE (eg, acute decompensated heart failure). The results of other readily available tests are nonspecific and unhelpful in diagnosing HAPE. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19945?source=see_link&amp;anchor=H16#H16\">",
"     \"Evaluation of the patient with suspected heart failure\", section on 'BNP and NT-proBNP'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pneumonia heads the list of differential diagnoses, but pulmonary embolism, acute decompensated heart failure (ADHF), acute coronary syndrome, bronchitis, and reactive airway disease are also included. Of note, HAPE and infection can coexist. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/26/26026?source=see_link\">",
"     \"Diagnostic approach to community-acquired pneumonia in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/57/6042?source=see_link\">",
"     \"Diagnosis of acute pulmonary embolism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/23/7544?source=see_link\">",
"     \"Evaluation of acute decompensated heart failure\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/39/25209?source=see_link\">",
"     \"Criteria for the diagnosis of acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Differentiating HAPE from such ailments as ADHF or pneumonia can be difficult, particularly in older patients with comorbid conditions. In such patients, HAPE is a diagnosis of exclusion and alternative diagnoses should be worked up in standard fashion. HAPE is associated with marked weakness and often severe hypoxemia (SpO2 of 50 to 75 percent; PaO2 of 25 to 40 mmHg). While ill-appearing, patients with HAPE generally look better than would be expected given their hypoxemia and rapidly improve with supplemental oxygen therapy.",
"   </p>",
"   <p>",
"    More commonly, the diagnosis of HAPE is entertained in otherwise healthy patients with a characteristic history and examination findings. Rapid response over hours to oxygen therapy strongly suggests the diagnosis of HAPE in this setting. In contrast, symptoms and signs of pneumonia require several days before clinical improvement. Rapid improvement with descent is another important diagnostic clue to the diagnosis of HAPE.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     General approach to treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early recognition of high altitude pulmonary edema (HAPE) and prompt intervention are critical to assuring a favorable outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?28/16/28936/abstract/1,8,15,16\">",
"     1,8,15,16",
"    </a>",
"    ]. Unlike high altitude cerebral edema (HACE), immediate descent is not mandatory in all treatment settings. Instead, treatment of HAPE varies depending upon a number of factors, including severity of illness, available treatments, setting, clinician experience, and patient preference. As examples, management of a resort skier at 2500 m may consist solely of supplemental oxygen and rest, while management of a mountaineer camping in a remote location at 5500 m and without access to supplemental oxygen requires descent.",
"   </p>",
"   <p>",
"    The key principle in successful treatment of HAPE, regardless of the setting or patient age, is prompt reduction of pulmonary artery (PA) pressure. Means to achieve this end include limiting physical exertion and cold exposure, providing supplemental oxygen via tank or concentrator, evacuation to a lower altitude, simulating descent using hyperbaric therapy, and giving appropriate medications. Descent (simulated or actual) and supplemental oxygen are often effective alone and appear to be superior to any pharmacologic therapy.",
"   </p>",
"   <p>",
"    No trials have been performed in patients with HAPE that directly compare treatment using oxygen and descent with pharmacologic therapy. Nevertheless, the clinical outcomes reported in studies in which",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    alone was used for treatment were poor compared with those involving standard treatment without medications [",
"    <a class=\"abstract\" href=\"UTD.htm?28/16/28936/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Nonpharmacologic interventions",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Oxygen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Supplemental oxygen is first-line therapy for HAPE and should be provided in all treatment settings when available [",
"    <a class=\"abstract\" href=\"UTD.htm?28/16/28936/abstract/1,13,18,19\">",
"     1,13,18,19",
"    </a>",
"    ]. It is life-saving. Relieving hypoxemia is the most effective method of reducing pulmonary artery (PA) pressure, reversing capillary leak, and protecting the brain and other organs. Supplemental oxygen immediately increases PaO2 and reduces both the heart and respiratory rates.",
"   </p>",
"   <p>",
"    In the field, oxygen may be limited, precluding its use as the sole treatment. Supplemental oxygen can be combined with descent (or hyperbaric therapy) and medication in such cases. However, while some studies have shown that oxygen combined with medication is more effective than oxygen alone in lowering PA pressure, clinical outcomes were not assessed [",
"    <a class=\"abstract\" href=\"UTD.htm?28/16/28936/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the hospital setting, supplemental oxygen and rest are generally sufficient therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/16/28936/abstract/13,15,22\">",
"     13,15,22",
"    </a>",
"    ]. A common regimen in North American hospitals near ski resorts (elevation ~2500 to 3000 m) is to treat with high flow supplemental oxygen by nasal cannula or face mask for several hours until the patient's oxygen requirement is &le;3",
"    <span class=\"nowrap\">",
"     L/min",
"    </span>",
"    with the SpO2 maintained at 90 percent or higher. If the patient is clinically improved and appropriate for outpatient therapy, he or she may be sent home with an oxygen concentrator to be used continuously and strict instructions to rest. The patient's condition and SpO2 are rechecked daily until an ambulatory SpO2, measured while the patient breathes room air, is &ge;90 percent. At this point, supplemental oxygen is discontinued and the patient is advised to slowly return to activity over the following one to three days. Descent is not mandatory but is always an option in this setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Rest and warmth",
"    </span>",
"    &nbsp;&mdash;&nbsp;Strenuous physical exertion and cold stress both elevate PA pressure and can exacerbate HAPE [",
"    <a class=\"abstract\" href=\"UTD.htm?28/16/28936/abstract/2\">",
"     2",
"    </a>",
"    ]. Thus, limiting exertion and avoiding exposure to cold are fundamental aspects of treatment. A patient with HAPE should not carry a pack while descending.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Descent",
"    </span>",
"    &nbsp;&mdash;&nbsp;In remote high-altitude settings where supplemental oxygen is unavailable, descent should begin as soon as HAPE is suspected [",
"    <a class=\"abstract\" href=\"UTD.htm?28/16/28936/abstract/1,15\">",
"     1,15",
"    </a>",
"    ]. HAPE can progress rapidly and the opportunity for evacuation may be lost if there is any delay. At higher elevations (&gt;4000 m), descent is mandatory, in part because of the risk of developing HACE. Ideally, immediate evacuation is undertaken to a hospital below 3000 m that is capable of providing high-flow oxygen.",
"   </p>",
"   <p>",
"    Nevertheless, in practice, scores of HAPE patients are treated successfully in remote clinics or base camps with modest descent and rest, sometimes in combination with hyperbaric therapy, low-flow supplemental oxygen, and medication. Many remote clinics are located only 500 to 1000 m below the elevation of HAPE onset. When HAPE is diagnosed early and treated in the manner described, many climbers go on to reascend slowly after two to three days of recovery. Recurrence of HAPE in such circumstances has not been reported. Severe cases require evacuation to a medical facility at lower elevation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Hyperbaric therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In remote settings, lightweight portable hyperbaric chambers may be life-saving, particularly when supplemental oxygen is unavailable or in short supply [",
"    <a class=\"abstract\" href=\"UTD.htm?28/16/28936/abstract/23\">",
"     23",
"    </a>",
"    ]. These devices, although costly, are well-suited to mountaineering and trekking expeditions at high altitude, where compressed oxygen cylinders are too heavy and bulky to transport and are difficult to maintain.",
"   </p>",
"   <p>",
"    In isolated mountain settings, hyperbaric therapy is commonly combined with pharmacotherapy and supplemental oxygen, if available. In the hospital setting, elevation is generally lower and high-flow oxygen is readily available. Hyperbaric therapy is not practical or necessary in such hospitals or clinics. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/6/1130?source=see_link&amp;anchor=H12#H12\">",
"     \"Acute mountain sickness and high altitude cerebral edema\", section on 'AMS treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/6/1130?source=see_link&amp;anchor=H21#H21\">",
"     \"Acute mountain sickness and high altitude cerebral edema\", section on 'HACE treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Positive airway pressure and other therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of a breathing mask providing pressure on expiration (EPAP) has been shown to improve gas exchange in HAPE, and may be useful as a temporizing measure [",
"    <a class=\"abstract\" href=\"UTD.htm?28/16/28936/abstract/24\">",
"     24",
"    </a>",
"    ]. A similar effect may be achievable by having the patient breathe through pursed lips.",
"   </p>",
"   <p>",
"    Continuous positive airway pressure (CPAP) is used in some ski resort clinics with anecdotal success. Nevertheless, no study has established that CPAP improves clinical outcome in patients with HAPE. A CPAP helmet has been used in the field [",
"    <a class=\"abstract\" href=\"UTD.htm?28/16/28936/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Pharmacologic interventions",
"    </span>",
"    &nbsp;&mdash;&nbsp;A summary of medications used to treat HAPE is provided (",
"    <a class=\"graphic graphic_table graphicRef76719 \" href=\"UTD.htm?40/16/41229\">",
"     table 3",
"    </a>",
"    ). More thorough discussions of these treatments are found below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Nifedipine",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the field setting, oxygen and descent remain the most important treatments for HAPE.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"     Nifedipine",
"    </a>",
"    may be considered adjunctive therapy when oxygen is unavailable and descent is difficult or impossible, although little clinical evidence supports the practice. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'General approach to treatment'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"     Nifedipine",
"    </a>",
"    is a nonspecific calcium channel blocker that acts by reducing pulmonary vascular resistance and PA pressure, as well as systemic resistance and blood pressure. It also slightly improves PaO2.",
"   </p>",
"   <p>",
"    Recommended dosages vary, but a common regimen is to give 30 mg of a slow release formulation every 12 hours.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"     Nifedipine",
"    </a>",
"    is well tolerated by most patients and is unlikely to cause significant hypotension in previously healthy persons. Clinicians should give or be prepared to give isotonic intravenous fluid (eg, normal saline) to any critically ill HAPE patient who may be intravascularly depleted and is receiving nifedipine.",
"   </p>",
"   <p>",
"    One unblinded uncontrolled study of six patients with HAPE found that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    treatment led to clinical improvement [",
"    <a class=\"abstract\" href=\"UTD.htm?28/16/28936/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Tadalafil and Sildenafil",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/4/19528?source=see_link\">",
"     Tadalafil",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"     sildenafil",
"    </a>",
"    are phosphodiesterase-5 (PDE-5) inhibitors which augment the pulmonary vasodilatory effects of nitric oxide by blocking the degradation of cyclic guanosine monophosphate (cGMP), the intracellular mediator of nitric oxide. Nitric oxide is a potent pulmonary vasodilator and reduces hypoxic pulmonary vasoconstriction (HPV) and pulmonary hypertension in HAPE [",
"    <a class=\"abstract\" href=\"UTD.htm?28/16/28936/abstract/15\">",
"     15",
"    </a>",
"    ]. Both tadalafil and sildenafil have been shown to be effective as prophylaxis for HAPE, but neither has been studied as treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?28/16/28936/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Prophylactic medications'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Nevertheless, based upon their mechanism of action, both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/4/19528?source=see_link\">",
"     tadalafil",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"     sildenafil",
"    </a>",
"    may be effective adjunct treatments for established HAPE when neither oxygen nor descent is available options. These drugs may have advantages over",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    because they lower PA pressure with less risk of lowering systemic blood pressure. The appropriate dose for treatment is unknown but might be similar to that used for prophylaxis (tadalafil 10 mg by mouth every 12 hours; sildenafil 50 mg by mouth every eight hours).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Dexamethasone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although glucocorticoids may have a role in prophylaxis, they have not been studied as treatment for HAPE. We reserve glucocorticoids for treatment of high altitude cerebral edema or severe acute mountain sickness. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Prophylactic medications'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Beta agonist",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/63/34806?source=see_link\">",
"     Salmeterol",
"    </a>",
"    may be useful in the treatment of HAPE, but this remains unstudied. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Prophylactic medications'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Suggested approach to prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gradual ascent remains the primary method for preventing all forms of high altitude illness, including HAPE. For patients with no history of medical problems at high altitude or of pulmonary hypertension, the risk of HAPE is low and routine prophylaxis is not warranted.",
"   </p>",
"   <p>",
"    In individuals at high-risk, particularly those with a history of HAPE, pharmacologic prophylaxis may be prudent, especially when time does not allow for adequate acclimatization.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"     Nifedipine",
"    </a>",
"    is the drug of choice for prophylaxis against HAPE. It should be started the day prior to ascent if possible and continued for five days at altitude, or until descent below 2500 m is completed.",
"   </p>",
"   <p>",
"    Further study is needed to determine whether",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    or phosphodiesterase 5 (PDE-5) inhibitors such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/4/19528?source=see_link\">",
"     tadalafil",
"    </a>",
"    are appropriate prophylactic medications. Based upon mechanism and clinical experience,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5752?source=see_link\">",
"     acetazolamide",
"    </a>",
"    is a reasonable medication for HAPE prophylaxis, but formal studies are lacking.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/63/34806?source=see_link\">",
"     Salmeterol",
"    </a>",
"    should be considered an adjunct treatment to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    in high-risk individuals with a clear history of recurrent HAPE.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Prophylactic medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;A summary of medications used for the prophylaxis and treatment of HAPE is provided (",
"    <a class=\"graphic graphic_table graphicRef76719 \" href=\"UTD.htm?40/16/41229\">",
"     table 3",
"    </a>",
"    ). More thorough discussions of the drugs used for prophylaxis are found below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Nifedipine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"     Nifedipine",
"    </a>",
"    is the preferred drug for the prevention of HAPE, but is used only in high-risk individuals and only when acclimatization is not possible. Ideally, treatment is started 24 hours prior to ascent and continued for five days at the destination altitude. In higher risk scenarios, treatment may be continued for a longer period. We give 30 mg of the extended release formulation every 12 hours.",
"   </p>",
"   <p>",
"    In a small randomized trial, 20 mg of a slow release formulation taken by mouth every eight hours while the participants performed a steep ascent prevented HAPE in 9 of 10 subjects with a history of repeated episodes documented by chest x-ray [",
"    <a class=\"abstract\" href=\"UTD.htm?28/16/28936/abstract/30\">",
"     30",
"    </a>",
"    ]. Seven of the eleven subjects given placebo developed radiographically-proven HAPE. Note that 20 mg extended release formulations are not available in the United States.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Dexamethasone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Further study is needed to determine whether",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    is an appropriate medication for prophylaxis against HAPE. In one randomized trial of 29 individuals with a history of HAPE, none of the 10 participants given dexamethasone prophylaxis (8 mg every 12 hours) developed HAPE during a rapid ascent from 490 to 4559 m with an overnight stay [",
"    <a class=\"abstract\" href=\"UTD.htm?28/16/28936/abstract/27\">",
"     27",
"    </a>",
"    ]. Prophylaxis with dexamethasone would have the added advantage of preventing",
"    <span class=\"nowrap\">",
"     AMS/HACE,",
"    </span>",
"    whereas",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    and the PDE-5 inhibitors have no such effect.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     Dexamethasone",
"    </a>",
"    's mechanism of action remains unclear. It may involve upregulation of nitric oxide production and upregulation of alveolar epithelial membrane sodium channels and sodium-potassium ATPase [",
"    <a class=\"abstract\" href=\"UTD.htm?28/16/28936/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Tadalafil and Sildenafil",
"    </span>",
"    &nbsp;&mdash;&nbsp;The phosphodiesterase 5 (PDE-5) inhibitors",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"     sildenafil",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/4/19528?source=see_link\">",
"     tadalafil",
"    </a>",
"    effectively prevented hypoxic pulmonary hypertension and the development of HAPE in small studies [",
"    <a class=\"abstract\" href=\"UTD.htm?28/16/28936/abstract/32-35\">",
"     32-35",
"    </a>",
"    ]. Optimal doses have not been established. Regimens for sildenafil have varied from a single dose of 50 or 100 mg just prior to exposure for acute ascent, to 40 mg three times a day for individuals who spend two to six days at altitude; we give 50 mg every eight hours. For tadalafil, 10 mg every 12 hours is the usual dose. These drugs are potentially safer than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    because there is less risk of hypotension. Sildenafil has shorter dosing intervals because its half-life is four to five hours; tadalafil's half-life is 17 hours.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Beta agonist",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/63/34806?source=see_link\">",
"     Salmeterol",
"    </a>",
"    prevented HAPE in 50 percent of subjects in one small study, and thus appears less effective than other agents [",
"    <a class=\"abstract\" href=\"UTD.htm?28/16/28936/abstract/36\">",
"     36",
"    </a>",
"    ]. However, it is safe and can be used in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5752?source=see_link\">",
"     acetazolamide",
"    </a>",
"    or other medications. Salmeterol was chosen for prophylactic studies because of its relatively longer duration of action.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/61/16344?source=see_link\">",
"     Albuterol",
"    </a>",
"    is less expensive and may be effective prophylaxis, but this has not been studied.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?23/18/23842?source=see_link\">",
"       \"Patient information: Altitude sickness (including mountain sickness) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?4/19/4403?source=see_link\">",
"       \"Patient information: High altitude illness (including mountain sickness) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      High altitude pulmonary edema (HAPE) generally occurs above 2500 m (8000 ft). The incidence depends upon individual susceptibility, altitude attained, rate of ascent, and time spent at altitude. Symptoms of acute mountain sickness (AMS) develop in approximately 50 percent of those with HAPE. High altitude cerebral edema (HACE) may also occur concomitantly. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathophysiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Epidemiology and risk factors'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/6/1130?source=see_link\">",
"       \"Acute mountain sickness and high altitude cerebral edema\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Preexisting conditions or anatomic abnormalities that lead to increased pulmonary blood flow, pulmonary hypertension, or increased pulmonary vascular reactivity may predispose to HAPE, even at altitudes below 2500 m. Such conditions include primary pulmonary hypertension and left-to-right intracardiac shunts, such as atrial septal defects and ventricular septal defects. Additional risk factors are described in the text. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Epidemiology and risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      HAPE generally begins with a subtle, nonproductive cough, mild shortness of breath, and difficulty walking uphill. Symptoms typically appear two to four days after arrival at higher altitude. As HAPE progresses, dyspnea becomes noticeable at rest and severe with any attempt at exertion. On physical examination, tachycardia, tachypnea, and low-grade fever are common. A cardinal clinical feature of HAPE is the rapid progression from dyspnea with exertion to dyspnea at rest. Oxygen saturation values are at least 10 points below normal for altitude, and usually range from 50 to 75 percent. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In children, HAPE presents as increasing respiratory distress over one to two days, but may develop more precipitously. Young children and infants may manifest only pallor and depressed consciousness or other nonspecific symptoms. It can be difficult to differentiate between HAPE and viral respiratory infection, and the two may coexist. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Presentation in children'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Chest radiography usually reveals characteristic patchy alveolar infiltrates, predominantly in the right central hemithorax, which become more confluent and bilateral as the illness progresses. A significant discrepancy often exists between the extensive infiltrates on x-ray and the clinical status of the patient, who often does not appear severely ill and steadily improves with oxygen therapy. Other commonly available tests are nonspecific. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Diagnostic studies and tests'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Differentiating HAPE from such ailments as acute decompensated heart failure or pneumonia can be difficult, particularly in older patients with comorbid conditions. In such patients, HAPE is a diagnosis of exclusion. In general, HAPE is associated with marked weakness and hypoxemia is more severe than that associated with most cases of pneumonia. Rapid response over hours to oxygen therapy strongly suggests the diagnosis of HAPE. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Early recognition of HAPE and prompt intervention are critical to assuring a favorable outcome. Immediate descent is not mandatory in all cases; treatment varies depending upon the severity of illness, available treatments, setting, and clinician experience. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Supplemental oxygen is first-line therapy for HAPE and should be provided in ALL treatment settings when available. Oxygen and descent (simulated or actual) are often effective alone and appear to be superior to any pharmacologic therapy. In the hospital setting, supplemental oxygen and rest are generally sufficient treatment. In remote high-altitude settings, descent should begin as soon as HAPE is suspected. Adjunctive medical therapies may be helpful and are discussed in the text. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with no history of medical problems at high altitude, the risk of HAPE is low and routine prophylaxis is not warranted. We suggest prophylaxis with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"       nifedipine",
"      </a>",
"      for individuals with a history of HAPE or with known predisposing factors who must ascend to altitudes above 2500 m without adequate time for acclimatization (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). In such circumstances, we give nifedipine 30 mg of a slow release formulation every 12 hours. Additional adjunct medications for prophylaxis are discussed in the text. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H94886622\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;We are saddened by the untimely death of John Marx, MD, who passed away in July 2012. We wish to acknowledge Dr. Marx's dedication and his many contributions to UpToDate, in particular, his work as editor-in-chief for Emergency Medicine and as a section editor and author for Adult Trauma.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/16/28936/abstract/1\">",
"      Stream JO, Grissom CK. Update on high-altitude pulmonary edema: pathogenesis, prevention, and treatment. Wilderness Environ Med 2008; 19:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/16/28936/abstract/2\">",
"      B&auml;rtsch P, Mairb&auml;url H, Maggiorini M, Swenson ER. Physiological aspects of high-altitude pulmonary edema. J Appl Physiol 2005; 98:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/16/28936/abstract/3\">",
"      Luo Y, Zou Y, Gao Y. Gene polymorphisms and high-altitude pulmonary edema susceptibility: a 2011 update. Respiration 2012; 84:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/16/28936/abstract/4\">",
"      Hackett PH, Rennie D, Levine HD. The incidence, importance, and prophylaxis of acute mountain sickness. Lancet 1976; 2:1149.",
"     </a>",
"    </li>",
"    <li>",
"     Singh I, Roy SB. High altitude pulmonary edema: Clinical hemodynamic and pathologic studies. In: Biomedical Problems of High Terrestrial Elevations, Hegnauer A.  (Ed), Federal Scientific Technical Informatino Service, Springfield 1962. p.108.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/16/28936/abstract/6\">",
"      Hultgren HN, Honigman B, Theis K, Nicholas D. High-altitude pulmonary edema at a ski resort. West J Med 1996; 164:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/16/28936/abstract/7\">",
"      Jones BE, Stokes S, McKenzie S, et al. Management of high altitude pulmonary edema in the Himalaya: a review of 56 cases presenting at Pheriche medical aid post (4240 m). Wilderness Environ Med 2013; 24:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/16/28936/abstract/8\">",
"      Hackett PH, Roach RC. High-altitude illness. N Engl J Med 2001; 345:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/16/28936/abstract/9\">",
"      Schoene RB. Illnesses at high altitude. Chest 2008; 134:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/16/28936/abstract/10\">",
"      Duster MC, Derlet MN. High-altitude illness in children. Pediatr Ann 2009; 38:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/16/28936/abstract/11\">",
"      Yaron M, Niermeyer S, Lindgren KN, Honigman B. Evaluation of diagnostic criteria and incidence of acute mountain sickness in preverbal children. Wilderness Environ Med 2002; 13:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/16/28936/abstract/12\">",
"      Yaron M, Waldman N, Niermeyer S, et al. The diagnosis of acute mountain sickness in preverbal children. Arch Pediatr Adolesc Med 1998; 152:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/16/28936/abstract/13\">",
"      Pollard AJ, Niermeyer S, Barry P, et al. Children at high altitude: an international consensus statement by an ad hoc committee of the International Society for Mountain Medicine, March 12, 2001. High Alt Med Biol 2001; 2:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/16/28936/abstract/14\">",
"      Vock P, Brutsche MH, Nanzer A, B&auml;rtsch P. Variable radiomorphologic data of high altitude pulmonary edema. Features from 60 patients. Chest 1991; 100:1306.",
"     </a>",
"    </li>",
"    <li>",
"     Hackett PH, Roach RC. High-Altitude Medicine. In: Wilderness Medicine, 5th, Auerbach PS.  (Ed), Mosby, Philadelphia 2007. p.2.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/16/28936/abstract/16\">",
"      Luks AM, McIntosh SE, Grissom CK, et al. Wilderness Medical Society consensus guidelines for the prevention and treatment of acute altitude illness. Wilderness Environ Med 2010; 21:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/16/28936/abstract/17\">",
"      Oelz O, Maggiorini M, Ritter M, et al. Nifedipine for high altitude pulmonary oedema. Lancet 1989; 2:1241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/16/28936/abstract/18\">",
"      Marticorena E, Hultgren HN. Evaluation of therapeutic methods in high altitude pulmonary edema. Am J Cardiol 1979; 43:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/16/28936/abstract/19\">",
"      Zafren K, Reeves JT, Schoene R. Treatment of high-altitude pulmonary edema by bed rest and supplemental oxygen. Wilderness Environ Med 1996; 7:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/16/28936/abstract/20\">",
"      Hackett PH, Roach RC, Hartig GS, et al. The effect of vasodilators on pulmonary hemodynamics in high altitude pulmonary edema: a comparison. Int J Sports Med 1992; 13 Suppl 1:S68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/16/28936/abstract/21\">",
"      Anand IS, Prasad BA, Chugh SS, et al. Effects of inhaled nitric oxide and oxygen in high-altitude pulmonary edema. Circulation 1998; 98:2441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/16/28936/abstract/22\">",
"      Luks AM. Do we have a \"best practice\" for treating high altitude pulmonary edema? High Alt Med Biol 2008; 9:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/16/28936/abstract/23\">",
"      Freeman K, Shalit M, Stroh G. Use of the Gamow Bag by EMT-basic park rangers for treatment of high-altitude pulmonary edema and high-altitude cerebral edema. Wilderness Environ Med 2004; 15:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/16/28936/abstract/24\">",
"      Schoene RB, Roach RC, Hackett PH, et al. High altitude pulmonary edema and exercise at 4,400 meters on Mount McKinley. Effect of expiratory positive airway pressure. Chest 1985; 87:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/16/28936/abstract/25\">",
"      Koch RO, Hinterhuber L, Faulhaber M, et al. A successful therapy of high-altitude pulmonary edema with a CPAP helmet on Lenin Peak. Clin J Sport Med 2009; 19:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/16/28936/abstract/26\">",
"      Oelz O, Maggiorini M, Ritter M, et al. Prevention and treatment of high altitude pulmonary edema by a calcium channel blocker. Int J Sports Med 1992; 13 Suppl 1:S65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/16/28936/abstract/27\">",
"      Maggiorini M, Brunner-La Rocca HP, Peth S, et al. Both tadalafil and dexamethasone may reduce the incidence of high-altitude pulmonary edema: a randomized trial. Ann Intern Med 2006; 145:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/16/28936/abstract/28\">",
"      Bates MG, Thompson AA, Baillie JK. Phosphodiesterase type 5 inhibitors in the treatment and prevention of high altitude pulmonary edema. Curr Opin Investig Drugs 2007; 8:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/16/28936/abstract/29\">",
"      B&auml;rtsch P, Swenson ER, Maggiorini M. Update: High altitude pulmonary edema. Adv Exp Med Biol 2001; 502:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/16/28936/abstract/30\">",
"      B&auml;rtsch P, Maggiorini M, Ritter M, et al. Prevention of high-altitude pulmonary edema by nifedipine. N Engl J Med 1991; 325:1284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/16/28936/abstract/31\">",
"      Swenson ER. Hypoxic lung whiteout: further clearing but more questions from on high. Ann Intern Med 2006; 145:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/16/28936/abstract/32\">",
"      Richalet JP, Gratadour P, Robach P, et al. Sildenafil inhibits altitude-induced hypoxemia and pulmonary hypertension. Am J Respir Crit Care Med 2005; 171:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/16/28936/abstract/33\">",
"      Ghofrani HA, Reichenberger F, Kohstall MG, et al. Sildenafil increased exercise capacity during hypoxia at low altitudes and at Mount Everest base camp: a randomized, double-blind, placebo-controlled crossover trial. Ann Intern Med 2004; 141:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/16/28936/abstract/34\">",
"      Humpl T, Reyes JT, Holtby H, et al. Beneficial effect of oral sildenafil therapy on childhood pulmonary arterial hypertension: twelve-month clinical trial of a single-drug, open-label, pilot study. Circulation 2005; 111:3274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/16/28936/abstract/35\">",
"      Baquero H, Soliz A, Neira F, et al. Oral sildenafil in infants with persistent pulmonary hypertension of the newborn: a pilot randomized blinded study. Pediatrics 2006; 117:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/16/28936/abstract/36\">",
"      Sartori C, Allemann Y, Duplain H, et al. Salmeterol for the prevention of high-altitude pulmonary edema. N Engl J Med 2002; 346:1631.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 183 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-89.32.226.102-E9F4F161E5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_16_28936=[""].join("\n");
var outline_f28_16_28936=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY AND RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Clinical presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Presentation in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Diagnostic studies and tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      General approach to treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Nonpharmacologic interventions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Oxygen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Rest and warmth",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Descent",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Hyperbaric therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Positive airway pressure and other therapies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Pharmacologic interventions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Nifedipine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Tadalafil and Sildenafil",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Dexamethasone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Beta agonist",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Suggested approach to prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Prophylactic medications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Nifedipine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Dexamethasone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Tadalafil and Sildenafil",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Beta agonist",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H94886622\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/183\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/183|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?2/21/2384\" title=\"diagnostic image 1\">",
"      HAPE xray",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?26/50/27428\" title=\"diagnostic image 2\">",
"      HAPE CT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/183|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/24/8588\" title=\"table 1\">",
"      Physiologic effects of high altitude",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/4/71\" title=\"table 2\">",
"      High altitude sites",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/16/41229\" title=\"table 3\">",
"      Pharmacologic treatment of high altitude illness",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/6/1130?source=related_link\">",
"      Acute mountain sickness and high altitude cerebral edema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26201?source=related_link\">",
"      Classification and clinical features of isolated atrial septal defects in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/3/38970?source=related_link\">",
"      Clinical features and diagnosis of community-acquired pneumonia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/39/25209?source=related_link\">",
"      Criteria for the diagnosis of acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/57/6042?source=related_link\">",
"      Diagnosis of acute pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/26/26026?source=related_link\">",
"      Diagnostic approach to community-acquired pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/23/7544?source=related_link\">",
"      Evaluation of acute decompensated heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19945?source=related_link\">",
"      Evaluation of the patient with suspected heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/14/22762?source=related_link\">",
"      Fever without a source in children 3 to 36 months of age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/18/297?source=related_link\">",
"      High altitude illness: Physiology, risk factors, and general prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/19/8506?source=related_link\">",
"      Pathophysiology and clinical features of isolated ventricular septal defects in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/15/4344?source=related_link\">",
"      Pathophysiology of left to right shunts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/18/23842?source=related_link\">",
"      Patient information: Altitude sickness (including mountain sickness) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?4/19/4403?source=related_link\">",
"      Patient information: High altitude illness (including mountain sickness) (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_16_28937="Pressure points hemorrhage";
var content_f28_16_28937=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F75765&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F75765&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 561px\">",
"   <div class=\"ttl\">",
"    Major pressure points",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 541px; height: 685px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_16_28937=[""].join("\n");
var outline_f28_16_28937=null;
var title_f28_16_28938="Evaluation of the adult with dyspnea in the emergency department";
var content_f28_16_28938=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation of the adult with dyspnea in the emergency department",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/16/28938/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/16/28938/contributors\">",
"     Azeemuddin Ahmed, MD, MBA",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/16/28938/contributors\">",
"     Mark A Graber, MD, FACEP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/16/28938/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/16/28938/contributors\">",
"     Robert S Hockberger, MD, FACEP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/16/28938/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/16/28938/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/16/28938/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 22, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dyspnea is the perception of an inability to breathe comfortably [",
"    <a class=\"abstract\" href=\"UTD.htm?28/16/28938/abstract/1\">",
"     1",
"    </a>",
"    ]. The adult patient with acute dyspnea presents difficult challenges in diagnosis and management. The emergency clinician must work through a wide differential diagnosis while providing appropriate initial treatment for a potentially life-threatening illness. Airway, breathing, and circulation are the emergency clinician's primary focus when beginning management of the acutely dyspneic patient. Once these are stabilized, further clinical investigation and treatment can proceed.",
"   </p>",
"   <p>",
"    For the purpose of this review, we will use the term \"dyspnea\" to encompass all patients with disordered or inadequate breathing. This topic review will provide a differential diagnosis of the life-threatening and common causes of dyspnea in the adult, describe important historical and clinical findings that can help to narrow the differential diagnosis, discuss the use of common diagnostic studies, and provide recommendations for initial management and disposition. Detailed discussions of specific diagnoses are found elsewhere in the program.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The respiratory system is designed to maintain homeostasis with respect to gas exchange and acid-base status. Derangements in oxygenation as well as acidemia lead to breathing discomfort. The development of dyspnea is a complex phenomenon generally involving stimulation of a variety of mechanoreceptors throughout the upper airway, lungs, and chest wall, and chemoreceptors at the carotid sinus and the medulla. The pathophysiology of dyspnea is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/40/8839?source=see_link\">",
"     \"Physiology of dyspnea\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33925?source=see_link\">",
"     \"Oxygenation and mechanisms of hypoxemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dyspnea is a common chief complaint among patients who come to the emergency department (ED). A chief complaint of dyspnea or shortness of breath made up 3.5 percent of the more than 115 million visits to United States EDs in 2003. Other dyspnea-related chief complaints (cough, chest discomfort) comprised 7.6 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/16/28938/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    According to one prospective observational study, the most common diagnoses among elderly patients presenting to an ED with a complaint of acute shortness of breath and manifesting signs of respiratory distress (eg, respiratory rate &gt;25, SpO2 &lt;93 percent) are decompensated heart failure, pneumonia, chronic obstructive pulmonary disease, pulmonary embolism, and asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?28/16/28938/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A table listing life-threatening and common causes of dyspnea that present to the emergency department is provided (",
"    <a class=\"graphic graphic_table graphicRef52926 \" href=\"UTD.htm?10/33/10781\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Life-threatening upper airway causes",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tracheal foreign objects &ndash; Common objects include food, coins, bones, dentures, medication tablets, and a multitude of other objects that can be placed in the mouth and become lodged in the upper and lower airways. This is an uncommon cause of acute dyspnea in adults. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/36/35399?source=see_link\">",
"       \"Airway foreign bodies in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Angioedema &ndash; Angioedema can cause significant swelling of the lips, tongue, posterior pharynx, and most dangerously the larynx over minutes to hours, and may progress to severe dyspnea. The skin may be erythematous or normal in color, but is usually not pruritic. Although first described over a century ago, the pathophysiology, origin, and treatment of angioedema are not completely understood. The various types include allergic, NSAID-induced, ACE-inhibitor induced, and complement-related (C1-esterase inhibitor deficiency or a nonfunctional allele). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/55/33657?source=see_link\">",
"       \"Hereditary angioedema: Treatment of acute attacks\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38391?source=see_link\">",
"       \"An overview of angioedema: Pathogenesis and causes\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Anaphylaxis &ndash; Often triggered by foods, insect bites, and various medications, anaphylaxis may cause severe swelling of the upper airway and tongue, and possibly airway occlusion. Symptoms and signs develop over minutes to hours and may include skin and mucosal findings (eg, hives, flushing, oropharyngeal swelling), respiratory compromise (eg, wheezing, stridor, hypoxia), cardiovascular compromise (eg, hypotension, tachycardia, syncope), and gastrointestinal complaints (eg, abdominal pain, vomiting). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35290?source=see_link\">",
"       \"Anaphylaxis: Rapid recognition and treatment\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Infections of the pharynx and neck &ndash; A number of oropharyngeal infections can cause acute dyspnea [",
"      <a class=\"abstract\" href=\"UTD.htm?28/16/28938/abstract/4-7\">",
"       4-7",
"      </a>",
"      ]. Epiglottitis generally presents with rapidly progressive sore throat, dysphagia, hoarseness (\"hot potato\" voice), and fever. Although once a predominately pediatric disease, epiglottitis now occurs more often in adults. Pertussis may present with severe paroxysms of cough, but can be difficult to diagnose clinically. Deep space infections of the neck, from Ludwig's angina, severe tonsillitis, peritonsillar abscess, and retropharyngeal abscess, can cause swelling and pain, which may manifest in part as acute dyspnea. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/45/4826?source=see_link\">",
"       \"Epiglottitis (supraglottitis): Clinical features and diagnosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/37/13911?source=see_link\">",
"       \"Clinical manifestations and diagnosis of Bordetella pertussis infections in adolescents and adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36569?source=see_link\">",
"       \"Deep neck space infections\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Airway trauma &ndash; Blunt or penetrating injuries of the head or neck can cause hemorrhage, anatomic distortion, and swelling, which can compromise the airway and cause acute dyspnea. Suspect a larynx fracture in patients complaining of dyspnea in the setting of severe neck pain and dysphonia following blunt trauma. Patients who have sustained facial burns or smoke inhalation are at risk for rapidly progressive airway compromise and must be emergently evaluated. Early endotracheal intubation is often indicated. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/62/2026?source=see_link\">",
"       \"Penetrating neck injuries\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/53/17242?source=see_link\">",
"       \"Emergency care of moderate and severe thermal burns in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/16/22790?source=see_link\">",
"       \"Smoke inhalation\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Life-threatening pulmonary causes",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pulmonary embolism &ndash; The diagnosis of pulmonary embolism (PE) should be considered in any patient with acute dyspnea. Risk factors include a history of deep venous thrombosis or pulmonary embolism, prolonged immobilization, recent trauma or surgery (particularly orthopedic), pregnancy, malignancy, stroke or paresis, oral contraceptive use and smoking, and a personal or family history of hypercoagulability. Presentation varies widely, but dyspnea at rest and tachypnea are the most common signs. A large minority of patients have no known risk factor at the time of diagnosis. Other embolic phenomena include fat embolism, especially after a long bone fracture, and amniotic fluid embolism. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/22/4456?source=see_link\">",
"       \"Overview of acute pulmonary embolism\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/57/6042?source=see_link\">",
"       \"Diagnosis of acute pulmonary embolism\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      COPD &ndash; Exacerbations of chronic obstructive pulmonary disease (COPD) can present with acute shortness of breath. Most often, a viral or bacterial respiratory infection exacerbates the patient's underlying illness. Pulmonary emboli may be responsible for up to 25 percent of apparent \"COPD exacerbations\" and should be suspected when the patient fails to improve with standard COPD treatment measures. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/5/23641?source=see_link\">",
"       \"Management of acute exacerbations of chronic obstructive pulmonary disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Asthma &ndash; Asthma exacerbations generally present with dyspnea and wheezing. Signs of severe disease include the use of accessory muscles, brief fragmented speech, profound diaphoresis, agitation, and failure to respond to aggressive treatment. Extreme fatigue, cyanosis, and depressed mental status portend imminent respiratory arrest. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/56/5002?source=see_link\">",
"       \"Treatment of acute exacerbations of asthma in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pneumothorax and pneumomediastinum &ndash; Any simple pneumothorax can develop into a life-threatening tension pneumothorax. In addition to trauma and medical procedures (eg, central venous catheter placement), a number of medical conditions increase the risk for developing a pneumothorax. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/39/34426?source=see_link\">",
"       \"Initial evaluation and management of blunt thoracic trauma in adults\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Risk factors for primary spontaneous pneumothorax include smoking, a family history, and Marfan syndrome. Patients are generally in their 20s and complain of sudden onset dyspnea and pleuritic chest pain that began at rest. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/3/10297?source=see_link\">",
"       \"Primary spontaneous pneumothorax in adults\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Patients with certain pulmonary diseases (including COPD, cystic fibrosis, tuberculosis, and AIDS patients with pneumocystis pneumonia) are at risk for secondary spontaneous pneumothorax. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/35/24121?source=see_link\">",
"       \"Secondary spontaneous pneumothorax in adults\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Patients who have sustained chest trauma or who have been coughing vigorously may present with dyspnea, sharp pleuritic chest pain, and subcutaneous emphysema over the supraclavicular area and anterior neck from pneumomediastinum associated with a pneumothorax",
"     </li>",
"     <li>",
"      Pulmonary infection &ndash; Lung infections such as severe bronchitis or pneumonia can cause shortness of breath and hypoxia. Productive cough, fever, and pleuritic chest pain are common but insensitive signs. The onset of dyspnea in these patients is generally not acute unless underlying chronic pulmonary disease is present. A chest radiograph is generally necessary for diagnosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/26/26026?source=see_link\">",
"       \"Diagnostic approach to community-acquired pneumonia in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Noncardiogenic pulmonary edema (Adult Respiratory Distress Syndrome [",
"      <strong>",
"       ARDS",
"      </strong>",
"      ]) &ndash; ARDS can complicate a wide range of conditions and is characterized by rapidly progressive dyspnea, hypoxia, and bilateral infiltrates on chest x-ray. It can be difficult to distinguish from acute decompensated heart failure purely on clinical grounds. Brain natriuretic peptide (BNP) and echocardiography can be helpful for diagnosis. Potential causes include sepsis, shock, severe trauma, toxic inhalations (aspiration, thermal injury, anhydrous ammonia, chlorine), infections (Hantavirus, SARS), blood transfusion, and drug overdose (cocaine, opioids,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/15/29945?source=see_link\">",
"       \"Acute respiratory distress syndrome: Epidemiology; pathophysiology; pathology; and etiology\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10505?source=see_link\">",
"       \"Acute respiratory distress syndrome: Clinical features and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Direct pulmonary injury &ndash; A pulmonary contusion or laceration is a possible source for acute dyspnea in any patient with chest trauma. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/39/34426?source=see_link\">",
"       \"Initial evaluation and management of blunt thoracic trauma in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pulmonary hemorrhage &ndash; Hemorrhage from an injury or an underlying disease (eg, malignancy, tuberculosis) can cause acute dyspnea.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Life-threatening cardiac causes",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute coronary syndrome (ACS) &ndash; Patients, particularly the elderly, suffering from a myocardial infarction (MI) may present with dyspnea as their sole symptom. Clinicians are more likely to miss an MI in the patient whose chief complaint is dyspnea. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/39/25209?source=see_link\">",
"       \"Criteria for the diagnosis of acute myocardial infarction\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Acute decompensated heart failure (ADHF) &ndash; Symptomatic ADHF can be caused by volume overload, systolic or diastolic dysfunction, or outflow obstruction (eg, aortic stenosis, hypertrophic cardiomyopathy, severe systemic hypertension). Myocardial ischemia and arrhythmia are common precipitants. Symptoms range from mild dyspnea on exertion to severe pulmonary edema requiring emergent airway management. Common findings include tachypnea, pulmonary crackles, jugular venous distension, S3 gallop, and peripheral edema. ADHF is among the most common causes of acute respiratory failure among patients over 65 years. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/23/7544?source=see_link\">",
"       \"Evaluation of acute decompensated heart failure\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Flash pulmonary edema &ndash; The sudden onset and rapid progression of pulmonary edema can be caused by ischemia, arrhythmia, or drug overdose.",
"     </li>",
"     <li>",
"      High output heart failure &ndash; High output heart failure may be precipitated by a number of conditions, including severe anemia, pregnancy, Beriberi (thiamine deficiency), and thyrotoxicosis. Signs may include tachycardia, bounding pulses, a venous hum heard over the internal jugular veins, and carotid bruits. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/47/9978?source=see_link\">",
"       \"High-output heart failure\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cardiomyopathy &ndash; The physiologic derangements associated with cardiomyopathy (primarily dilated cardiomyopathy) may result in pulmonary edema and manifest as dyspnea. Potential causes include cardiac ischemia, hypertension, alcohol abuse, cocaine abuse, and a number of systemic diseases (eg, sarcoidosis, systemic lupus erythematosus). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/0/19465?source=see_link\">",
"       \"Causes of dilated cardiomyopathy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cardiac arrhythmia &ndash; Cardiac conduction abnormalities, such as atrial flutter, atrial fibrillation, second and third degree heart block, and tachyarrhythmias (eg, SVT and ventricular tachycardia) can result in dyspnea. Such abnormalities may stem from underlying disease, including myocardial ischemia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/22/361?source=see_link\">",
"       \"Overview of atrial fibrillation\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39481?source=see_link\">",
"       \"Clinical manifestations, diagnosis, and evaluation of narrow QRS complex tachycardias\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/19/31034?source=see_link\">",
"       \"Approach to the diagnosis and treatment of wide QRS complex tachycardias\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Valvular dysfunction &ndash; Aortic stenosis, mitral regurgitation, or ruptured chordae tendinae can present with acute dyspnea. A murmur may be appreciable, but the absence of an audible murmur does not exclude the diagnosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/36/34377?source=see_link\">",
"       \"Valvular heart disease in elderly adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cardiac tamponade &ndash; Whether due to trauma, malignancy, uremia, drugs, or infection, cardiac tamponade can present with acute dyspnea. The classically described findings of hypotension, distended neck veins, and muffled heart tones suggest the diagnosis, but are often absent. The electrocardiogram generally shows sinus tachycardia and low voltage, and may uncommonly reveal electrical alternans. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/52/19273?source=see_link\">",
"       \"Cardiac tamponade\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Life-threatening neurologic causes",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stroke &ndash; Although dyspnea is not the chief complaint of patients with an acute stroke, a number of respiratory abnormalities may result from a sufficiently severe injury or one affecting regions involved in respiration. Such abnormalities may include aspiration pneumonia, neurogenic pulmonary edema, and a number of abnormal respiratory patterns, including apnea, that can lead to severe hypoxia or hypocapnia. Invasive airway management may be required. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/54/10087?source=see_link\">",
"       \"Stroke-related pulmonary complications and abnormal respiratory patterns\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Neuromuscular&nbsp;disease &ndash; A number of neuromuscular diseases, including multiple sclerosis, Guillain-Barr&eacute; syndrome, myasthenia gravis, and amyotrophic lateral sclerosis, can cause weakness of the respiratory muscles, leading to acute respiratory failure. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/44/32458?source=see_link\">",
"       \"Epidemiology and clinical features of multiple sclerosis in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/22/5481?source=see_link\">",
"       \"Clinical features and diagnosis of Guillain-Barr&eacute; syndrome in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/51/17206?source=see_link\">",
"       \"Clinical manifestations of myasthenia gravis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/21/40280?source=see_link\">",
"       \"Clinical features of amyotrophic lateral sclerosis and other forms of motor neuron disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Life-threatening toxic and metabolic causes",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Poisoning &ndash; A number of toxins can cause derangements in respiratory function, leading to dyspnea. Organophosphate poisoning causes an increase in airway sections and bronchospasm. Petroleum distillates and paraquat can cause respiratory difficulty. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/25/33176?source=see_link\">",
"       \"Organophosphate and carbamate poisoning\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/45/11991?source=see_link\">",
"       \"Paraquat poisoning\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Salicylate poisoning &ndash; Salicylate overdose leads to stimulation of the medullary respiratory center, causing hyperventilation and respiratory alkalosis initially, followed by metabolic acidosis. In some cases, pulmonary edema may occur with severe poisoning. Prominent extrapulmonary signs include fever, tinnitus, vertigo, vomiting, diarrhea, and in more severe cases mental status changes. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/28/19913?source=see_link\">",
"       \"Salicylate (aspirin) poisoning in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Carbon monoxide poisoning &ndash; Carbon monoxide is a potentially lethal toxin that impairs oxygen metabolism. Carbon monoxide poisoning may present with tachypnea and acute dyspnea in moderate cases, and pulmonary edema in severe cases. Extrapulmonary signs are generally more prominent and often nonspecific. They can include headache, malaise, chest discomfort, and altered mental status. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/6/10345?source=see_link\">",
"       \"Carbon monoxide poisoning\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Toxin related metabolic acidosis &ndash; Toxic ingestions, including methanol and ethylene glycol, may cause a metabolic acidosis and compensatory tachypnea that manifest as respiratory distress and may lead to respiratory failure. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/3/4154?source=see_link\">",
"       \"Methanol and ethylene glycol poisoning\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Diabetic ketoacidosis &ndash; Diabetic ketoacidosis can cause tachypnea and dyspnea largely from the body's attempt to correct the metabolic acidosis. Patients with diabetic ketoacidosis give a history of polyuria, polydipsia, polyphagia, and progressive weakness; signs of severe disease include hyperventilation, altered mental status, and abdominal pain. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/55/4986?source=see_link\">",
"       \"Clinical features and diagnosis of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Sepsis &ndash; Severe sepsis often causes respiratory compromise secondary to tachypnea and respiratory fatigue, which may stem from underlying pneumonia, compensation for lactic acidosis, or some other process. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/51/21306?source=see_link\">",
"       \"Evaluation and management of severe sepsis and septic shock in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Anemia &ndash; Acute anemia from hemorrhage, hemolysis, or production abnormalities may result in dyspnea due to the lack of oxygen carrying capacity. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/46/29418?source=see_link\">",
"       \"Approach to the adult patient with anemia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Acute chest syndrome &ndash; Chest pain syndrome is a potentially life-threatening complication of sickle cell disease. In the United States, it is seen predominantly in the African American population. Patients generally complain of severe chest pain and acute dyspnea and have a fever, while chest x-ray reveals a new pulmonary infiltrate. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/11/42170?source=see_link\">",
"       \"Overview of the clinical manifestations of sickle cell disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/28/27082?source=see_link\">",
"       \"Pulmonary complications of sickle cell disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Miscellaneous causes",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lung cancer &ndash; Shortness of breath is a common symptom in patients with lung cancer at the time of diagnosis, occurring in approximately 25 percent of cases. Dyspnea may be due to extrinsic or intraluminal airway obstruction, obstructive pneumonitis or atelectasis, lymphangitic tumor spread, tumor emboli, pneumothorax, pleural effusion, or pericardial effusion with tamponade. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/57/16282?source=see_link\">",
"       \"Overview of the risk factors, pathology, and clinical manifestations of lung cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pleural effusion &ndash; A pleural effusion, secondary to infection, ascites, pancreatitis, cancer, heart failure, or trauma, can cause severe acute dyspnea. Analysis of the pleural fluid is often necessary to determine the source. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/7/16505?source=see_link\">",
"       \"Diagnostic evaluation of a pleural effusion in adults: Initial testing\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Intraabdominal processes &ndash; A number of conditions such as peritonitis, ruptured viscous, or bowel obstruction can cause severe pain that affects respiration and may manifest as acute shortness of breath, although this is generally not the patient's primary complaint [",
"      <a class=\"abstract\" href=\"UTD.htm?28/16/28938/abstract/8\">",
"       8",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/50/41770?source=see_link\">",
"       \"Evaluation of the adult with abdominal pain in the emergency department\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Ascites &ndash; Ascites secondary to malignancy or liver disease can distend the abdominal cavity, placing pressure on the diaphragm and thereby increasing the work of breathing [",
"      <a class=\"abstract\" href=\"UTD.htm?28/16/28938/abstract/9\">",
"       9",
"      </a>",
"      ]. In such cases, symptoms often improve after large-volume paracentesis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/43/14010?source=see_link\">",
"       \"Evaluation of adults with ascites\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pregnancy &ndash; A number of physiologic changes occur during pregnancy that effect respiratory function, including an increase in minute ventilation, a decrease in functional residual capacity, a decrease in hematocrit, and elevation of the diaphragm. Approximately two-thirds of women experience dyspnea during the course of normal pregnancy.",
"      <br/>",
"      <br/>",
"      However, pregnancy increases the risk for several potentially life-threatening conditions that may manifest with dyspnea, notably pulmonary embolism. Pulmonary edema may be identified in the setting of a number of diseases associated with pregnancy, including preeclampsia, amniotic fluid embolism, and cardiomyopathy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/33/39446?source=see_link\">",
"       \"Dyspnea during pregnancy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/27/39353?source=see_link\">",
"       \"Deep vein thrombosis and pulmonary embolism in pregnancy: Epidemiology, pathogenesis, and diagnosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/55/39801?source=see_link\">",
"       \"Eclampsia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/42/15016?source=see_link\">",
"       \"Amniotic fluid embolism syndrome\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/62/18410?source=see_link\">",
"       \"Peripartum cardiomyopathy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/34/1577?source=see_link\">",
"       \"Management of heart failure in pregnancy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Massive obesity &ndash; Massive abdominal girth can interfere with ventilation, causing dyspnea and hypoxia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/2/21541?source=see_link\">",
"       \"Pathogenesis of obesity hypoventilation syndrome\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/35/30266?source=see_link\">",
"       \"Health hazards associated with obesity in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hyperventilation and anxiety &ndash; Hyperventilation from anxiety is a diagnosis of exclusion in the emergency department. Even among young healthy patients with a known anxiety disorder, it is prudent to perform a history and physical examination to screen for medical causes of dyspnea. To complicate matters, anxiety is common among patients with severe medical disease. As an example, COPD patients have a three-fold increase in the prevalence of anxiety disorders compared with the general population [",
"      <a class=\"abstract\" href=\"UTD.htm?28/16/28938/abstract/10\">",
"       10",
"      </a>",
"      ]. In such patients, it is best to assume that an exacerbation of their underlying medical disease is the cause of dyspnea, until proven otherwise.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The history is critical to the evaluation of the acutely dyspneic patient, but can be difficult to obtain when the patient has difficulty speaking and the clinician must concentrate on ensuring that the patient maintains adequate oxygenation and ventilation. Relevant history can be obtained from the patient, EMS providers, family and friends, pharmacists, and primary care clinicians. The following details should be obtained whenever possible:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      General historical features &ndash; Ask about the events leading up to the episode, particularly any recent symptoms or specific triggers for the acute dyspnea. As examples, noncompliance with medications or diet may lead to an episode of acute decompensated heart failure (ADHF), exposure to cold or an allergen may trigger an asthma flare, acute dyspnea immediately following a meal suggests an allergic reaction, a new productive cough suggests a pulmonary infection, recent surgery or immobilization increases the risk for pulmonary embolism (PE), while recent trauma may have caused a pneumothorax or pulmonary contusion.",
"     </li>",
"     <li>",
"      Past history &ndash; Determine whether the problem is new or recurring. Ask about preexisting medical conditions, such as asthma, COPD, or ischemic heart disease, and whether the patient has experienced similar acute episodes before. If it resembles prior episodes, the current problem is often an exacerbation of a preexisting illness. The medical record and medication list can provide important diagnostic clues.",
"     </li>",
"     <li>",
"      Prior intubation &ndash; Patients with a history of endotracheal intubation for medical conditions have a higher risk for severe disease and the need for subsequent intubation. As an example, patients who have required intubation for a severe asthma exacerbation are at increased risk for subsequent episodes of near-fatal asthma attacks. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/26/13735?source=see_link\">",
"       \"Identifying patients at risk for fatal asthma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Time course &ndash; Ask whether the dyspnea developed suddenly or gradually. Keep in mind that exacerbations of a single illness can present in different ways and over different periods of time. As examples, an asthma flare may develop over minutes or days, as may episodes of heart failure. A table is provided to help differentiate causes of respiratory distress based on time course (",
"      <a class=\"graphic graphic_table graphicRef64683 \" href=\"UTD.htm?38/51/39740\">",
"       table 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Severity &ndash; When asked to grade the severity of their distress using a scale of 1 to 10 (1 = just noticeable, 3 = slight, 5 = moderate, 7 = moderately severe, 9 = very severe and 10 = panic level), patients with acute exacerbations of asthma, COPD and ADHF tend to rate their distress as moderately severe (score of 7), while those experiencing dyspnea associated with normal pregnancy, neuromuscular disorders or PE tend to rate their distress as only moderate (score of 5) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/16/28938/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Chest pain &ndash; Chest pain in association with dyspnea occurs with a number of diseases, including acute coronary syndrome (ACS), pneumothorax, and PE. Of note, a sizable minority of patients with ACS or PE complain of dyspnea alone. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/39/20090?source=see_link\">",
"       \"Evaluation of chest pain in the emergency department\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Trauma &ndash; Injury to the airway, neck, chest wall, lungs, heart, mediastinal structures, or abdomen can lead to dyspnea. Acute symptoms may not manifest until a day or longer following trauma. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/39/34426?source=see_link\">",
"       \"Initial evaluation and management of blunt thoracic trauma in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Fever &ndash; Fever can be associated with an infection, hypersensitivity pneumonitis, aspiration pneumonitis, or poisoning. As an example of the latter,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      overdose can present with fever and abnormal breathing. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/28/19913?source=see_link\">",
"       \"Salicylate (aspirin) poisoning in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Paroxysmal nocturnal dyspnea (PND) &ndash; Keep in mind that PND is NOT specific for ADHF. Patients with COPD may present with a similar history.",
"     </li>",
"     <li>",
"      Hemoptysis &ndash; Hemoptysis is associated with a number of diseases, including PE, tuberculosis, and malignancy, when tumors erode into a vascular structure. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/47/30454?source=see_link\">",
"       \"Massive hemoptysis: Initial management\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cough and sputum &ndash; The presence and quality of sputum may be helpful. Purulent sputum suggests pneumonia and white or pink frothy sputum suggests ADHF, while frankly bloody sputum suggests infection (eg, tuberculosis) or pulmonary hemorrhage (eg, pulmonary embolism or malignancy). A nonproductive cough is a nonspecific symptom, and may be associated with asthma, heart failure, respiratory infection, or PE.",
"     </li>",
"     <li>",
"      Medications &ndash; A review of the patient's medications can prove helpful. In addition to information about chronic or acute illness (eg, recent antibiotic prescription), a medication list may provide information about recent changes in medications or dosing. It is important to ask about compliance. Obtaining information directly from the patient's pharmacy can be helpful.",
"     </li>",
"     <li>",
"      Tobacco and drugs &ndash; Knowledge of the patient's tobacco and drug use can provide insight into the differential diagnosis. Tobacco use increases the risk for a number of chronic conditions (COPD, malignancy), while inhaled drug use can lead to such conditions as crack lung and ARDS. Noninhalational use or overdose of certain drugs, such as opioids and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      , can produce acute lung injury. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/30/23018?source=see_link\">",
"       \"Cocaine: Acute intoxication\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/51/3897?source=see_link\">",
"       \"Opioid intoxication in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/28/19913?source=see_link\">",
"       \"Salicylate (aspirin) poisoning in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/34/38439?source=see_link\">",
"       \"Overview of pulmonary disease in injection drug users\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Psychiatric conditions &ndash; Psychogenic causes for acute dyspnea represent diagnoses of exclusion in the emergency department. Organic causes MUST be thoroughly considered first. Nevertheless, among patients younger than 40 years with no medical conditions, psychogenic dyspnea (eg, anxiety attack) may be the cause in a sizable minority of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?28/16/28938/abstract/12,13\">",
"       12,13",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     PHYSICAL EXAMINATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Clinical danger signs",
"    </span>",
"    &nbsp;&mdash;&nbsp;The emergency clinician should perform a screening physical examination looking for signs of significant respiratory distress in all patients with acute dyspnea. A brief inspection is often sufficient for this purpose.",
"   </p>",
"   <p>",
"    Signs that portend imminent respiratory arrest include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Depressed mental status",
"     </li>",
"     <li>",
"      Inability to maintain respiratory effort",
"     </li>",
"     <li>",
"      Cyanosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Many patients in respiratory distress appear anxious and sit bolt upright or in a tripod position. They often breathe rapidly, use accessory muscles, and sweat profusely. They may be unable to answer questions with anything more than a few words. Stridor or wheezing may be audible.",
"   </p>",
"   <p>",
"    Signs suggestive of severe respiratory distress include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Retractions and the use of accessory muscles",
"     </li>",
"     <li>",
"      Brief, fragmented speech",
"     </li>",
"     <li>",
"      Inability to lie supine",
"     </li>",
"     <li>",
"      Profound diaphoresis; dusky skin",
"     </li>",
"     <li>",
"      Agitation or other altered mental status",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Retractions occur with airway obstruction (eg, asthma, COPD, foreign body) and can be seen in the suprasternal, intercostal, and subcostal areas [",
"    <a class=\"abstract\" href=\"UTD.htm?28/16/28938/abstract/14\">",
"     14",
"    </a>",
"    ]. They are an ominous sign suggesting extreme respiratory distress. The use of accessory muscles to breathe suggests fatigue of the respiratory muscles and suggests the potential for respiratory failure.",
"   </p>",
"   <p>",
"    Diaphoresis reflects extreme sympathetic stimulation associated with severe disease (myocardial infarction, severe asthma flare). Cyanosis is uncommon and indicates severe hypoxia or methemoglobinemia.",
"   </p>",
"   <p>",
"    Altered mental status (eg, agitation or somnolence) in the dyspneic patient suggests severe hypoxia or hypercarbia. It may also be caused by a toxin (eg, salicylate overdose, carbon monoxide) or underlying pathology (eg, hypoglycemia, sepsis).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     General examination findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once a screen for clinical danger signs is completed and any necessary resuscitation is initiated, a more thorough physical examination is performed. Important items to note are described below and in the accompanying table (",
"    <a class=\"graphic graphic_table graphicRef76513 \" href=\"UTD.htm?1/1/1053\">",
"     table 3",
"    </a>",
"    ). Keep in mind that an unremarkable pulmonary and cardiac examination does NOT rule out significant disease. As examples, the sensitivity and specificity of the pulmonary examination are limited for making the diagnosis of pneumonia or acute decompensated heart failure (ADHF) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/16/28938/abstract/15-19\">",
"     15-19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Respiratory rate &ndash; Patients with serious underlying disease may have a fast, normal, or slow respiratory rate (RR). As an example, patients with a pulmonary embolism may have a RR in the normal range. Note that measurements of the respiratory rate obtained during triage may not be accurate [",
"      <a class=\"abstract\" href=\"UTD.htm?28/16/28938/abstract/20,21\">",
"       20,21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Pulse oximetry &ndash; Pulse oximetry provides crucial information about arterial oxygenation. However, clinicians must be aware that standard pulse oximeters are NOT accurate in the setting of hypothermia, shock, carbon monoxide poisoning, and methemoglobinemia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/32/9736?source=see_link\">",
"       \"Pulse oximetry\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      In general, healthy individuals demonstrate an oxygen saturation (SpO2) of 95 percent or greater. Elders and patients who are obese or smoke heavily often maintain levels between 92 and 95 percent, while patients with severe chronic lung disease may have baseline levels below 92 percent. In the setting of acute dyspnea, oxygenation levels lower than expected, or below a patient's known baseline, should be investigated and explained. A drop in SpO2 associated with exercise is characteristic of Pneumocystis pneumonia. SpO2 levels before and after exercise should be noted in patients suspected or known to have HIV. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/25/7577?source=see_link\">",
"       \"Clinical presentation and diagnosis of Pneumocystis infection in HIV-infected patients\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Other vital signs &ndash; Clinicians must review a complete set of vital signs. Dyspnea and hypotension are an ominous combination.",
"     </li>",
"     <li>",
"      Abnormal breath sounds",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Stridor occurs when there is airway obstruction. Inspiratory stridor suggests obstruction above the vocal cords (eg, foreign body, epiglottitis, angioedema). Expiratory stridor or mixed inspiratory and expiratory stridor suggests obstruction below the vocal cords (eg, croup, bacterial tracheitis, foreign body).",
"     </li>",
"     <li>",
"      Wheezing suggests obstruction below the level of the trachea and is found with asthma, anaphylaxis, a foreign body in a mainstem bronchus, acute decompensated heart failure (ADHF), or a fixed lesion such as a tumor.",
"     </li>",
"     <li>",
"      Crackles (rales) suggest the presence of interalveolar fluid, as seen with pneumonia or ADHF. They can also occur with pulmonary fibrosis. However, the absence of crackles does not rule out the presence of pneumonia, ADHF, or pulmonary fibrosis [",
"      <a class=\"abstract\" href=\"UTD.htm?28/16/28938/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Diminished breath sounds can be caused by anything that prevents air from entering the lungs. Such conditions include: severe COPD, severe asthma, pneumothorax, tension pneumothorax, and hemothorax, among others.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cardiovascular signs",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      An abnormal heart rhythm may be a response to underlying disease (eg, tachycardia in the setting of PE) or the cause of dyspnea (eg, atrial fibrillation in the setting of chronic heart failure).",
"     </li>",
"     <li>",
"      Heart murmurs may be present with acute decompensated heart failure (ADHF) or diseased or otherwise compromised cardiac valves. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/56/22410?source=see_link\">",
"       \"Auscultation of heart sounds\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      An S3 heart sound suggests left ventricular systolic dysfunction, especially in the setting of ADHF.",
"     </li>",
"     <li>",
"      An S4 heart sound suggests left ventricular dysfunction and may be present with severe hypertension, aortic stenosis, hypertrophic cardiomyopathy, ischemic heart disease, or acute mitral regurgitation.",
"     </li>",
"     <li>",
"      Muffled or distant heart sounds suggest the presence of cardiac tamponade, but must be interpreted in the context of the overall clinical setting.",
"     </li>",
"     <li>",
"      Elevated jugular venous pressure may be present with ADHF or cardiac tamponade. It can be assessed by observing jugular venous distension or examining hepatojugular reflux.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pulsus paradoxus &ndash; Pulsus paradoxus can occur when right heart function is compromised, such as can be seen with severe asthma, pulmonary embolism, or cardiac tamponade. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/57/11158?source=see_link\">",
"       \"Pulsus paradoxus in pericardial disease\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Under normal conditions, inspiration increases systemic venous return and right heart volumes increase; the free wall of the right ventricle expands into the unoccupied pericardial space with little impact on left heart volume.",
"      <br/>",
"      <br/>",
"      When the contents of the pericardial sac acutely increase, due to the accumulation of pericardial fluid or with cardiac dilatation, the effective compliance of all chambers becomes that of the tightly-stretched pericardium. As a result, the increase in right heart filling that occurs during inspiration can only be accommodated by a bowing of the interventricular septum toward the left heart. This leads to a reduction in left ventricular diastolic volume, a lower stroke volume, and a consequent decrease in systolic pressure during inspiration.",
"      <br/>",
"      <br/>",
"      In order to determine if a pulsus paradoxus is present, measure the patient's systolic blood pressure after a normal exhalation. Then have the patient inhale normally and determine systolic pressure when the lungs are expanded. Pulsus paradoxus exists if the difference in systolic pressures is greater than 10 mmHg. Keep in mind that the absence of pulsus paradoxus does not rule out any disease.",
"     </li>",
"     <li>",
"      Inspection &ndash; Examine the skin for discoloration suggesting hypoxia or poor perfusion, signs of an allergic reaction, and evidence of trauma.",
"     </li>",
"     <li>",
"      Extremities &ndash; Peripheral edema may not occur with acute left heart failure, but if present suggests ADHF as the cause of dyspnea. Clubbing is associated with conditions causing chronic hypoxemia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     ANCILLARY STUDIES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     General approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ancillary testing should be performed in the context of the history and examination findings. Random testing without a clear differential diagnosis can mislead the clinician and delay appropriate management. The use of dyspnea biomarker panels does not appear to improve accuracy beyond clinical assessment and focused testing [",
"    <a class=\"abstract\" href=\"UTD.htm?28/16/28938/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. Nevertheless, a chest x-ray and an electrocardiogram are obtained in most emergency department (ED) patients with acute dyspnea.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Chest x-ray (CXR)",
"    </span>",
"    &nbsp;&mdash;&nbsp;A CXR is obtained for most ED patients with acute dyspnea. When abnormalities are identified, it is useful to compare the radiograph to past studies.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute heart failure &ndash; Signs of ADHF that may appear on a CXR include: cardiomegaly, cephalization of blood vessels, interstitial edema (eg, \"Kerley B\" lines, peribronchial cuffing), and vascular congestion. Pleural effusions may be present. Keep in mind that the radiograph may lag behind the clinical picture and approximately 20 percent of patients admitted with ADHF have a nondiagnostic CXR [",
"      <a class=\"abstract\" href=\"UTD.htm?28/16/28938/abstract/24\">",
"       24",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19945?source=see_link\">",
"       \"Evaluation of the patient with suspected heart failure\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pneumonia &ndash; Although an infiltrate on CXR is considered the \"gold standard\" for diagnosing pneumonia, radiographs obtained early in the clinical course may be nondiagnostic [",
"      <a class=\"abstract\" href=\"UTD.htm?28/16/28938/abstract/25\">",
"       25",
"      </a>",
"      ]. Volume depletion may also lead to a negative initial CXR. Contrary to past teaching, the appearance of the CXR (lobar versus diffuse disease) does not accurately predict the nature of the pneumonia (typical versus atypical). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/26/26026?source=see_link\">",
"       \"Diagnostic approach to community-acquired pneumonia in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pneumothorax &ndash; A pneumothorax sufficient to cause acute dyspnea is usually visible on CXR. An expiratory view may be helpful [",
"      <a class=\"abstract\" href=\"UTD.htm?28/16/28938/abstract/26\">",
"       26",
"      </a>",
"      ]. Patients in extremis with a suggestive history and examination findings consistent with a tension pneumothorax (hypotension, elevated neck veins, unilateral diminished or absent breath sounds) should be treated with immediate needle decompression before obtaining a CXR. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/19/22838?source=see_link\">",
"       \"Imaging of pneumothorax\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      COPD and asthma &ndash; Large lung volumes and a flattened diaphragm on CXR suggest air trapping, which occurs with COPD or asthma. Unilateral air trapping suggests a foreign body. Many patients with mildly or moderately severe COPD and most patients with asthma have an unremarkable CXR. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/14/30954?source=see_link\">",
"       \"Chronic obstructive pulmonary disease: Definition, clinical manifestations, diagnosis, and staging\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/56/5002?source=see_link\">",
"       \"Treatment of acute exacerbations of asthma in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Electrocardiogram",
"    </span>",
"    &nbsp;&mdash;&nbsp;An electrocardiogram (ECG) with ST segment changes constitutes strong evidence supporting the diagnosis of cardiac ischemia. However, clinicians must remember that neither normal biomarkers nor a nondiagnostic ECG can rule out cardiac disease in the ED. The initial ECG is normal in approximately 20 percent of patients subsequently diagnosed with a myocardial infarction, and only 33 percent of initial ECGs are diagnostic. The ECG may also reveal signs of pulmonary embolism (right heart strain), pericardial effusion (diffuse low voltage, electrical alternans), and other disease processes. It is helpful to compare the ECG to prior studies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/39/25209?source=see_link\">",
"     \"Criteria for the diagnosis of acute myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/57/6042?source=see_link\">",
"     \"Diagnosis of acute pulmonary embolism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/59/4025?source=see_link\">",
"     \"Diagnosis and treatment of pericardial effusion\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Cardiac biomarkers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elevated biomarkers support the diagnosis of cardiac ischemia. However, the initial cardiac biomarkers (eg, troponin I) obtained in the ED are frequently normal. Serial measurements of cardiac biomarkers are necessary to rule out an acute coronary syndrome. Cardiac biomarkers have limited specificity and may be elevated in the setting of pulmonary embolism, sepsis, pericarditis, myocarditis,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    use, renal failure, and interference with the assay (generally from monoclonal antibodies or rheumatoid factor). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/38/39530?source=see_link\">",
"     \"Troponins and creatine kinase as biomarkers of cardiac injury\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/30/2537?source=see_link\">",
"     \"Elevated cardiac troponin concentration in the absence of an acute coronary syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Brain natriuretic peptide",
"    </span>",
"    &nbsp;&mdash;&nbsp;The measurement of brain natriuretic peptide (BNP) may be helpful when the diagnosis of acute decompensated heart failure (ADHF) is in question. BNP testing is not helpful when used indiscriminately in patients with acute dyspnea [",
"    <a class=\"abstract\" href=\"UTD.htm?28/16/28938/abstract/27\">",
"     27",
"    </a>",
"    ]. The length of stay of patients presenting to the ED with acute dyspnea may be slightly reduced if BNP testing is performed [",
"    <a class=\"abstract\" href=\"UTD.htm?28/16/28938/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A BNP of less than 100",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    has a negative predictive value of over 90 percent for ADHF. Likewise, a BNP above 500",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    strongly suggests ADHF, with a positive predictive value over 90 percent. A level between 100",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    and 500",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    cannot differentiate between ADHF and other causes of elevated BNP. Causes of a false positive BNP (generally between 100",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    and 500",
"    <span class=\"nowrap\">",
"     pg/mL)",
"    </span>",
"    include pulmonary embolism, fluid overload states (renal failure, liver failure), critical illness, and other causes of right ventricular distension (cor pulmonale, pulmonary hypertension). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/22/19818?source=see_link\">",
"     \"Natriuretic peptide measurement in heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     D-Dimer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use of the d-dimer depends upon the patient's pretest probability for PE. Patients at low risk for PE according to a validated scoring system (eg, modified Wells criteria for PE, PERC rule) and a negative ELISA d-dimer can be ruled out for PE without further testing. It is NOT appropriate to use a d-dimer to screen patients at higher risk for thromboembolic disease. Patients with malignancy or recent surgery and elderly patients are more likely to have a falsely elevated d-dimer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/57/6042?source=see_link\">",
"     \"Diagnosis of acute pulmonary embolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Arterial and venous blood gas",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of the arterial blood gas (ABG) in the diagnosis and treatment of the acutely dyspneic patient is limited. Oxygenation is easily assessed using transcutaneous pulse oximetry. Acid-base status can be assessed using a venous blood gas and the serum bicarbonate. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/33/15894?source=see_link\">",
"     \"Arterial blood gases\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/35/13877?source=see_link\">",
"     \"Venous blood gases and other alternatives to arterial blood gases\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A venous blood gas may be useful in the assessment of the patient presumed to be somnolent from CO2 retention. In many patients the presence of CO2 retention can be determined using end-tidal CO2 monitors. The PaCO2 should be low in the acutely dyspneic patient, who is usually hyperventilating. A normal or elevated CO2 in the setting of dyspnea and tachypnea portends respiratory failure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Carbon dioxide monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Capnography (ie, end-tidal CO2) provides dynamic monitoring of ventilatory status in patients with acute respiratory distress. By measuring end-tidal CO2 and respiratory rate with each breath, capnography provides instantaneous feedback on the clinical status of the patient, while trends enable the clinician to determine whether the patient's ventilation is worsening despite treatment (increasing EtCO2), stabilizing (stable EtCO2), or improving (decreasing EtCO2). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/18/44328?source=see_link\">",
"     \"Carbon dioxide monitoring (capnography)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Chest CT and VQ scan",
"    </span>",
"    &nbsp;&mdash;&nbsp;A multidetector computed tomography (MDCT) scan of the chest can be used to diagnose multiple problems, including PE, malignancy, pneumonia, and pulmonary edema. Often these diseases can be diagnosed by history, examination, and basic testing, without the use of MDCT. MDCT entails risk for several complications, including contrast-induced nephropathy, allergic reaction to contrast, and radiation, and should be used with discretion. Ventilation-perfusion scanning is an alternative method for diagnosing PE in patients unsuitable for MDCT who have a normal chest radiograph.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Peak flow and pulmonary function tests (PFTs)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The peak expiratory flow rate (PEFR) can be helpful in distinguishing pulmonary and cardiac causes of dyspnea and determining the severity of bronchoconstriction in cases of severe asthma. Normal values vary with gender, height, and age, and accuracy depends upon patient cooperation.",
"   </p>",
"   <p>",
"    Small observational studies suggest PEFR is generally higher in patients with a cardiac cause of dyspnea [",
"    <a class=\"abstract\" href=\"UTD.htm?28/16/28938/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. During acute asthma exacerbations, PEFR measurements provide a screening tool for the presence of hypercapnia and obviate the need for routine arterial blood gases. In the absence of respiratory depressant medications (eg, narcotics or sedatives), hypercapnia occurs only when the PEFR falls below 25 percent of normal. Bedside spirometry is less prone to error but may be difficult to perform in the ED. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/53/854?source=see_link\">",
"     \"Peak expiratory flow rate monitoring in asthma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/53/4952?source=see_link\">",
"     \"Overview of pulmonary function testing in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Negative inspiratory force",
"    </span>",
"    &nbsp;&mdash;&nbsp;Negative inspiratory pressure (NIF) and forced vital capacity measurements can be obtained at the bedside to assess dyspneic patients with possible neuromuscular disease (eg, myasthenia gravis, Guillain-Barr&eacute;) or musculoskeletal disease (ankylosing spondylitis, severe scoliosis, or kyphosis). If the NIF is less than 30 cm H2O or the forced vital capacity (FVC) is less than 20",
"    <span class=\"nowrap\">",
"     mL/kg,",
"    </span>",
"    the patient should be admitted to an intensive care unit in anticipation of the need for mechanical ventilation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/16/28938/abstract/31\">",
"     31",
"    </a>",
"    ]. These numbers are guidelines only and do not always predict which patients need respiratory support. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/18/11560?source=see_link\">",
"     \"Tests of respiratory muscle strength\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Initial interventions and differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;For any patient with acute severe dyspnea, the following measures are performed immediately:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Oxygen is provided",
"     </li>",
"     <li>",
"      Intravenous access is established and blood obtained for laboratory measurements",
"     </li>",
"     <li>",
"      Cardiac and pulse oximetry monitoring is instituted",
"     </li>",
"     <li>",
"      Airway management equipment is brought to the bedside",
"     </li>",
"     <li>",
"      A screening examination, including an assessment of airway difficulty and a search for rapidly reversible causes (tension pneumothorax, pericardial tamponade, upper airway foreign body) is performed. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/7/18552?source=see_link\">",
"       \"The difficult airway in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Bedside ultrasound can be of great benefit in determining the presence of pneumothorax or tamponade.",
"   </p>",
"   <p>",
"    Common life-threatening causes of dyspnea to be considered in all cases include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Acute coronary syndrome",
"     </li>",
"     <li>",
"      Acute heart failure",
"     </li>",
"     <li>",
"      Arrhythmia",
"     </li>",
"     <li>",
"      Pericardial tamponade",
"     </li>",
"     <li>",
"      Pulmonary embolism",
"     </li>",
"     <li>",
"      Pneumonia or other infection",
"     </li>",
"     <li>",
"      COPD exacerbation",
"     </li>",
"     <li>",
"      Asthma",
"     </li>",
"     <li>",
"      Angioedema and anaphylaxis",
"     </li>",
"     <li>",
"      Poisoning (eg, carbon monoxide)",
"     </li>",
"     <li>",
"      Trauma (eg, pneumothorax, hemothorax)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A more complete list of potential diagnoses is provided above. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Differential diagnosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Emergent management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three primary goals exist for the emergency clinician faced with an acutely dyspneic patient:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Optimize arterial oxygenation",
"     </li>",
"     <li>",
"      Determine the need for emergent airway management and ventilatory support",
"     </li>",
"     <li>",
"      Establish the most likely causes of dyspnea and initiate treatment",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The initial decision to provide noninvasive or invasive ventilatory support is made based upon clinical grounds, not laboratory values. Emergent airway management is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/12/22726?source=see_link\">",
"     \"The decision to intubate\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/55/1912?source=see_link\">",
"     \"Rapid sequence intubation in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/7/18552?source=see_link\">",
"     \"The difficult airway in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/50/4905?source=see_link\">",
"     \"Emergent surgical cricothyrotomy (cricothyroidotomy)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Oxygen is a potent and readily available treatment for many causes of dyspnea and should be administered liberally. For patients with mild dyspnea and normal room-air arterial oxygen saturation (SpO2), 2 liters per minute (LPM) of oxygen via nasal cannula is typically adequate. For hypoxic patients with respiratory difficulty, 50 to 60 LPM of oxygen should be provided via a nonrebreather mask. To deliver this much oxygen, open the flow meter valve until the indicator lies well beyond the 15 LPM mark.",
"   </p>",
"   <p>",
"    Patients breathing 100 percent oxygen deliver five times as much oxygen to the alveoli per unit of ventilation as those breathing room air and in the absence of parenchymal disease can maintain a normal SpO2 with only two or three breaths per minute. Note, however, that the best nonrebreather oxygen delivery systems provide only 85 percent oxygen.",
"   </p>",
"   <p>",
"    Do NOT withhold oxygen from patients with COPD. The target oxygen saturation in such patients is 90 to 94 percent with the understanding that this may result in hypercarbia and reduce ventilatory drive. However, failure to oxygenate the patient may have profoundly adverse consequences. If a clinician determines that a COPD patient requires endotracheal intubation, oxygen delivery should be maximized without regard for the target oxygen saturation or hypercarbia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/5/23641?source=see_link\">",
"     \"Management of acute exacerbations of chronic obstructive pulmonary disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/63/3064?source=see_link\">",
"     \"Use of oxygen in patients with hypercapnia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While oxygen is provided and initial interventions (eg, IV access) are made, the clinician determines the need for airway management and ventilatory support. For patients that require ventilatory assistance to overcome an infraglottic challenge (eg, bronchospasm or parenchymal disease) or nonpulmonary disease (eg, neuromuscular disease), both noninvasive and invasive strategies exist. Noninvasive ventilation with a mask delivering continuous positive airway pressure (CPAP) or bilevel positive airway pressure (BLPAP) can increase minute ventilation, reduce the work of breathing, recruit alveoli, and improve hemodynamics. Noninvasive ventilation improves outcomes in patients with acutely decompensated heart failure (ADHF) or a COPD exacerbation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/51/1850?source=see_link\">",
"     \"Noninvasive positive pressure ventilation in acute respiratory failure in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/7/41079?source=see_link\">",
"     \"Treatment of acute decompensated heart failure: General considerations\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Noninvasive ventilation does NOT improve outcomes in patients with acute exacerbations of asthma and diseases that do not respond rapidly to medical therapy (eg, pneumonia and ARDS). In such instances, endotracheal intubation and controlled mechanical ventilation should be pursued aggressively when ventilatory support is needed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/56/5002?source=see_link\">",
"     \"Treatment of acute exacerbations of asthma in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/1/40986?source=see_link\">",
"     \"Treatment of community-acquired pneumonia in adults who require hospitalization\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/54/9065?source=see_link\">",
"     \"Supportive care and oxygenation in acute respiratory distress syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/25/6554?source=see_link\">",
"     \"Mechanical ventilation of adults in the emergency department\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As with all life-threatening complaints, dyspnea is managed by clinicians performing therapeutic interventions and diagnostic assessment concurrently. Often therapy assists in diagnosis. As examples, an improvement in SpO2 immediately after the administration of low-flow oxygen indicates a ventilation-perfusion",
"    <span class=\"nowrap\">",
"     (V/Q)",
"    </span>",
"    mismatch, while rapid improvement following treatment with bronchodilators strongly suggests bronchoconstriction. Failure to improve with oxygen administration may indicate a right to left shunt. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33925?source=see_link\">",
"     \"Oxygenation and mechanisms of hypoxemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An electrocardiogram (ECG) and stat portable chest x-ray (CXR) should be obtained early in the course of management when appropriate. The ECG may reveal signs of cardiac ischemia, such as ST segment deviations or inverted T waves. Findings of right heart strain (eg, inverted T waves in the right precordial or inferior leads, complete or incomplete right bundle branch block, right axis deviation) are consistent with pulmonary embolism (PE). Diffuse low voltage or electrical alternans in a patient with dyspnea and hypotension suggests pericardial tamponade. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Electrocardiogram'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/39/25209?source=see_link\">",
"     \"Criteria for the diagnosis of acute myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/57/6042?source=see_link\">",
"     \"Diagnosis of acute pulmonary embolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A portable CXR may reveal cardiomegaly and other signs of pulmonary edema, a pneumothorax, hyperinflated lungs with flattened diaphragms suggestive of COPD, or an infiltrate suggestive of pneumonia. Nevertheless, many life-threatening causes of dyspnea may not manifest any abnormality on CXR. Bedside ultrasound can be useful in making the diagnosis of pneumothorax or pericardial tamponade. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Chest x-ray (CXR)'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Clinicians should take care not to confuse pneumonia and ADHF, which can have a similar appearance on CXR and sound similar with auscultation. Blood pressure, treatment response, and brain natriuretic peptide (BNP) can help to distinguish the two. Pneumonia is more often associated with a normal or low blood pressure, does not respond to early therapy, and is generally NOT associated with a rise in BNP. ADHF is generally associated with a high blood pressure, often responds to aggressive early therapy, and is associated with a rise in BNP. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Brain natriuretic peptide'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The diagnosis of PE can be difficult to make. Although most patients with dyspnea secondary to a PE demonstrate some abnormality on CXR or ECG, there are no pathognomonic findings in either test. A definitive diagnosis is made based upon imaging with a multidetector CT or ventilation perfusion scan.",
"   </p>",
"   <p>",
"    Although obvious causes of dyspnea are treated as they are identified, in some instances the cause of dyspnea is not immediately apparent. In such cases, the ED clinician must intervene with treatments or by obtaining emergent consultation based upon the clinical context and available data. As examples, such interventions may include broad spectrum antibiotics when infection is suspected or stress dose glucocorticoids for patients who use such medications chronically.",
"   </p>",
"   <p>",
"    When managing a life-threatening complaint with a broad differential diagnosis such as severe, acute dyspnea, it is crucial that emergency clinicians not fall prey to premature diagnostic closure. Clinical, laboratory, and radiographic findings that contradict the clinicians initial impressions must be carefully considered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Nonemergent management",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most instances, the emergency clinician can determine the diagnosis or the need for hospital admission based upon a thorough history, physical examination, chest radiograph, and electrocardiogram. Close attention should be paid to the patient's history of present illness, comorbidities, vital signs, oxygen saturation, and examination of the airway, lungs, and cardiovascular system.",
"   </p>",
"   <p>",
"    Common, potentially life-threatening causes of dyspnea should be considered in all cases. These are listed above. (See",
"    <a class=\"local\" href=\"#H28\">",
"     'Initial interventions and differential diagnosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Often the cause of dyspnea cannot be determined with certainty in the ED. In such cases, the clinician's job is to treat and appropriately triage the patient based upon the clinical scenario and an assessment of the patient's risk. High risk dyspneic patients include the elderly and those who are immunocompromised, have severe underlying lung or heart disease, or demonstrate unexplained abnormal vital signs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     DISPOSITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient's condition, preliminary diagnosis, and risk assessment determine disposition. Patients with severe disease or those at risk of rapid deterioration who require close monitoring should be admitted to an intensive care setting. Those with less severe disease but who fail to improve with treatment in the ED or who have significant comorbidities or risk factors are admitted to the appropriate hospital ward.",
"   </p>",
"   <p>",
"    Stable patients whose evaluation has ruled out significant disease or determined that the risk for such disease is acceptably low may be discharged. Patients being discharged must have a clear understanding of their discharge diagnosis, written discharge instructions, and planned follow-up with clear instructions to return to the ED if their condition worsens. Particularly with elderly patients, the clinician must consider such factors as the patient's living situation and access to medical follow-up when determining the appropriateness of discharge.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     PITFALLS IN MANAGEMENT",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Failure to secure the airway in a timely manner.",
"     </li>",
"     <li>",
"      Failure to recognize and act on abnormal vital signs and signs of impending respiratory failure.",
"     </li>",
"     <li>",
"      Over-reliance upon a single finding (physical examination or test result) to establish a diagnosis.",
"     </li>",
"     <li>",
"      Failure to generate a proper differential diagnosis (ie, premature diagnostic closure).",
"     </li>",
"     <li>",
"      Failure to monitor the patient's clinical course.",
"     </li>",
"     <li>",
"      Failure to consider CO poisoning or pulmonary embolism.",
"     </li>",
"     <li>",
"      Misinterpreting tachypnea, which may not represent a respiratory abnormality and may reflect nonpulmonary disease (eg, metabolic acidosis or impending herniation of the brainstem).",
"     </li>",
"     <li>",
"      Allowing patients with a tenuous respiratory status to leave the ED and deteriorate in the radiology suite.",
"     </li>",
"     <li>",
"      Discharging patients with inadequate follow-up or unclear instructions.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?6/46/6883?source=see_link\">",
"       \"Patient information: Shortness of breath (dyspnea) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?27/50/28450?source=see_link\">",
"       \"Patient information: Shortness of breath (dyspnea) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7771153\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dyspnea is the perception of an inability to breathe comfortably and is a common chief complaint among emergency department patients. The differential diagnosis of dyspnea is broad and may involve abnormalities affecting the upper airway, lungs, heart, chest wall, diaphragm, and nervous system, including both mechanical and chemical receptors. The differential diagnosis is described by organ system in the text (",
"      <a class=\"graphic graphic_table graphicRef52926 \" href=\"UTD.htm?10/33/10781\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Common life-threatening causes of acute severe dyspnea include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Acute coronary syndrome",
"     </li>",
"     <li>",
"      Acute heart failure",
"     </li>",
"     <li>",
"      Arrhythmia",
"     </li>",
"     <li>",
"      Pericardial tamponade",
"     </li>",
"     <li>",
"      Pulmonary embolism",
"     </li>",
"     <li>",
"      Pneumonia or other infection",
"     </li>",
"     <li>",
"      COPD exacerbation",
"     </li>",
"     <li>",
"      Asthma",
"     </li>",
"     <li>",
"      Angioedema and anaphylaxis",
"     </li>",
"     <li>",
"      Poisoning (eg, carbon monoxide)",
"     </li>",
"     <li>",
"      Trauma (eg, pneumothorax, hemothorax)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most common diagnoses among elderly patients presenting to an ED with a complaint of acute shortness of breath and manifesting signs of respiratory distress (eg, respiratory rate &gt;25, SpO2 &lt;93 percent) are decompensated heart failure, pneumonia, chronic obstructive pulmonary disease, pulmonary embolism, and asthma. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Important elements of the history and physical examination in patients with acute dyspnea are described in the text. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'History'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Physical examination'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Signs that portend imminent respiratory arrest include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Depressed mental status",
"     </li>",
"     <li>",
"      Inability to maintain respiratory effort",
"     </li>",
"     <li>",
"      Cyanosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Many patients in respiratory distress often appear anxious and sit bolt upright or in a tripod position. They often breathe rapidly. Stridor or wheezing may be audible. Signs suggestive of severe respiratory distress include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Retractions and the use of accessory muscles",
"     </li>",
"     <li>",
"      Brief, fragmented speech",
"     </li>",
"     <li>",
"      Inability to lie supine",
"     </li>",
"     <li>",
"      Profound diaphoresis; dusky skin",
"     </li>",
"     <li>",
"      Agitation or other altered mental status",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A plain chest radiograph and an electrocardiogram are obtained in most emergency department (ED) patients with acute dyspnea. Dyspnea biomarker panels do not appear to improve accuracy beyond clinical assessment and focused testing. The use of ancillary studies in the patient with acute dyspnea is discussed in the text. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Ancillary studies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Three primary goals exist for the emergency clinician faced with an acutely dyspneic patient: optimize arterial oxygenation; determine the need for emergent airway management and ventilatory support; and, establish the most likely causes of dyspnea and initiate treatment. For any patient with acute severe dyspnea, the following measures are performed immediately:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Oxygen is provided",
"     </li>",
"     <li>",
"      Intravenous access is established and blood obtained for laboratory measurements",
"     </li>",
"     <li>",
"      Cardiac and pulse oximetry monitoring is instituted",
"     </li>",
"     <li>",
"      Airway management equipment is brought to the bedside",
"     </li>",
"     <li>",
"      A screening examination, including an assessment of airway difficulty and a search for rapidly reversible causes (tension pneumothorax, pericardial tamponade, upper airway foreign body) is performed. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Initial interventions and differential diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H29\">",
"       'Emergent management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/16/28938/abstract/1\">",
"      Simon PM, Schwartzstein RM, Weiss JW, et al. Distinguishable sensations of breathlessness induced in normal volunteers. Am Rev Respir Dis 1989; 140:1021.",
"     </a>",
"    </li>",
"    <li>",
"     American College of Emergency Physicians. www.acep.org/webportal/Newsroom/NewsMediaResources/StatisticsData/default.htm (Accessed on February 04, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/16/28938/abstract/3\">",
"      Ray P, Birolleau S, Lefort Y, et al. Acute respiratory failure in the elderly: etiology, emergency diagnosis and prognosis. Crit Care 2006; 10:R82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/16/28938/abstract/4\">",
"      Herzon FS, Martin AD. Medical and surgical treatment of peritonsillar, retropharyngeal, and parapharyngeal abscesses. Curr Infect Dis Rep 2006; 8:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/16/28938/abstract/5\">",
"      Saifeldeen K, Evans R. Ludwig's angina. Emerg Med J 2004; 21:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/16/28938/abstract/6\">",
"      Sethi DS, Stanley RE. Deep neck abscesses--changing trends. J Laryngol Otol 1994; 108:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/16/28938/abstract/7\">",
"      Berg S, Trollfors B, Nyl&eacute;n O, et al. Incidence, aetiology, and prognosis of acute epiglottitis in children and adults in Sweden. Scand J Infect Dis 1996; 28:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/16/28938/abstract/8\">",
"      Newton E, Mandavia S. Surgical complications of selected gastrointestinal emergencies: pitfalls in management of the acute abdomen. Emerg Med Clin North Am 2003; 21:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/16/28938/abstract/9\">",
"      Angueira CE, Kadakia SC. Effects of large-volume paracentesis on pulmonary function in patients with tense cirrhotic ascites. Hepatology 1994; 20:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/16/28938/abstract/10\">",
"      Brenes GA. Anxiety and chronic obstructive pulmonary disease: prevalence, impact, and treatment. Psychosom Med 2003; 65:963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/16/28938/abstract/11\">",
"      Simon PM, Schwartzstein RM, Weiss JW, et al. Distinguishable types of dyspnea in patients with shortness of breath. Am Rev Respir Dis 1990; 142:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/16/28938/abstract/12\">",
"      Bass C. Chest pain and breathlessness: relationship to psychiatric illness. Am J Med 1992; 92:12S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/16/28938/abstract/13\">",
"      Martinez FJ, Stanopoulos I, Acero R, et al. Graded comprehensive cardiopulmonary exercise testing in the evaluation of dyspnea unexplained by routine evaluation. Chest 1994; 105:168.",
"     </a>",
"    </li>",
"    <li>",
"     Retractions www.nlm.nih.gov/medlineplus/ency/article/003322.htm (Accessed on February 02, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/16/28938/abstract/15\">",
"      Wipf JE, Lipsky BA, Hirschmann JV, et al. Diagnosing pneumonia by physical examination: relevant or relic? Arch Intern Med 1999; 159:1082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/16/28938/abstract/16\">",
"      Leuppi JD, Dieterle T, Koch G, et al. Diagnostic value of lung auscultation in an emergency room setting. Swiss Med Wkly 2005; 135:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/16/28938/abstract/17\">",
"      Metlay JP, Kapoor WN, Fine MJ. Does this patient have community-acquired pneumonia? Diagnosing pneumonia by history and physical examination. JAMA 1997; 278:1440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/16/28938/abstract/18\">",
"      Chakko S, Woska D, Martinez H, et al. Clinical, radiographic, and hemodynamic correlations in chronic congestive heart failure: conflicting results may lead to inappropriate care. Am J Med 1991; 90:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/16/28938/abstract/19\">",
"      Mueller C, Frana B, Rodriguez D, et al. Emergency diagnosis of congestive heart failure: impact of signs and symptoms. Can J Cardiol 2005; 21:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/16/28938/abstract/20\">",
"      Lovett PB, Buchwald JM, St&uuml;rmann K, Bijur P. The vexatious vital: neither clinical measurements by nurses nor an electronic monitor provides accurate measurements of respiratory rate in triage. Ann Emerg Med 2005; 45:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/16/28938/abstract/21\">",
"      Bianchi W, Dugas AF, Hsieh YH, et al. Revitalizing a vital sign: improving detection of tachypnea at primary triage. Ann Emerg Med 2013; 61:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/16/28938/abstract/22\">",
"      Singer AJ, Thode HC Jr, Green GB, et al. The incremental benefit of a shortness-of-breath biomarker panel in emergency department patients with dyspnea. Acad Emerg Med 2009; 16:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/16/28938/abstract/23\">",
"      Gruson D, Thys F, Ketelslegers JM, et al. Multimarker panel in patients admitted to emergency department: a comparison with reference methods. Clin Biochem 2009; 42:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/16/28938/abstract/24\">",
"      Collins SP, Lindsell CJ, Storrow AB, et al. Prevalence of negative chest radiography results in the emergency department patient with decompensated heart failure. Ann Emerg Med 2006; 47:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/16/28938/abstract/25\">",
"      Basi SK, Marrie TJ, Huang JQ, Majumdar SR. Patients admitted to hospital with suspected pneumonia and normal chest radiographs: epidemiology, microbiology, and outcomes. Am J Med 2004; 117:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/16/28938/abstract/26\">",
"      Seow A, Kazerooni EA, Pernicano PG, Neary M. Comparison of upright inspiratory and expiratory chest radiographs for detecting pneumothoraces. AJR Am J Roentgenol 1996; 166:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/16/28938/abstract/27\">",
"      Schneider HG, Lam L, Lokuge A, et al. B-type natriuretic peptide testing, clinical outcomes, and health services use in emergency department patients with dyspnea: a randomized trial. Ann Intern Med 2009; 150:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/16/28938/abstract/28\">",
"      Lam LL, Cameron PA, Schneider HG, et al. Meta-analysis: effect of B-type natriuretic peptide testing on clinical outcomes in patients with acute dyspnea in the emergency setting. Ann Intern Med 2010; 153:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/16/28938/abstract/29\">",
"      McNamara RM, Cionni DJ. Utility of the peak expiratory flow rate in the differentiation of acute dyspnea. Cardiac vs pulmonary origin. Chest 1992; 101:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/16/28938/abstract/30\">",
"      Malas O, Calayan B, Fidan A, et al. Cardiac or pulmonary dyspnea in patients admitted to the emergency department. Respir Med 2003; 97:1277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/16/28938/abstract/31\">",
"      Lawn ND, Fletcher DD, Henderson RD, et al. Anticipating mechanical ventilation in Guillain-Barr&eacute; syndrome. Arch Neurol 2001; 58:893.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 292 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-58.240.65.66-BC5B390E05-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_16_28938=[""].join("\n");
var outline_f28_16_28938=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H7771153\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Life-threatening upper airway causes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Life-threatening pulmonary causes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Life-threatening cardiac causes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Life-threatening neurologic causes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Life-threatening toxic and metabolic causes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Miscellaneous causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      HISTORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      PHYSICAL EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Clinical danger signs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      General examination findings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      ANCILLARY STUDIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      General approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Chest x-ray (CXR)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Electrocardiogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Cardiac biomarkers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Brain natriuretic peptide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      D-Dimer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Arterial and venous blood gas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Carbon dioxide monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Chest CT and VQ scan",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Peak flow and pulmonary function tests (PFTs)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Negative inspiratory force",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Initial interventions and differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Emergent management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Nonemergent management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      DISPOSITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      PITFALLS IN MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7771153\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/292\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/292|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/33/10781\" title=\"table 1\">",
"      Dyspnea differential",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/51/39740\" title=\"table 2\">",
"      Dyspnea onset",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/1/1053\" title=\"table 3\">",
"      Dyspnea signs",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10505?source=related_link\">",
"      Acute respiratory distress syndrome: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/15/29945?source=related_link\">",
"      Acute respiratory distress syndrome: Epidemiology; pathophysiology; pathology; and etiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/36/35399?source=related_link\">",
"      Airway foreign bodies in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/42/15016?source=related_link\">",
"      Amniotic fluid embolism syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38391?source=related_link\">",
"      An overview of angioedema: Pathogenesis and causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35290?source=related_link\">",
"      Anaphylaxis: Rapid recognition and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/46/29418?source=related_link\">",
"      Approach to the adult patient with anemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/19/31034?source=related_link\">",
"      Approach to the diagnosis and treatment of wide QRS complex tachycardias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/33/15894?source=related_link\">",
"      Arterial blood gases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/56/22410?source=related_link\">",
"      Auscultation of heart sounds",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/18/44328?source=related_link\">",
"      Carbon dioxide monitoring (capnography)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/6/10345?source=related_link\">",
"      Carbon monoxide poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/52/19273?source=related_link\">",
"      Cardiac tamponade",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/0/19465?source=related_link\">",
"      Causes of dilated cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/14/30954?source=related_link\">",
"      Chronic obstructive pulmonary disease: Definition, clinical manifestations, diagnosis, and staging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/22/5481?source=related_link\">",
"      Clinical features and diagnosis of Guillain-Barr&eacute; syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/55/4986?source=related_link\">",
"      Clinical features and diagnosis of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/21/40280?source=related_link\">",
"      Clinical features of amyotrophic lateral sclerosis and other forms of motor neuron disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/37/13911?source=related_link\">",
"      Clinical manifestations and diagnosis of Bordetella pertussis infections in adolescents and adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/51/17206?source=related_link\">",
"      Clinical manifestations of myasthenia gravis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39481?source=related_link\">",
"      Clinical manifestations, diagnosis, and evaluation of narrow QRS complex tachycardias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/25/7577?source=related_link\">",
"      Clinical presentation and diagnosis of Pneumocystis infection in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/30/23018?source=related_link\">",
"      Cocaine: Acute intoxication",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/39/25209?source=related_link\">",
"      Criteria for the diagnosis of acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36569?source=related_link\">",
"      Deep neck space infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/27/39353?source=related_link\">",
"      Deep vein thrombosis and pulmonary embolism in pregnancy: Epidemiology, pathogenesis, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/59/4025?source=related_link\">",
"      Diagnosis and treatment of pericardial effusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/57/6042?source=related_link\">",
"      Diagnosis of acute pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/26/26026?source=related_link\">",
"      Diagnostic approach to community-acquired pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/7/16505?source=related_link\">",
"      Diagnostic evaluation of a pleural effusion in adults: Initial testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/33/39446?source=related_link\">",
"      Dyspnea during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/55/39801?source=related_link\">",
"      Eclampsia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/30/2537?source=related_link\">",
"      Elevated cardiac troponin concentration in the absence of an acute coronary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/53/17242?source=related_link\">",
"      Emergency care of moderate and severe thermal burns in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/50/4905?source=related_link\">",
"      Emergent surgical cricothyrotomy (cricothyroidotomy)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/44/32458?source=related_link\">",
"      Epidemiology and clinical features of multiple sclerosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/45/4826?source=related_link\">",
"      Epiglottitis (supraglottitis): Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/51/21306?source=related_link\">",
"      Evaluation and management of severe sepsis and septic shock in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/23/7544?source=related_link\">",
"      Evaluation of acute decompensated heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/43/14010?source=related_link\">",
"      Evaluation of adults with ascites",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/39/20090?source=related_link\">",
"      Evaluation of chest pain in the emergency department",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/50/41770?source=related_link\">",
"      Evaluation of the adult with abdominal pain in the emergency department",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19945?source=related_link\">",
"      Evaluation of the patient with suspected heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/35/30266?source=related_link\">",
"      Health hazards associated with obesity in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/55/33657?source=related_link\">",
"      Hereditary angioedema: Treatment of acute attacks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/47/9978?source=related_link\">",
"      High-output heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/26/13735?source=related_link\">",
"      Identifying patients at risk for fatal asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/19/22838?source=related_link\">",
"      Imaging of pneumothorax",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/39/34426?source=related_link\">",
"      Initial evaluation and management of blunt thoracic trauma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/5/23641?source=related_link\">",
"      Management of acute exacerbations of chronic obstructive pulmonary disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/34/1577?source=related_link\">",
"      Management of heart failure in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/47/30454?source=related_link\">",
"      Massive hemoptysis: Initial management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/25/6554?source=related_link\">",
"      Mechanical ventilation of adults in the emergency department",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/3/4154?source=related_link\">",
"      Methanol and ethylene glycol poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/22/19818?source=related_link\">",
"      Natriuretic peptide measurement in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/51/1850?source=related_link\">",
"      Noninvasive positive pressure ventilation in acute respiratory failure in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/51/3897?source=related_link\">",
"      Opioid intoxication in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/25/33176?source=related_link\">",
"      Organophosphate and carbamate poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/22/4456?source=related_link\">",
"      Overview of acute pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/22/361?source=related_link\">",
"      Overview of atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/34/38439?source=related_link\">",
"      Overview of pulmonary disease in injection drug users",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/53/4952?source=related_link\">",
"      Overview of pulmonary function testing in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/11/42170?source=related_link\">",
"      Overview of the clinical manifestations of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/57/16282?source=related_link\">",
"      Overview of the risk factors, pathology, and clinical manifestations of lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33925?source=related_link\">",
"      Oxygenation and mechanisms of hypoxemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/45/11991?source=related_link\">",
"      Paraquat poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/2/21541?source=related_link\">",
"      Pathogenesis of obesity hypoventilation syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?27/50/28450?source=related_link\">",
"      Patient information: Shortness of breath (dyspnea) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/46/6883?source=related_link\">",
"      Patient information: Shortness of breath (dyspnea) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/53/854?source=related_link\">",
"      Peak expiratory flow rate monitoring in asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/62/2026?source=related_link\">",
"      Penetrating neck injuries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/62/18410?source=related_link\">",
"      Peripartum cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/40/8839?source=related_link\">",
"      Physiology of dyspnea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/3/10297?source=related_link\">",
"      Primary spontaneous pneumothorax in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/28/27082?source=related_link\">",
"      Pulmonary complications of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/32/9736?source=related_link\">",
"      Pulse oximetry",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/57/11158?source=related_link\">",
"      Pulsus paradoxus in pericardial disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/55/1912?source=related_link\">",
"      Rapid sequence intubation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/28/19913?source=related_link\">",
"      Salicylate (aspirin) poisoning in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/35/24121?source=related_link\">",
"      Secondary spontaneous pneumothorax in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/16/22790?source=related_link\">",
"      Smoke inhalation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/54/10087?source=related_link\">",
"      Stroke-related pulmonary complications and abnormal respiratory patterns",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/54/9065?source=related_link\">",
"      Supportive care and oxygenation in acute respiratory distress syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/18/11560?source=related_link\">",
"      Tests of respiratory muscle strength",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/12/22726?source=related_link\">",
"      The decision to intubate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/7/18552?source=related_link\">",
"      The difficult airway in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/7/41079?source=related_link\">",
"      Treatment of acute decompensated heart failure: General considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/56/5002?source=related_link\">",
"      Treatment of acute exacerbations of asthma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/1/40986?source=related_link\">",
"      Treatment of community-acquired pneumonia in adults who require hospitalization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/38/39530?source=related_link\">",
"      Troponins and creatine kinase as biomarkers of cardiac injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/63/3064?source=related_link\">",
"      Use of oxygen in patients with hypercapnia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/36/34377?source=related_link\">",
"      Valvular heart disease in elderly adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/35/13877?source=related_link\">",
"      Venous blood gases and other alternatives to arterial blood gases",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_16_28939="Risk of cardiac catheterization and coronary angiography";
var content_f28_16_28939=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F60388&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F60388&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Risk of cardiac catheterization and coronary angiography (based on 59,792 patients)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mortality",
"       </td>",
"       <td>",
"        0.11",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Myocardial infarction",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cerebrovascular accident",
"       </td>",
"       <td>",
"        0.07",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Arrhythmia",
"       </td>",
"       <td>",
"        0.38",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vascular complications",
"       </td>",
"       <td>",
"        0.43",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Contrast reaction",
"       </td>",
"       <td>",
"        0.37",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hemodynamic complications",
"       </td>",
"       <td>",
"        0.26",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Perforation of heart chamber",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        0.28",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Other complications",
"       </td>",
"       <td class=\"sublist_other\">",
"        0.28",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Total of major complications",
"       </td>",
"       <td>",
"        1.70",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Noto, TJ Jr, Johnson, LW, Krone, R, et al. Cardiac catheterization 1990: A report of the Registry of the Society for Cardiac Angiography and Interventions (SCA&amp;I). Cathet Cardiovasc Diagn 1991; 24:75. Copyright &copy; Wiley-Liss, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_16_28939=[""].join("\n");
var outline_f28_16_28939=null;
var title_f28_16_28940="POW and TREE mnemonics";
var content_f28_16_28940=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F71856&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F71856&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    POW and TREE mnemonics for writing strategy instruction for a child with writing disability",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\">",
"        POW mnemonic*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        <strong>",
"         P",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         Pick",
"        </strong>",
"        my idea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        <strong>",
"         O",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         Organize",
"        </strong>",
"        my notes:",
"        <sup>",
"         &Delta;",
"        </sup>",
"        <ul>",
"         <li>",
"          Who is the main character?",
"         </li>",
"         <li>",
"          When does the story take place?",
"         </li>",
"         <li>",
"          Where does the story take place?",
"         </li>",
"         <li>",
"          What does the main character do or want to do? What do other characters do?",
"         </li>",
"         <li>",
"          What happens then? What happens with other characters?",
"         </li>",
"         <li>",
"          How does the story end?",
"         </li>",
"         <li>",
"          How does the main character feel? How do other characters feel?",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        <strong>",
"         W",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         Write",
"        </strong>",
"        and say more",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\">",
"        TREE mnemonic",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        <strong>",
"         T",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         Topic sentence:",
"        </strong>",
"        Make a statement you believe in",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        <strong>",
"         R",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         Reasons:",
"        </strong>",
"        List three or more reasons why you believe what you wrote in the topic sentence",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        <strong>",
"         E",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         Ending:",
"        </strong>",
"        Wrap it up",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        <strong>",
"         E",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         Examine:",
"        </strong>",
"        Check your work and make sure you completed all of the steps",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Designed for students who are writing a story.",
"     <br>",
"      &Delta; A graphic organizer can be used to answer the questions in this step.",
"      <br>",
"       <span class=\"lozenge\">",
"        &loz;",
"       </span>",
"       Can be used to write a persuasive essay.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Modified and reproduced with permission from: Harris K, Graham Sl, Mason L. Self-regulated strategy development in the classroom: Part of a balanced approach to writing instruction for students with disabilities. Focus on Exceptional Children 2003; 35:1. Copyright &copy; 2003 Love Publishing Company.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_16_28940=[""].join("\n");
var outline_f28_16_28940=null;
var title_f28_16_28941="Optimal surveillance Barretts";
var content_f28_16_28941=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F76263&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F76263&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Optimal surveillance intervals in Barrett's esophagus (example data for cost-effectiveness analysis)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 318px; height: 304px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Depiction of the optimal endoscopic surveillance intervals in patients with Barrett's esophagus according to the annual incidence of esophageal cancer. More frequent surveillance is associated with increased quality-adjusted life expectancy as the incidence of esophageal cancer increases. In populations with a low incidence of esophageal adenocarcinoma (less than 0.2 percent), not performing surveillance endoscopy produced the optimal quality-adjusted life expectancy. In contrast, annual surveillance (gray area) was optimal in populations with a high incidence of esophageal adenocarcinoma (more than 2 percent). These data were derived from a decision analysis using a Markov model.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Provenzale D, et al, Am J Gastroenterol 1999; 94:2043.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_16_28941=[""].join("\n");
var outline_f28_16_28941=null;
var title_f28_16_28942="Course of thyroiditis";
var content_f28_16_28942=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F75131&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F75131&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 531px\">",
"   <div class=\"ttl\">",
"    Characteristic course of thyroiditis (painless, postpartum or subacute)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 511px; height: 324px; background-image: url(data:image/gif;base64,R0lGODlh/wFEAfcAAP///4CAgAAAAH9/f0BAQMDAwIDMzP8AAH/MzP+AgKCg+RAQEDAwMFBQUKCgoHBwcP9/f5CQkCAgIICA7tDQ0ODg4PDw8GBgYP/AwAAA3bCwsBAQ7wCZmZ+f+P+fnwAA7lBQ84CA9/+/v39/9sDA9/+goCAg8P9AQPDw/v9QUJCQ+E9P8+/v/b/l5bCw+v8QENDQ/P+wsP/w8KDZ2cDm5p/Y2K/f3/9gYA8P70+4uP+vr/9wcEBA5v/Q0FC5uf8gIA+fnxCfn0BA8rDf3/+QkO/4+B8f8P9PT/D5+f/g4P/v7/8wML/m5v8PD9Ds7BAQ3/Dw/R+lpa+v+SCmpkCzs6Cg8jAw8eDg+/8fH9DQ+eDg/XBw9XBw7P9vb2Bg6o+P97Cw9M/P+/8/P2/FxT8/8j+yslBQ6GC/vyAg4f9fXzAw439/7nDGxn8/P4/S0s/r6295eQBMTJCQ8ODz81+/vzCsrJDT08DA+0BmZn8flhAQeECMjN/f/O74+D9mZnBwf5/Z2TAwev+Pj4Cmpi8v8W9v9YDLy29vfmBg9AAAd5/P3gAJ6CAgef/Pz0Bv16Cg9O8ADs+gzH8/tu/5+YCAuzBfX3B6ev8vLyAg7EBAtoBAtv/f30BAey+srB8feY/I13DFxQAv0y9C5n8Ad+/v/l9ffXCW4B8f4WCP2l9ycgAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAAD/AUQBAAj/AAEIHEiwoMGDCBMqXMiwocOHECNKnEixosWLGDNq3Mixo8ePIEOKHEmypMmTKFOqXMmypcuXMGPKnEmzps2bOHPq3Mmzp8+fQIMKHUq0qNGjSJMqXcq0qdOnUKNKnUq1qtWrWLNq3cq1q9evYMOKHUu2rNmzaNOqXcu2rdu3cOPKnUu3rt27ePPq3cu3r9+/gAMLHky4sOHDOgsUEFihQAWPFAg4uPiAQEEHBChctKBYsWaGBB5cxPxZYOTJCBs/BqBYI+mLoQvG3ti5gAWdjTuvVniasmWClQG8PixAgMAAAgJoRL64QPLRygkyv+i8uIDfBp1Hv049wG7WzxEi/99uvCKB8tMtBkA9kPtG68U15ERuPbrB6dqhyzZewDvi4sclZ8F6AFQQgAYGalCZfAVeQMAFmjngXQQFnHeBA849UJlyFATQXAAU9EcBhgBo0AABEQgkoWknnreYRc4x4Blr/vVXwQXXKXddBA9aMOBkCRpYgAaTUeDgA7fZCIAFDjYQ3kHjCQRgBNEFkOJ6PEZnQWUQsiZBcv0JEIGD8lF53JUOdLgkl58RCEAAD7qnEYAOuFfAiUiqiKePbALQ4Yea3Rnabet1+CeNpSWE3AWKPebmehVYiKEAGhKgnAb+SWiBhBVE8BiPDTC4YokENPAljY8ZWepkEmowqIOJ0v9VXABwPifBAgBEIMCkEgTAgAAUVLAAAwEsgOt5C4j5JQMPVEdAsg5UIEADADhpoADJHjjtA5QCcF6Bxtb6YkXO9erhmwIsxtyvElhWHANfXgDArbnu6lyyBAhL7LDoLvbrAzjad1+O9AGAIwUUCCAvtg84mSIDC/i6QAUO4CshtucJcCOwCS+crHEQS/wYd9w2gBx2GU2pcInbTouuyRIUEDLEFUhLrbUatEwttsXZXK3GDJ1M68i/XUfBss0W9+yudaa4gATe8lwAtw0LIN+3ORN7KnPSEnsBtedJ8OUCYeMF36zoagAxeJcmp+sF4p53W79ss6zceT4jx6CTt63//a2uk6VHLnzKTcdcfgBwZwF3eq+doUC6ysdth+l2XLd4Z/NH6eSJW7Z4Zt3mnOK3dHOr2ObAJs6AaaGL2TkAT0uJMkbwMXCbk7SeGvuSj4setQVk/5y7cQKsLhDeLg9U3ZPoWreYe4ynW3fOAQDPgO9yC8Tv4mAbZ23U/SYswQMR3PZtfqTbBSC6ynXdbX7aLUqrd+nj91x+df4qX3qkf/ut4dKDkZzodrjwQM8y7hMN4gAYptMpB3FQMmB5biUB4x0Qfs8hHQPn9TQL/gaDOnJX0WZ3keJwSwLmS878XicQEApHYbuK2vxCOJD8WY0gnGmUdJh3QLq5EEe/SmF7/0YIvv4ZZzquStbqzpfB8qgPPeHJWKAUJjOOFU8DU4uME8fjwLoBD1sBepGutNU98DSgQgEcnLkmoyutpcs5oWKhe6R4uYSdkV7MAV7MuCWwgkQpcVB0neoKgCOnxcxJmjmPBiinLunRJ0UshN0hU8cdRdaJhBYB0HmopaszakBeDrtTAZ52p9QtDlu36eSQFoadL+KqIUI7V7IAFj0PubA61AKfQJyEKdf9Lzka2NobL4BFY4EPfU6sy/r+mL8WCmBsqFHbuyLlxAp86Yz3Cw+OREM3gTwgWQ0QIgC4Naw0UmR5ijsPA5y0GGTJ8TfNvJxwlqWZ6VTsOszzowQZU/+cuWFrlqZhVzSTRSVHSk9aAvAndiggUNn56UvnwWRFACSsGAbgSy5jUrIkUAGGPpM9OJLXcTC6M5Rt0yH0QVvFFsAtBF7ThfO6oS6X5CSWHs84FgibMB3zq+IlUnN3S2ZfuIUaCGrkV98xClFVkjORRrIiTRULUlGyOKghhiTGmptRMZIwiQ4lqyph5xAxIlawdDUlY7yqWtfK1ra69a1wzcpspjLXoNQ1rnjNyQCjstef9DWvgGUJliwlOx5dIEktgqSJHrSYGz0oVjIZ7HZQ1CPWJFYgi2VUgx5rEskWtrKCQhFmT6RZx3YpsKjNJEsdBkh4rSwAcDuPA+pkMpP/6atYr6wJw1j7rni9KbZMm1YAbDss3Jpkt67r7WuBO1vhEndfuU2tdCGiOO5U13MRaMCvrFQ8Ar1NXDa57us+t6TsbreN3lUYeEkiXvFawLxu6y4b1eui6drXIT3sIcQikNZaUUp+QwsvEfW7AP4+x78PALB/2DtgIu63vxlLsHoDfN8KJ6R4hEzugPfotmbRNmHXy2J4ZVTIdyaOw1by8LRAjMUHQPYjGC5xflEcARU3gMUitrCOC/LPbpm4Tvg8EElvI83iJTUmPeZmD4F8HiEXJ5wl6ikDjgxjY/l4yUoD5pCjPM0de9mhVPlrT8T85TJP1KtMIfNO1GzmNrv5/81wjrOc4XyHENj5znjGswpgQJbWmMTPWgH0nKlCiUzk+dB2BsEGNgCCPO95K7Q6SaQh3cdBR2XSDYGBCvKsaEY/2iqYJkmosTJqS0Ol1BLRdKdBoII7TAXVIIE1VWRt6qXQOtUqQIQVPmAFRHyaKbfmSLBPXelaN2XYFLmDClb966MgOyPPPnaxjW3raXdE1YtmNZ+LEu2LdLva1L60tUGCbU9vGyjfrki6k7LucPOk3RgptxAU8BN4R8Te3B63u/MdE02bwAT0fre+hT1wYu/bKfjmiAL+7YKdJBylBX/Kww8+k4lvRAGMRsF8Ig5tjkub4sD2+ElQoOiA28TiC/9Beb1FDnKdqHwjLvi3ySvOcnXXnN03b/nJc26ShZug4TSXNM+N8nKdq6ToHcH4FoLe2aHz2+jOdrpJtGAFK2ghJki/j9SHknWol6TrHdnCBoDuErAPxOw3QbvXY731k7gg42Vve9Dkjm66rx0lat8IyTcw85SoPe80AfzdNyJ4jcQc4Cv5u919UvjBY6TxGvF5s0W9ePFUXuCOFwrkLy6ERQuB7CJRPFc2n/mJkJ4jmoZ76C+v9dGzvvQeOX1H9g762L9eOrfHiexhD/GnvB0EGv+I6CnNe8bnfiV7n3zHhe764vdk9yBxQec38HnCH/9N168J9J2vqOy3JPXAX37/05vPfZd73yV7V0Dwbc584pd/41mR/gfmzf7xu//9aT9/TFDg87733v5asX34h3te4XO1N3ftF4D6N4AI+BUYF37/93ULCBMCyIDYFxbpF4GUR34WyHRhoQAf4H9Qcn0VCIAdiHUTeBMgKIJ+RIIpGHcn6IFisYIp54IcGIMvUYIvoXQKMXwKiIMoeBZUZ3WWl4BZoYP4h4QwIXYi6INH+IJAeIFpQYMtaISkBoVAqIQxQYVnZ4P3F4WChYU7wYVSKIE3CIZHJ4ZjGIJdaIVXoYXcB4cyQYVOeIVo2BJyOIcfoAJluIFfeId4p4Y94XOc4IU/CIhpKBcKwAiMwIK2/3eGiGiGchEAgcCGfniIkeiGbUErZMh2kJiJqzcXkdaJj/iHoBiKkxgdPBgSeViKp3iJcIFpQ3h1wieIgfiKkhgXoyZ2Byh+mIiLrGiLxmcQv7d+yyGMJgiMtSiKxZaB1veJyviMqZgQpFh/vxiNHdGKgTdu1Wh6yJiL2JiN3+hw+taN9zaOI6GNpaeOkTVw5vgQ7HiM4biM08gQ7whL6IiK80hwzOgQ91iD0LiP1hiLHPeP3ReQAumN/fgQBjmCCJmQ57iQDGmJEWmKEEkR8UiBLKcCJqCQFnmREpGROVhziFeR1wiSHqmLNbdwIZmPwYiS3uaS+UcRJQmPMkmPMP+JkTepfTf3dsbYgCeZkzYpkRIBAiAAESIZk0Kpk0QZESgwdkP5kUsJkPVIET6pgXY4lSZJkBdhlFj5hjsJe0mJh0P3lL3YelKplUVYlRVxlVQZlGp5kGxZEV75lk8Yl1GpkhlhlnaZlXgJlFyZESzZg2HJj38JmG8xcTXpkGl5mMdRmO14cR0pl3DpmG04lxexmFXYmI45lmGocEJAmXdpmaKZmHKHAh/wk5dZmaTpmYlHd/THmKxpma6ZiAo3mWh5kiKQALzJm0TQA3hZm35nd5r5mJAoAhCQnMl5BE3wAimQABgwlcJ5i0mHmwSYFSWgAwEwAA7RCIIAASIgnZD/GYQeUZzTqRAyUAIJ8ANYoAMDwJ2kuZZ66RGDeZ1SEQMncABH0AUeIBDvGZ/yGZjl2XfnWRAykAJN4AFKUBD/CaC5KaDVuZlOgQEJ8AJHsKAG0aAWUQIlAJEFCo4dYQJ8uJpNIQJdoAMJoaEV4QEH0KEC+aGwmHQUCaMMoaIr2qIvOp4aKRJ0qKMYYaMregIuGo40qo8gQYNFqhBAeqP9SaQ+CoMjsYKeWQJNChFLeqM3MKTAmKSeSBIgGAhPWgI3cABV+hBXuqJpgKPKyKU4GaWJ8AdFUQIHkAZlaqbw2REsqqWnyKauSBJ/oAe0GBRyWqdWeqd4SqiZyKfiKGl6/2AFQjGoFnGmrfmkZCl0VrB0PiGmZHoRkkqblPqZTacFUMkTcrqpnGqoDmqcmPmSbqkTHkCnGdGpnfmpr9l+dWkVsnqYimqYkviUjugUufqXuyqNudiQSBGsGaEDMRCJwyqPJmisRoGsGKEDLyADiNisvhij0EoU0ooRR5AC10qrtgmiABACoQkTVBoS3XoRStAEy3qH2Pp4hjgQMLABLxEDO2CqH7GuF+EBPwCI8aqUySgQG3BuKpEEL6Cv+4qqJYEFiHqCAase8zoQQjCiK7EEYvCwG8GvExEGXzACIyAJeTACjmawSSiuw6mJrXoSMZACl1ASHMsCHQCyNFuzNv+7AjiAAytAs3kwCpqAZ6umfifblEZKELdqEjLwAk2wCTDLsAchszW7Ah+wszZbtSD7BWFQEDogBglgEKr2AY0WAlvwqx6RBSRwtmebBQNxtlBgEVnAA1UwEFCAtmgLBVdQBRMgB1dgFhE7kOk4bXx5EikgBijatAYBtTQrtVQLsh3AAhchAuGJEPx3ZyaACRNwuZibuZq7uZrLBXGrEDyQAaIrujwgEFUguiRgESSQAROwtqM7uiQQuqL7BG1LFn3LlAM7ECpwriURA02AoYYrEDKruDXbuC/xCFzAucq7uWvQvM17CmgABglhtl6QAV5AAmp7BU+AugVRBTzAA2b/IL1XMAFgwAU80LoAAAVeAL6sK7dni7okAAVgAAVQoAYZkLq2i7LUSa70aq8moQOFaxLvObxTa7xSUQXSqxAT0L4C8b2hi78DYQbJiwYZcAWrmwE8sL1xa79cUL3oSxCiSxDj+wSlWxa3m5IxWhAFCxWH4AkF7LhiscDoKwdPcAUPXBDjywMU/L6tCwasmwXWCwCr+8EDEcID8bYkXLtjccItqYkUa7FLwQIrkAilAMNkIcMN/Lr3OxDaqwZVUL08LMSsO8RiTMQCYcQEgcX5S7QvmRArixQdoLOH4LRgocZmSwL2KwdKvLpmELv3S8ZDDAVPgAYkwAUMDMIZMBBo/5C8GmzC+uvEbXoQR2sUHWAERiAFAMCxU6HGA3HDBFG9T2C/YUzGVbC9oWvGAIDGZjC7qAwWTLyVf7sQgVsUUmDJHTAQmpyTr4yUE3sQu9sRGBC5JCHFOHDLBJHLeKqn5bfLeZnCXuu/G5ECGssRcbwCVozLdLwSecqAzPyVbbwQK6wRMnAAwBsSHfABxpyh2azNavp+3YyPkGy0UGwRMXADR0AS55zO6lwTXXADA/jOiFm0CKEAR4kRSdsFwgwS+ayk67wSOtAEKWCty/zIudulspyaGJEC9zwSLFDMC4HMH6EER/ACyryOFM2/Fr0QIEC2DFECv0sSK7ACNdrQLf/BotO8dgDdlwKNEMu2oQoLElKAA9eMECAdEh5w016X04QZzwRRrxUBqSRhBPqcojStFUlABAlABBItED2AAUlQECVwAsCpEV2NAV5NEDJg1gNR1hgw1hvRA0KqeyftzCkNzib7EEddEpXsEEWtErvZm9DJEfl5AAewBGudsF1LEAlwANGpEYNN2DswEPl6AO/62CcgERhwAIltEJm92TzJxnWtEKy2E1LN11VtE8ipnGJwAoCd0ATx142dEDEgAzLwA4wtEEtA2J4NAItNBDdwAu/asidABAJBoV9t3BTaAyUQ2wCQn15N2ANh2wfgzwKx2LutngKB3RSKASmQAsD/OaasDQBhfQIpsKydDQAxkADAyd0nsANbXaurGtrUWNA4sdemjRSprZyuPRCw7RC2/dUVmq+7vdgvMNhJEAMHkAL5GtmLHZ0NTuCaTRDO3QMH8K/ofQBEkLASbd0FkZ8C4eGLzdov8AIAkNs/cNkKvp4HkASdndn+jOAKnuBQOp8ofRCoqZozQQZTzdBoQQQHENkUnt4Rrti3na/cfQDWugQk3uC8zdiL/a4STtgH8AJjPaZJMKYuyuFR/uEH0OTRaeTnDQBJkAAnYNtm/eMvsATWmgKareIzDqGx/BCxaRMs8AFDzeNmka/UvdhSPuTVfdsN7uHN3eVM/uC33eE//07YwDnOB1Dmhf3nuy3oIA7ojH3eCLsEmnrmI16tgw7Yb26aTF0Q9VkTHUAGhWoWbP4DvOnVZj2mN/DVA1HojO3jCQDjAODjS6DiFHroUb7rPyADPn4DvJmwPdADru7WAMDmCp6wTU4EMTDiAJDZ5S3tGODcmb0DPg6u2Y4B9fzpblGHDFGcMVHadmoWfe7nWh7rlP7lCRvRACAD+bkEbL7rzM3l0ZnbN5DbEr3glk0QPWDbKZDbTW7bPzDW+UniY5rmlR7h+UncKi7jlRrfkWyP1okQwYwS9l3u+8bkOAfaEx/uZCvNKEHuGu9uHI8USl2aO70Qb4zW5HwSGV/yqf+qqjRO1ypN3wWBAfZ8Eh2NyRHR1x4613Fe4woxywSRAmmw3yER0yg88ykfoEMfEaMuEONcziMhBRtACk2fqk8vmzYP8gRRzxvtEEVQAwhw9gjQAgTRAmiPADXQBwZRsbg78zQP5yvfEKP+A0nvEDZQBhyQA22v9gPB9mifAxzgA2MwBAMRzk1M93UP6hXtEIin81hA9jkABDVQBBBR9ggABD6ABE4993Tf9Q8a9RLxdk0OAQwxBGwQBDmg+RRRBDkQBI7Au43v+KQvoV/fEI4LASdQ7wWBBD4ABGNgAxnxCYtgCn7L9UJ/931aERCw2wUxA64P+xmxAqLAATMg+k7/3/zfvPsOcQTEjRAzwAE1wBFBzQI1oP1b76C5b5/g3xBNEAnkb/4dQe41EARIcPujDxABAAwkWNDgQYQJFS5k2NDhw4UBBEKkiFBiRYSNIJk4SIMNhxoYGXYwUjCHD4wXRa5k2dLlS5gxZc5kqZLmTZwubeYsuHOloBMmFBhsMSYkTSMdChYBwoYGRZ88pU6lWtXq1ahXtd7MmrMrRSwlXGxAQZXkQRsIWkCduNXtW7hxtX6VW9chXZp4G3rAMhAECKpklL7Ua9fwYcR1Cyc+vBim44Q6dAxEsQGVDZ4sPrB43JbxZ9ChqUIW7ZZ0ywEDZrpYpIjnFzIxT5emXds2/4DZt6XmFpl65oxQK3J2+DBYYYunDXnrZt4c7nLnMqFT9B0TSRBFOKTcJG5c4RgDdz1HJ1/e8HTzNcdLrQ7TRw4AUnDwmdndoY0gSJSvT9/f/1T0/mPrqvZcGgKIIgYqhBCZ7HvopP0ElHDCvPijkCsLcSqwJSrcKIiQQmBy8CGmZmAowAtT7A9FFS3K8KYNWQrijYL4wME7kUaEqAYOTFSIxRaDZA5IIQciUqEYHfLAg4KcAOIgHSliYYUbV+LRRxeL1FLLI4XsEqEkGfLggBIIouE9hKJ0SL4VOGOpBiB80O+gL7e087wX7xzQqjAVGrNMgnygY600cWjzoSm1g/+piByCGILOPPWUtLk6Vay0oD4RUqIJQAdCgoMEFUr0izAWCuMLQ92MaQwfnDDo0kljHS1SWX+kNaZMDzoiBYNmgK8hKcjAwdAO3GShAypxIGM7mlrIAYggqPAR1lqrrdDalG6FKdeCdHhBBoN88BCiU1f4YAVzVyCVqjfciGKKGajFdt6W5JVQXm4H2jSGg2YU6dhi3aohijjgoPfg0OwVMADV+Gy4oV0PcpK8VB4GoAUEDNA4uTudoOHjj11FYgaNXQXg44HmoGEOhL3Slt58cbVYIW/BLWgINKMrEGMEetb4542FpIIDoommwokgop2Cg6eIHsgADsJrGcOpGYr/eduZI+PXoCkGJa9Pnnv2GWiyOS5thkcX8vgMDs6gwYmh0x7CVacBgFrqqqV7ed6rX+q7oBmiMK/vsMUWm9CBmCB7ccY1ZqIgxRuXPGiCIjdgiigwa+jugdgOwgc7WAaAaI2HxjvvzlBP6G/Usn7IBs2/dv2lwg23/Xa1Cqodd94RvzhjUACBiHMAkGCb6CDoLpp01WXbG1vWWYrev+mDJH5OGkwfnYOno24+9e8xnV3D8YOsvkXiqThjCBrqYHr77k8PXySF/zu/ovvLy/9C4u1wn4M6pK1uxJvfSupHvfLRhHWw68/+CvjAVz3PWg50SIwko5BJACF2+ksgBD0I/5EDNrCDMtnQpiaDkCGU4VfpoeAHCxhCFo5QZgY5whEUMgUEIdCFOzSgBKvVQqtZzANNUEJCArfBwcmQh0s0kg9rBcSFtOdPNzyKDpl4xRM5UVZQRFLDpmhEwQmIi1hEGAyTSCDVfBEh10FiDMn4RkhBcIxgUg0WiLCQnIlRiXCEoBk5iEYP/EAhQ2BDDiU0Rz5Wy4+yQ6MOtnaQ64yhjSJMJB8XqbM9uiRTeZwQIisZq0s6x5PiG6QhKTQALX5yaqFszigJgkoqWiqVqizjLCXlyiaCsUWspKV/eKkbXOKGP0OYQhUv9MtemgeZtkGkCERAkKxgLkjLTGZ0qEkbRP92oQvQXA8gMjdNW1ZTkeG80xzVGBUGglOcPLxmacaoRmFOqp3rtM08Q8NFeMZTUvakZ2n4+Rko5jOeMzBmkf7ZT9AcNDFAFKgwZwCSOykUoYmR6GEoKIIukCkhAagERCNKzonaqaKGuegOOnUQS8ShoFwCaUhZKsdMrgQJPiiYPFvqUi/dtEijnEEQcgCHmP5npDiNy1DrgsgZYA4zwWSMUYlqGp0KKXoeOOEgMVdFplI0qk+lkFPj8jcdYAELVS3IyHAGhILCcp9b5eq92KqiXIkAAnM9QhNekAIMdMQHHAACB3IQqp68VTRebWtVCPuWPslVDGKYKxF6sMYZUIH/Dn1IZxzXWljURUWuc+VsZ5+JkM12FgIeKKJCQivauX72IKdFrWoNwlrRurYgsJ1rG9ogW4JsFrcDaVcOOOADA5gtS5fFbNU0mwDkJle5uwWACJSb3BQc4AjMletzl5sQ51o3udTVLmepi9ra3rYiNnhWnGYwpwgRt7gtq5QMSsDct/DMd7vjndj84IfcEcQGNaDvsz6Xtj3p6bDrxcmA6Yu7MpQhv4mbHOPwgAcDPE6/UeBAJxBgiIxpzA4mo59gE+ZhAjtnEHto8M8kzOD6pni+KVax7nqW4AtnWHLC7bARJ1kvEH9mwCGeyYhL7DjI/ZhxJwaA5YRs4iBrzHcA/8rxjiviZB6D74VNznFTqxzl2kDZKvLS8kO6jOUe9pHKNgUztr7MZKxcGTFnLnOA58dlNTcmzm1uKgEkcmc851nPe+Zzn/38Z0AHWtB/JoCdB33oPRca0YtmdKMXrWhHR1rSky4AnaFp6ElnWtCQ1nSn/cxpT4c6z6AWdalJXepQn1oilba0PnUjUVjPWT2UknUiY01rXA+p1jVuta1y/epdZ+vXt2EzmXU97HoG+8nKdnOvI4jsLDMbhNL2MrXF4+yEFIDVutF2c7rNnG9ze9u3CTe2zX1udKdb3etmd7stbQEHBMABFtBNBSIQgAjQ+zYUKEAFmAPvfwI83+SmAP9BAD7vXjNAAAQQAAN0w3ABNHzfCxCAtRdCAYoTQAK2sYDCGb4AfYuGAgFYOEE8LnFLa0AADQBAAwSggdtowAIWkIAAxi0ahVdcNzUvOLklzvCbfwbiBBiIylnucpjTmeQCWXpzau5v2gRgAQ/QuW0oIAAJ1Jzltel4wyVwAdsUoOS40XnTlV72qt8mAgJ4QG2urgGz10bsDCiAwh3A9QssoOYMCLloxE50sjM97WVee9upHgHdUB3sWY544y2OkKsTPe6iWbtAXP54g/x9IIUHwOEtXQGsF+Dpt3G5BFZNmwpo+wICuADUa1NzDSg86J9xQMPrLoC7l4YCa6e7BUD/LwHRC8D1bXZAzSWQe9s0PuKYp9PgaUMBhS8A+bR5AMVNXxuIR7zSxcf69N39ffCHX/zjJ3/5zX9+9Kdf/etnf/vd/374x1/+86f/97Stb34PHyIUIID36///CYk4xAM954sImwMAsWM+AFxAloi4jaO6qosAAmiApJM3CbwA32O4C3AAsXuAB7CzgaCAC5hA/2NAEywNrHs5vdM5qnsApAOAiGOAmrsACti7BxC7haM4BwA9BgiAC9i6EwxCFJzABViAplsAh7OAlYNBolNCyTvABAQAlQuAq5OABxg4IcxC0Fg4lXuAphu7kgPDJ6y0KIxCDSAAinM4LVxDxCi5gwKwgKZDOpJDPDEMPG3TuQQsgAvQgAIoQjb8Q7sYu8ADAAtwuakbiDqsAK0rw4qrgJxjgJ4DREmcREqsREu8REzMRE3cRE7sRE/8RFAMRVEcRVIsRVM8RVRMRVVcRVZsRVd8RViMRVmcRVqsRVu8RVzMRV3cRV7sRV/8RWAMRmGks4AAADs=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The initial thyroid inflammation damages thyroid follicles and activates proteolysis of the thyroglobulin stored within the follicles. The result is",
"    <strong>",
"     unregulated",
"    </strong>",
"    release of large amounts of thyroxine (T4) and triiodothyronine (T3) into the circulation and therefore hyperthyroidism. This state lasts only until the stores of thyroglobulin are exhausted, because new hormone synthesis ceases. As the inflammation subsides, the thyroid follicles regenerate and thyroid hormone synthesis and secretion resume. There may be a transient period of hypothyroidism and increased TSH secretion before thyroid secretion becomes normal again. However, some patients have only a hyperthyroid or hypothyroid phase.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_16_28942=[""].join("\n");
var outline_f28_16_28942=null;
var title_f28_16_28943="Contents: Adolescent medicine";
var content_f28_16_28943=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?17/55/18302\">",
"       Pediatrics",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Adolescent medicine",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Adolescent medicine",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Adolescent sexuality",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/40/9866\">",
"           Adolescent sexuality",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/5/12378\">",
"           Overview of gender development and clinical presentation of gender nonconformity in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/25/10650\">",
"           Overview of the management of gender nonconformity in children and adolescents",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Drug abuse",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/30/23018\">",
"           Cocaine: Acute intoxication",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/47/1784\">",
"           Designer drugs of abuse",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/61/33753\">",
"           Inhalant abuse in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/21/22874\">",
"           Opioid intoxication in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/35/570\">",
"           Phencyclidine (PCP) intoxication in children and adolescents",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Eating disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/2/23593\">",
"           Eating disorders: Epidemiology, pathogenesis, clinical features, and course of illness",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/63/44023\">",
"           Eating disorders: Treatment",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Endocrinology",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/22/21865\">",
"           Acquired hypothyroidism in childhood and adolescence",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/13/39130\">",
"           Clinical features and diagnosis of polycystic ovary syndrome in adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/29/7641\">",
"           Clinical manifestations and diagnosis of hyperthyroidism in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/13/42201\">",
"           Contraception: Overview of issues specific to adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/9/34970\">",
"           Definition, pathogenesis, and etiology of polycystic ovary syndrome in adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/57/22424\">",
"           Diagnosis and treatment of delayed puberty",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/16/28935\">",
"           Epidemiology and pathogenesis of premenstrual syndrome and premenstrual dysphoric disorder",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/37/14937\">",
"           Evaluation of oligomenorrhea in adolescence",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/25/1434\">",
"           Normal puberty",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/8/23690\">",
"           Ovarian and fallopian tube torsion",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/34/21033\">",
"           Ovarian cysts and neoplasms in infants, children, and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/25/31125\">",
"           Primary dysmenorrhea in adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/0/12\">",
"           Steroid hormone metabolism in polycystic ovary syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/46/24297\">",
"           Treatment of polycystic ovary syndrome in adolescents",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Gastroenterology",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/20/11593\">",
"           Causes of acute abdominal pain in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/17/1306\">",
"           Evaluation of the child and adolescent with chronic abdominal pain",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/52/6984\">",
"           Management of the child and adolescent with chronic abdominal pain",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/40/29315\">",
"           Patient information: Chronic abdominal pain in children and adolescents (Beyond the Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         General issues",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/2/10282\">",
"           Body piercing in adolescents and young adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/62/33770\">",
"           Clinical features; evaluation; and diagnosis of adolescent idiopathic scoliosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/2/10281\">",
"           Confidentiality in adolescent health care",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/24/5512\">",
"           Consent in adolescent health care",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/35/19000\">",
"           Guidelines for adolescent preventive services",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/9/35993\">",
"           Tattooing in adolescents and adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/49/3864\">",
"           The choking game and other strangulation activities in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/28/39370\">",
"           Treatment of acne vulgaris",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Infectious diseases",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/0/1032\">",
"           Clinical features and diagnosis of pelvic inflammatory disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/10/13480\">",
"           Clinical trials of human papillomavirus vaccines",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/56/3976\">",
"           Disseminated gonococcal infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/45/11992\">",
"           Pathogenesis of and risk factors for pelvic inflammatory disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/17/19738\">",
"           Recommendations for the use of human papillomavirus vaccines",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/51/37689\">",
"           Sexually transmitted diseases: Overview of issues specific to adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/39/26229\">",
"           The life cycle, natural history, and immunology of human papillomaviruses",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/63/35832\">",
"           Treatment of pelvic inflammatory disease",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Nutritional issues",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/24/16778\">",
"           Adolescent eating habits",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/6/40040\">",
"           Calcium requirements in adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/11/23735\">",
"           Dietary energy requirements in adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/61/42967\">",
"           Fast food for children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/14/4329\">",
"           Iron requirements and iron deficiency in adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/4/8266\">",
"           Vegetarian diets for children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/3/29753\">",
"           Zinc deficiency and supplementation in children and adolescents",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Psychosocial issues",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/12/15561\">",
"           Date rape: Identification and management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/38/33385\">",
"           Date rape: Risk factors and prevention",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/10/5289\">",
"           Depression in adolescents: Epidemiology, clinical manifestations, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/23/15736\">",
"           Effect of antidepressants on suicide risk in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/11/38071\">",
"           Evaluation and management of suicidal behavior in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/26/13738\">",
"           Overview of treatment for adolescent depression",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/42/40617\">",
"           Peer violence and violence prevention",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/52/30538\">",
"           Psychopharmacological treatment for adolescent depression",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/14/4328\">",
"           Psychosocial treatment for adolescent depression",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/17/23834\">",
"           Suicidal behavior in children and adolescents: Epidemiology and risk factors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/25/40343\">",
"           Television and media violence",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Reproductive health issues",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/40/9866\">",
"           Adolescent sexuality",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/13/39130\">",
"           Clinical features and diagnosis of polycystic ovary syndrome in adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/13/42201\">",
"           Contraception: Overview of issues specific to adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/23/25975\">",
"           Definition and evaluation of abnormal uterine bleeding in adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/9/34970\">",
"           Definition, pathogenesis, and etiology of polycystic ovary syndrome in adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/45/34522\">",
"           Depot medroxyprogesterone acetate for contraception",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/8/11402\">",
"           Diagnosis and treatment of endometriosis in adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/57/11160\">",
"           Differential diagnosis and approach to the adolescent with abnormal uterine bleeding",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/16/28935\">",
"           Epidemiology and pathogenesis of premenstrual syndrome and premenstrual dysphoric disorder",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/37/14937\">",
"           Evaluation of oligomenorrhea in adolescence",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/7/17529\">",
"           Management of abnormal uterine bleeding in adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/34/21033\">",
"           Ovarian cysts and neoplasms in infants, children, and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/37/3673\">",
"           Overview of breast disorders in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/49/42776\">",
"           Overview of breast masses in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/18/35113\">",
"           Overview of causes of genital tract bleeding in women",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/24/39306\">",
"           Overview of contraception",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/8/35973\">",
"           Patient information: Adolescent sexuality (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/2/27685\">",
"           Physiology of the normal menstrual cycle",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/31/10744\">",
"           Pregnancy in adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/25/31125\">",
"           Primary dysmenorrhea in adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/0/12\">",
"           Steroid hormone metabolism in polycystic ovary syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/46/24297\">",
"           Treatment of polycystic ovary syndrome in adolescents",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Urologic issues",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/47/43766\">",
"           Causes of painless scrotal swelling in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/39/32376\">",
"           Causes of scrotal pain in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/38/2663\">",
"           Evaluation of scrotal pain or swelling in children and adolescents",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-282C56675D-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f28_16_28943=[""].join("\n");
var outline_f28_16_28943=null;
